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Abstract
In response to adverse conditions, many bacterial species can switch from a planktonic
growth to a surface associated growth mode and form biofilm communities. A key fac-
tor triggering the formation of biofilms in a multitude of bacterial species is the second
messenger bis-(3’-5’)cyclic dimeric guanosine (c-di-GMP). The biosynthesis of c-di-GMP by
condensation of two GTP molecules is performed by diguanylate cyclases (DGCs). DGCs
consist of catalytic GGDEF domains in combination with N-terminal, environment sensing
regulatory domains. A significant fraction of DGCs are linked to N-terminal sequences of
unknown function indicating that c-di-GMP signaling is linked to numerous undiscovered
environmental and cellular signals. In this study structural and biochemical analysis on the
DGC YdeH from E. coli was undertaken, to elucidate its regulatory mechanism.
Three-dimensional structures of YdeH were determined, which reveal in the regulation of
YdeH. The N-terminal sensory domain of YdeH shows a new fold, a four helical bundle,
which harbors a zinc-binding site compromised of three histidines and one cysteine. It
could be shown that the DGC activity of YdeH is inhibited by zinc binding to the N-
terminal sensory domain with an inhibition constant in the femtomolar range. A model for
the inhibition of YdeH by zinc is proposed, in which upon zinc binding the linker between
the regulatory domain and the enzymatic domain is fixed in a conformation, which prevents
the productive encounter of the two GGDEF domains.
In the structures of YdeH, substrate and product binding to the active site could be shown,
however the dimeric arrangement of the two DGC domains, each harboring only one half
of the active site, are not in a competent constellation. With the help of the determined
structures of YdeH a model of a competent dimer was generated, which provides insights
into the regulation of YdeH. Product binding to the inhibitory site of YdeH was shown in the
crystal structures and inhibition by c-di-GMP was demonstrated in enzymatic experiments.
YdeH represents the first example of a biological zinc-sensor that exerts its downstream
e ects post-transcriptionally and the first example of a metal sensory c-di-GMP signaling
protein.
A protocol for the enzymatic large-scale synthesis of c-di-GMP by using the DGC YdeH
from E. coli was developed and optimized. In contrast to the chemical synthesis of c-di-
GMP, enzymatic c-di-GMP production is a one-step reaction that can easily be performed
vii
Abstract
with the equipment of a standard biochemical lab. The protocol allows the production of
milligram amounts of c-di-GMP within one day and paves the way for extensive biochemical
and biophysical studies on c-di-GMP-mediated processes.
In biofilms cells are entrapped within a extracellular polymeric matrix. One component of
this matrix is the poly-—-1,6-N-Acetyl-glucosamine (poly-1,6-GlcNAc), which is synthesized
and exported by the four proteins of the pgaABCD operon. PgaC and PgaD are responsi-
ble for the synthesis of poly-1,6-GlcNAc and are allosterically regulated by c-di-GMP. The
deacetylase PgaB and the outer membrane protein PgaA are involved in the modification
and export of the poly-1,6-GlcNAc chain.
For PgaA and PgaB an expression and purification protocol was established and resulted in
stable and homogenous proteins. The predicted deacetylase activity of PgaB was demon-
strated in vitro with an activity assay, which is suitable for rapid screening of di erent
reaction conditions and for the search of inhibitors for PgaB and PgaC, which are of spe-
cific pharmaceutical interest.
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1 Introduction
1.1 The second messenger c-di-GMP
In response to adverse conditions, many bacterial species can switch from a planktonic
growth to a surface associated growth mode and form biofilm communities. It is well known
that cells in biofilms are protected from physical, chemical or biological stress. Part of this
stress tolerance is based on the production of a viscous extracellular matrix, consisting of
polysaccharides and pili or fimbriae. The matrix protects biofilms from sheer forces, graz-
ing predators, such as immune cells in host environments and other stressors. In addition,
biofilm cells have a remarkable ability to survive antibiotic treatment [1]. Because of this
tolerance against antibiotics and the host immune system, biofilm associated infections,
such as lung infections in cystic fibrosis patients caused by Pseudomonas aeruginosa, or
recurring urinary tract infections caused by uropathogenic Escherichia coli are notoriously
di cult to treat and thus represent a major health problem.
A key factor triggering the formation of biofilms in a multitude of bacterial species, includ-
ing pathogenic E. coli or P. aeruginosa, is the second messenger bis-(3’-5’)cyclic dimeric
guanosine (c-di-GMP) [2]. C-di-GMP was first identified 20 years ago as an activating factor
of cellulose synthase in Acetobacter xylinum [3], but in the mean time it has been shown
to play a central role in the transition between a motile, single-cell state to a sessile, sur-
face attached state found in biofilms [4–6]. Moreover, c-di-GMP controls the virulence of
pathogens [2, 7–9], cell cycle progression [10], antibiotic production [11] and other cellular
functions.
1.2 The structure of c-di-GMP
C-di-GMP is a two-fold symmetrical molecule that consists of two GMP moieties forming
a 12 membered ribose-phosphate ring (Figure 1.1). Several X-ray structures of c-di-GMP
have been determined [12–14]. They show similar conformations for the ribose and phosphate
moiety in a rather rigid macrocycle. The torsion around the glycosidic bond and therefore
the orientation of the guanyl base with respect to the macrocycle is variable. In all the
available small molecule crystal structures, c-di-GMP is dimeric with intercalated bases
and H-bonding between the guanine N1 and the phosphate group (Figure 1.1). In some
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Figure 1.1: Chemical and three-dimensional structure of c-di-GMP. (A) Chemical structure and atom
numbering of monomeric c-di-GMP in anti conformation. The numbering is adapted
from the PDB entry 2von. (B) Three-dimensional structure of monomeric c-di-GMP as
it is found in the active site of the EAL phosphodiesterase YkuI from B. subtilis (PDB:
2w27). (C) Stereo view of dimeric c-di-GMP as it is bound to the inhibitory site of the
diguanylate cyclase PleD from C. crescentus (PDB: 1w25). Intermolecular H-bonds are
shown as dashed lines.
of the structures a divalent metal ion (Mg2+ or Co2+) is coordinated by the N7 atoms of
the central bases of the c-di-GMP dimer, which does not change the structure significantly
[12, 13]. The same form of dimeric c-di-GMP has been observed in protein complexes,
where it binds to the inhibition site of diguanylate cyclases [15–18], PilZ receptors [19, 20]
and response regulators [21]. The monomeric form of c-di-GMP was found in c-di-GMP
specific phosphodiesterases [22–24], the active site of diguanylate cyclases [15] and in a PilZ
receptor [25]. NMR studies in solution at high c-di-GMP concentrations (> 1mM) reveal
a rich polymorphism, ranging from dimers to several forms of tetramers and octamers in a
cation dependent equilibrium [26, 27]. However, a very recent NMR study has shown that
c-di-GMP is monomeric at physiological sub-micromolar concentrations [28].
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1.3 Biosynthesis and degradation of c-di-GMP
The intracellular concentration of c-di-GMP is controlled by the opposing activities of two
signaling enzyme families: diguanylate cyclases (DGCs) and phosphodiesterases (PDEs).
DGCs catalyze the condensation of two GTP molecules to c-di-GMP (Figure 1.2). They
harbor a characteristic GGDEF domain that is named after a linear motif of amino acids in
the active site, which is essential for catalytic activity [29, 30]. The GGDEF domain consists
of a five-stranded central —-sheet surrounded by five helices [15]. This fold is related to that
of class III nucleotidyl cyclases and type I DNA polymerases, which implies a similar cat-
alytic mechanism using magnesium as metal ions [15, 16]. The active DGC is a dimer of two
GGDEF domains, in which both active sites are located at the dimer interface [15, 16]. This
allows an antiparallel alignment of two GTP molecules and the synthesis of the two-fold
symmetrical c-di-GMP by the formation of two intermolecular phosphodiester bonds. Most
of the DGCs show allosteric product inhibition with an inhibition constant in the range of
cellular c-di-GMP concentrations [15, 31]. The feedback control avoids excessive GTP con-
sumption and limits the maximal c-di-GMP concentration. The inhibition involves dimeric
c-di-GMP binding to a primary inhibition site (Ip) characterized by the RxxD-motif and
binding to a secondary inhibition site (Is) located either on the other GGDEF domain or on
a associated regulatory domain [15–17]. Thus c-di-GMP acts as a crosslinker and prevents
the encounter of the two active sites.
C-di-GMP is degraded to the linear dinucleotide 5’-phosphoguanylyl-(3’-5’)-guanosine
(pGpG) by specific PDEs, which can be further degraded to GMP by nonspecific enzymes
(Figure 1.2). C-di-GMP specific PDEs either possess an EAL domain or an HD-GYP
domain, named after conserved active site residues [32–35]. EAL containing PDEs hydrolyze
one ester bond of c-di-GMP to open the c-di-GMP macrocycle [33, 36]. They show high
substrate a nity with a KM in the sub-micromolar range [32, 34, 36] and require Mg2+
or Mn2+ for catalysis [32, 33]. They fold into a TIM-barrel, in which the active site is
located on the bottom of the barrel [22]. The HD-GYP domain proteins are a subfamily of
metal-dependent phosphohydrolases and are unrelated to EAL proteins [37]. In contrast
to EAL proteins, they catalyze the hydrolysis of phosphodiester bonds to GMP directly [35].
Interestingly, many bacterial genomes encode for dozens of these c-di-GMP signaling pro-
teins, with largely unknown physiological functions. For example, the Escherichia coli K-12
genome encodes 29 proteins that harbor a GGDEF, an EAL domain, or both domains, while
no HD-GYP domain encoding gene is present. Not all of these proteins are enzymatically
active. Some carry alterations of critical active site residues and have adopted alternative
functions, that are not necessarily directly related to c-di-GMP signaling [38, 39], but most
3
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input domains
Figure 1.2: C-di-GMP signaling pathways. At the cellular level, c-di-GMP concentration is controlled
by diguanylate cyclases (green) and phosphodiesterases (orange). These enzymes respond
to internal or external signals that are sensed by the N-terminal accessory domains. C-di-
GMP binding to the inhibitory site of diguanylate cyclases results in feedback inhibition.
The interaction with di erent c-di-GMP receptors produces a output signal. Low c-di-
GMP concentrations are connected to motility and are required for the expression of
virulence genes. High c-di-GMP levels stimulate biofilm formation and are important for
cell cycle progression.
GGDEF/EAL domain proteins are predicted, or have been shown, to possess the ability to
synthesize or degrade c-di-GMP [40].
1.4 Modulation of the enzymatic activity of
c-di-GMP-metabolizing enzymes by signal input domains
The vast majority of c-di-GMP signaling proteins in E. coli and other bacterial species
harbor N-terminal sensory domains, which are believed to modulate the enzymatic activity
of the GGDEF or HD-GYP/EAL output domains after recognizing a specific signal. A
significant fraction of DGCs and PDEs contain N-terminal sequences of unknown function
indicating that c-di-GMP signaling may be linked to numerous undiscovered environmental
and cellular signals. Typical examples of sensory domains are phosphoryl group accepting
receiver domains, small molecule binding PAS domains, light sensing BLUF or LOV do-
mains, GAF or HAMP domains, and many others [40]. Most of these domains can also be
found in other types of sensory and signaling proteins such as histidine kinases, chemore-
ceptors of the MCP-type or transcription factors of the one component type [41].
However, the actual signal or ligand that is sensed by these input domains is not known
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for almost all c-di-GMP signaling proteins. The few marked exceptions are the PDE DosP,
the DGC DosC - both from E. coli - and the PDE AxPDE1 from A. xylinum, which have
been shown to respond to O2 [42, 43], the DGC AxDGC2 - also from A. xylinum - which
responds to altered redox conditions via a non-covalently bound FAD cofactor [44], the
DGC Lpg1057 from Legionella pneumophila which responds to NO via the auxiliary haeme
binding protein Hnox1 [45], the GTP sensing PDE CC3396 from Caulobacter crescentus [32]
and the blue light sensing PDE BlrP1 from Klebsiella pneumoniae [23](Figure 1.3). Based
on the crystal structures of BlrP1 a activation mechanism was proposed, where light absorp-
tion by the flavin molecule cause conformational changes in the BLUF domain, which are
transferred to the EAL active site [23]. Other examples are the well studied DGCs PleD and
WspR, from C. crescentus and P. aeruginosa, respectively, which both carry a N-terminal
receiver domain and become activated upon phosphorylation of an aspartate residue [30,
46]. Phosphorylation of the REC1 domain of PleD induces structural rearrangement in the
REC1-REC2 interfaces, which in turn, allows the tight dimerization of PleD. The dimeric
arrangement is a prerequisite for an e cient and productive encounter of the two GTP
loaded GGDEF domains to form c-di-GMP [16] (Figure 1.3). However, for PleD and WspR
the input cue controlling the activity of their cognate histidine kinases has not yet been
identified. For a small number of additional c-di-GMP signaling proteins input signals have
been inferred or predicted, but biochemical proof for direct e ects are lacking.
1.5 The diguanylate cyclase YdeH from E. coli
One example of a c-di-GMP signaling protein for which the input signal has not been iden-
tified so far, is the DGC YdeH from E. coli. C-di-GMP produced by YdeH posttranslation-
ally controls the production of the polysaccharide adhesin poly-—-1,6-N-Acetyl-glucosamine
(poly-—-1,6-GlcNAc) in vivo and thereby upregulates E. coli biofilm formation [47, 48]. Ex-
pression of YdeH is tightly controlled on the mRNA level by the RNA binding protein CsrA,
which prevents YdeH translation, and also represses expression of the pgaABCD operon, en-
coding for the poly-—-1,6-GlcNAc biosynthesis machinery [49, 50].
YdeH consists of 296 amino acids with a theoretical mass of 33.9 kDa and contains a C-
terminal GGDEF domain. The enzyme is predicted to be active, because it possesses all
amino acids, which have been shown to be essential for DGC activity. YdeH has a predicted
primary I-site, consisting of a RxxE-motif. This site di ers slightly from the canonical
RxxD-motif, which is present in the best characterized DGCs PleD from C. crescentus and
WspR from P. aeruginosa. Furthermore the secondary I-site residues, which are involved in
the crosslinking of the two GGDEF domains in PleD and WspR, are also present in YdeH.
This leads to the conclusion that YdeH might be product inhibited, too.
The N-terminus of YdeH harbors a signal input domain that consists of 126 amino acids and
5
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(A)
(B)
Figure 1.3: Diguanylate cyclases and phosphodiesterases with known input signals. (A) Schematic
drawing of the domain organization and the input signals of the DGCs and PDEs.
GGDEF and EAL domains are shown in red and blue, respectively. N-terminal reg-
ulatory domains are shown in green (REC), orange (PAS) and cyan (BLUF). The reg-
ulatory input signals are phosphorylation (P), FAD binding (green), oxygen (purple),
GTP (orange) and blue light (blue flash). (B) Mechanistic model of the PleD activation.
Phosphorylation of the REC1 domain by a cognate histidine kinase induces structural
rearrangement in the REC1-REC2 interface, which in turn, allows tight dimerization of
PleD. The dimeric arrangement is a prerequisite for an e cient and productive encounter
of the two GTP loaded GGDEF domains to form c-di-GMP. The figure is adapted from
[16].
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belongs to the Pfam family PB001058 [51]. This family comprises 98 signaling proteins from
a variety of bacterial species. 50% of these proteins are chemosensors that are predicted to
be involved in chemotaxis. One such chemosensory protein, TlpD from Helicobacter pylori,
has recently been shown to bind zinc via the PB001058 domain [52]. Based on the conserved
residues involved in zinc binding other PB001058 family members were also predicted to be
zinc binding proteins, and the domain was thus named CZB (chemoreceptor zinc binding).
1.6 Zinc and zinc binding proteins
Zinc is a transition metal and serves as a cofactor for many proteins that are involved in a
multitude of metabolic processes, including central cellular functions such as transcription
and translation [53]. Therefore, zinc represents an essential trace element and all cells pos-
sess highly e cient zinc uptake systems. However, due to the reactivity of zinc as a potent
Lewis acid, it is essential to strictly prevent nonspecific interaction of freely available zinc
with cellular biomolecules. As a consequence, bacteria and other organisms have to keep the
intracellular concentration of freely available zinc low, while allowing for full occupation of
the highly abundant zinc-cofactor containing proteins. To solve this problem, zinc-binding
proteins from bacteria exhibit a remarkably high a nity for the metal, with down to fem-
tomolar dissociation constants, while excess zinc is cleared from the cytoplasm by highly
e cient export systems [54]. The activity of zinc import and export systems is sensitively
balanced to ensure the maintenance of tight zinc homeostasis over a wide range of ambient
zinc concentrations that can vary between low nanomolar and high micromolar levels [55].
In the majority of zinc-binding proteins, the metal either functions as a catalyst or as a
pure structural factor, necessary for the formation of the proper secondary, tertiary or qua-
ternary structure of the zinc-binding protein [56]. The prototypical chemical function of a
catalytic zinc is to activate water molecules and make them available for a large variety
of biochemical reactions. The coordination number is four or five with a tetrahedral or
trigonal-bipyramidal geometry. In every case, water is present as a ligand. In these zinc
enzymes, the charges of the coordinating amino acids modulate the Lewis acidity of the zinc
ion, which can activate the bound water molecule. Structural zinc ions have four protein
ligands and no bound water molecule arranged in a tetrahedral manner [56]. Typical zinc-
liganding residues are histidine, cysteine, glutamate and aspartate.
Identifying a site as structural or catalytic is not as straightforward as it appears. Zinc sites
that have been classified as structural sites based on the presence of four protein ligands,
were shown to have additional functions such as redox activity [57]. Furthermore, the metal
in zinc-responsive signal transduction proteins has neither a catalytic nor a pure structural
function. Instead, the zinc allosterically controls the activity of an e ector domain, for
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example the DNA-binding domain of a transcription factor, or the histidine kinase activity
of two-component-systems signaling proteins [55, 58]. These regulators are - among other
functions - partially responsible for the maintenance of zinc homeostasis by modulating
the abundance of zinc exporters and importers in response to changes of the ambient zinc
concentrations [55]. Two zinc-responsive transcription factors are known in the bacterial
kingdom and both have representatives in E. coli: the MerR-type transcription activator
ZntR, which upon binding of zinc induces expression of the zinc exporter coding gene zntA
[59], and the Fur-like repressor Zur, which represses transcription of several genes coding for
zinc uptake systems and other genes facilitating growth under zinc-limited conditions [60,
61]. While ZntR binds two zinc ions via a single binding site that is composed of residues
from both protomers in the dimeric protein [62], a close homologue of Zur, FurB from
Mycobacterium tuberculosis, was found to bind three zinc ions via three distinct and proto-
typical tetrahedral sites per monomer [63]. The binding constant of ZntR was determined
to be in the femtomolar range [64]. Since the binding a nity of zinc in zinc proteins is very
high, kinetic mechanisms must exist for the dissociation of the tightly bound zinc [57].
1.7 C-di-GMP receptors
After DGCs have synthesized c-di-GMP in respond to external or internal signals, these
input signals have to be further transferred via c-di-GMP binding to an e ector compo-
nent by inducing a structural or functional change. As c-di-GMP controls a wide range of
cellular functions and processes, c-di-GMP receptors are highly diverse. Only a few types
of di erent c-di-GMP receptors are currently known. The best-studied class is the PilZ
proteins, which seem to be activated by c-di-GMP and to function by protein-protein in-
teraction. Structural studies revealed that c-di-GMP binding to the PilZ protein induces
dramatic conformational changes, which makes the PilZ domain more compact and provides
a novel surface for protein-protein interactions [25, 65, 66]. PilZ proteins can be standalone
proteins or can be linked to other domains, that generate a molecular output. PilZ proteins
are involved in regulation of biofilm formation, cellulose biosynthesis, motility, extracellular
enzyme production and virulence [65–68].
Another type of receptor proteins is the transcription factor FleQ of P. aeruginosa, which
is repressed by c-di-GMP [69], and PelD of P. aeruginosa, which is activated by binding of
c-di-GMP to a site similar to the I-site of DGCs [70].
Degenerated GGDEF proteins can also act as c-di-GMP receptors, where c-di-GMP binding
to the I-site alters protein function. PopA from C. crescentus, recruits the cell cycle regu-
lator CtrA to the cell pole after c-di-GMP binding to the I-site, thereby targeting CtrA for
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degradation [10]. Another I-site dependent c-di-GMP receptor is CdgG from Vibrio cholera,
that controls biofilm formation and motility [71].
An additional class of c-di-GMP receptors are riboswitches. The conserved GEMM domain
is present in the 5’-untranslated regions of di erent mRNAs, which regulate gene expression
via c-di-GMP binding [72].
1.8 A c-di-GMP responsive system: the pgaABCD operon of
E.coli
In biofilms, cells are entrapped within an extracellular polymeric matrix [73, 74]. While this
matrix contains a variety of components a ecting its properties, the structural integrity
of biofilm often depends on polysaccharides [48, 75–77]. Poly-—-1,6-N-Acetyl-glucosamine
(poly-1,6-GlcNAc) is a homopolymer originally found in Staphylococcus epidermidis [78],
but it can also be isolated from E. coli [48]. Poly-1,6-GlcNAc is an important cell-to-cell
and cell-to-surface adhesion molecule in biofilms and is essential for the formation of the
cellular architecture of E. coli biofilm microstructure [79, 80]. Furthermore, it is crucial
during the initial stages of biofilm development and has e ects on host-microbe interactions
[81–84].
The production of poly-1,6-GlcNAc in E. coli is dependent on the pgaABCD operon [48]
and is regulated by CsrA and NahR. The level of poly-1,6-GlcNAc is posttranscriptionally
repressed by the carbon storage regulator CsrA that binds to the coding region of pgaA
mRNA [50, 85]. Poly-1,6-GlcNAc synthesis requires the DNA-binding protein NahR, which
activates the pgaABCD transcription in response to high pH and high Na+ concentrations
[86].
The pgaABCD operon encodes for four proteins, that are responsible for the synthesis and
export of poly-1,6-GlcNAc. PgaC is a glycosyltransferase and has five predicted transmem-
brane helices anchoring the protein in the inner membrane and exposing a soluble domain
to the cytoplasm. Glycosyltransferases are involved in the synthesis of sugar chains and
in the biosynthesis of glycoproteins and glycolipids. They transfer a monosaccharide from
an activated sugar donor, for example UDP-GlcNAc, to a saccharide, a protein or a lipid.
Generally glycosyltransferases fold into a eight stranded —-sheet flanked by –-helices. For
catalysis, a metal ion is required [87]. In vivo experiments have shown, that PgaC is essential
for poly-1,6-GlcNAc accumulation [88].
PgaD is a small 137 amino acid containing inner membrane protein with two predicted
transmembrane helices at its N-terminus. For PgaD, no structural related proteins could
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be found. Like PgaC, PgaD is required for the poly-1,6-GlcNAc synthesis [88]. The ho-
mologue of PgaD, HmsS in Yersinia pestis, is no longer able to produce poly-1,6-GlcNAc,
if conserved residue in the predicted transmembrane helix 2 are mutated [89]. Thus, this
membrane spanning region might be a putative binding site for PgaC to promote the gly-
cosyltransferase activity. Very recent studies have shown, that PgaD interacts with PgaC
in a c-di-GMP dependent manner and that this interaction is required for the synthesis of
poly-1,6-GlcNAc (S. Steiner, unpublished data).
The 672 amino acid containing PgaB has a 28 amino acid signal sequence containing a lipo
box, which anchors the protein in the outer membrane by a lipid anchor. PgaB has an N-
terminal deacetylation domain and a C-terminal domain of unknown function. Polysaccha-
ride deacetylases cleave acetyl groups from sugars and thereby modify cell surface properties
and play a role in the protection against host defences [90–92]. Deacetylases fold in a TIM-
barrel with the active site at the C-terminal ends of the —-sheet [93]. Most of them require
a metal ion for catalysis [94, 95]. PgaB needs both domains for the export of the poly-1,6-
GlcNAc chains to the cell surface [88]. Because the active site residues of the deacetylation
domain are essential for the export of the poly-1,6-GlcNAc, deacetylation is required for the
transport through the outer membrane [88]. The deacetylation level was measured either
with NMR resulting in 3% deacetylated sugar groups [48] or with a ninhydrin assay which
gave a deacetylation level of 22% [88].
The last member of the pgaABCD operon is the outer membrane protein PgaA. It contains
807 amino acids including a 33 amino acid long signal sequence for the transport to the
outer membrane. In addition to the C-terminal membrane domain, that is predicted to
form a 16-stranded —-barrel, PgaA contains a large N-terminal soluble tetratrico peptide
repeat (TPR) domain. The TPR domain consists of a 34 amino acid motif, which folds
into two antiparallel –-helices linked by a turn. This motif occurs in tandem of three to 16
copies, where adjacent repeats stack in a parallel fashion. This domain is found in a variety
of proteins, where it is involved in protein-protein interactions. In vivo studies have shown,
that PgaA is essential for the export of poly-1,6-GlcNAc [88].
In Figure 1.4, a model of the proteins arrangement from the pgaABCD operon is shown.
The inner membrane proteins PgaC and PgaD are essential for the synthesis of the sugar
chain and these proteins interact probably via their transmembrane helices. So far, it is not
clear how the sugar chain that is synthesized in the cytosol crosses the inner membrane.
The poly-1,6-GlcNAc might be passed through a pore formed by the transmembrane helices
of PgaC and PgaD. In the periplasm, poly-1,6-GlcNAc is partially deacetylated by PgaB.
As PgaB and PgaA are needed for the export of the sugar chain, it is likely that PgaB
binds to the TPR domain of PgaA, which is known to mediate protein-protein interactions
in other TPR-domain containing proteins.
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Figure 1.4: Model of the synthesis and export of poly-1,6-GlcNAc by the proteins from the pgaABCD
operon. The orange asterisks mark deacetylated sugar groups. (OM: outer membrane,
IM: inner membrane).
1.9 Chemical and enzymatic synthesis of c-di-GMP
In order to carry out extensive studies on c-di-GMP mediated processes, su cient supply
of this compound is crucial. The chemical synthesis of c-di-GMP is a multistep reaction
process, which makes it time consuming and expensive [3, 26, 96–100]. Most of them make
use of phosphotriester, phosphoamidite or H-phosphonate chemistry, which is based on air
or water sensitive reagents. The purification of synthetic c-di-GMP involves several chro-
matographic steps and results in very low product yield.
In contrast, enzyme catalyzed synthesis of c-di-GMP from GTP by DGCs is straightforward
and e cient. In vitro enzymatic production of c-di-GMP has been described by the use of
the DGCs PleD, VCA0956 and WspR [32, 34, 69, 101, 102]. However, all these DGCs show
allosteric inhibition at micromolar product concentration and poor stability after purifica-
tion, which do not qualify them for the production of large amounts of the second messenger.
Recently, a thermophilic DGC has been described for the enzymatic synthesis of c-di-GMP.
In order to improve thermostability, only the DGC domain of the protein was used, and
product inhibition was avoided by site directed mutagenesis of the allosteric site [103].
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1.10 Aims of this work
Structural and enzymatic characterizations of diguanylate cyclase have already been initi-
ated earlier and provided insights in the catalysis and in the product inhibition of DGCs.
Major work was done on the DGCs PleD from C. crescentus and WspR from P. aeruginosa,
which both contain a REC domain as the N-terminal sensory domain. These DGCs are
regulated by phosphorylation of the REC domain followed by dimerization to receive active
protein. Several DGCs harbor undefined N-terminal domains and it is poorly understood,
wether these domains are able to form permanent dimers or wether dimer formation is
regulated by input signals. A few crystal structures of DGCs are available and illuminate
substrate and product binding in the active site. However, a structure of a catalytically
competent DGC dimer is still missing. Structural and enzymatic studies showed, that most
DGCs are allosterically product inhibited by the crosslinking of domains in an unproductive
state. In the Ip-site a conserved RxxD-motif is involved. However it is unclear, if DGCs
lacking this motif are also product inhibited.
In the present thesis, the DGC YdeH from E.coli was used to gain more information in
general by applying structural and biochemical approaches. The main focus was on crystal-
lizing YdeH to obtain structural information of the competent state and on the N-terminal
sensory domain. All experiments were carried out to elucidate the following questions: Is
YdeH an active diguanylate cyclase in vitro? Is it a permanent dimer? Does it show product
inhibition, although it has a slightly di erent primary inhibition motif? What is the input
signal for YdeH and how is YdeH regulated?
Furthermore, a protocol for the enzymatic production and purification of c-di-GMP should
be developed to generate large amounts of c-di-GMP, that is needed to carry out in vitro
research on c-di-GMP related topics.
The second part of the thesis deals with PgaA and PgaB, two proteins from the pgaABCD
operon, which is involved in c-di-GMP dependent exopolysaccharide production. A proto-
col for the expression and purification of these two proteins should be developed to carry
out structural and biochemical investigations. The questions addressed in this part of the
present thesis were the following: Can a protein-protein interaction between PgaA and PgaB
be demonstrated to prove the model for the export of the sugar chain? Is PgaB an active
deacetylase? The main objective was to obtain the crystal structures of PgaA and PgaB. It
is likely that the crystal structure of PgaA will help to get more precise information about
the export mechanism of the sugar. Furthermore, the structure of PgaB will analyze the
deacetylation process in detail and will probably provide more insights into the function of
its so far unidentified C-terminal domain. Furthermore both proteins are promising drug
targets and therefore structural information of both proteins is of specific pharmaceutical
interest.
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2.1 Cloning
Cloning of individual domains of YdeH
Coding regions corresponding to YdeHCZB (residues 1-126) and YdeHGGDEF (residues 127-
296) from E. coli were amplified by standard polymerase chain reaction (PCR) using the
YdeH containing plasmid pET28a/YdeH produced by Dr. A. Böhm as template DNA [47].
The DNA inserts were cloned into the pET28a expression plasmid (Novagen), yielding C-
terminally hexahistidine-tagged proteins.
Mutagenesis
YdeH mutants were generated using the QuikChange II Site-directed Mutagenesis Kit (Agi-
lent Technologies) based on the pET28a/YdeH plasmid according to manufacturers instruc-
tions.
Cloning of PgaA
The coding region corresponding to PgaA from E.coli with and without the signal sequence
as well as the coding region corresponding to the soluble TPR domain of PgaA (residues 33
- 519) were amplified by colony PCR using the E. coli strain MG1655 as template. DNA in-
serts containing full-length PgaA including the signal sequence were cloned in the expression
plasmids pET28a (Novagen) and pColdIV (Takara) yielding C-terminally hexahistidine-
tagged protein. DNA inserts of PgaA without the signal sequence were cloned into the
expression plasmids pET22b (Novagen) generating C-terminally hexahistidine-tagged pro-
tein, into pMal-p5X plasmid (NEB) yielding N-terminally MBP fusion protein and in the
pET40b plasmid (Novagen) resulting in N-terminally hexahistidine-tagged DsbC fusion pro-
tein. The MBP moiety and the hexahistidine-tagged DsbC moiety were cleavable by Factor
Xa or thrombin, respectively.
Cloning of PgaB
The coding region corresponding to PgaB from E.coli without the lipid anchor (residues
22-651) was amplified by colony PCR using the E. coli strain MG1655 as template. DNA
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inserts were cloned in the expression plasmids pET21b (Novagen) and pET28a (Novagen)
yielding N-terminally and C-terminally hexahistidine-tagged protein, respectively.
2.2 Protein production
2.2.1 Protein expression
Expression tests of YdeH
The pET28a/YdeH plasmid was transformed in di erent E.coli strains BL21(DE3)pLysS
(Novagen), BL21(DE3)pGroEL, Rosetta(DE3) (Novagen) and ArcticExpress(DE3) (Agi-
lent Technologies). 50mL LB-medium supplemented with antibiotics was inoculated with
overnight culture to a starting OD600 of 0.1. The cells were grown at 37 . At an
OD600 of 0.7, the protein expression was induced with 1mM IPTG (isopropyl-—-D-1-
thiogalactopyranoside). For the expression test at lower temperatures, cells were grown
at 37  until an OD600 of 0.5 was reached before temperature was reduced to 18 . Be-
fore and at several time points after induction samples were taken, which were centrifuged
(10 000 g, 10min, room temperature) and the cell pellet was resuspended in YdeH-Ni-A-
bu er (50mM NaH2PO4, pH 7.5, 200mM NaCl, 10mM imidazole, 50mM L-glutamic acid,
50mM L-arginine), where the volume of the used bu er corresponds to the cell density of
the sample. The cells were lysed by sonication and centrifuged (10 000 g, 10min, RT). The
supernatant containing the soluble protein fraction, was loaded on an SDS-PAGE to follow
YdeH expression.
Expression of YdeH
YdeH was produced using the E.coli Rosetta(DE3) strain transformed with the
pET28a/YdeH plasmid. Cells were cultivated at 37  in LB-medium supplemented with
kanamycin (100mg/mL) and chloramphenicol (34mg/mL) until the OD600 had reached 0.7.
Gene expression was induced by adding 1mM IPTG. After 4 h of incubation, the cells were
harvested by centrifugation (6800 g, 10min, 4 ) and the pellets were frozen at ≠20 .
Expression of individual domains of YdeH
Individual domains of YdeH were expressed in the E.coli Rosetta(DE3) strain transformed
with the plasmids pET28a/YdeHCZB or pET28a/YdeHGGDEF. Cells were grown in LB-
medium supplemented with kanamycin (100mg/mL) and chloramphenicol (34mg/mL) at
37  until the OD600 had reached 0.5. The temperature was then reduced to 18  and
gene expression was induced by adding 1mM IPTG. After 20 hours, cells were harvested by
centrifugation (6800 g, 10min, 4 ) and the pellets were frozen at ≠20  for further use.
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Expression of selenomethionine labeled YdeHCZB
Selenomethionine substituted YdeHCZB was expressed in the auxotrophic strain B834(DE3)
(Novagen) in LeMaster-medium [104]. Overnight culture, grown in LB-medium supple-
mented with kanamycin (100mg/mL) and chloramphenicol (34mg/mL) was centrifuged
(4200 g, 10min, 4 ) and resuspended in LeMaster-medium. After a second centrifugation
step, the cells were again resuspended in LeMaster-medium and used for inoculation of the
main culture (LeMaster-medium supplemented with kanamycin (100mg/mL) and chloram-
phenicol (34mg/mL)). The bacterial culture was incubated at 37  until the OD600 had
reached 0.6, after which the temperature was reduced to 18  and gene expression was in-
duced by adding 1mM IPTG. Incubation was continued for 20 h, before cells were harvested
by centrifugation (6800 g, 10min, 4 ) and frozen at ≠20  for further use.
Expression tests of PgaA
PgaA containing expression plasmids were transformed in di erent E.coli strains. 125mL
LB-medium supplemented with antibiotics was inoculated with 1mL overnight culture.
Cells were grown at 37 . At an OD600 of 0.7, protein expression was induced with 1mM
IPTG. For the expression test at lower temperatures, cells were grown at 37  until an OD600
of 0.5 was reached before the temperature was reduced to 18 . Before and at several time
points after induction 25mL samples were taken, which were centrifuged (4500 g, 10min,
4 ) and the cell pellets were resuspended in 8mL extraction-bu er (50mM NaH2PO4,
pH 7.5, 200mM NaCl). Cells were lysed with a French press at 15 000 psi and centrifuged
(4500 g, 15min, 4 ) to remove unbroken cells and inclusion bodies. The supernatant was
ultracentrifuged (100 000 g, 30min, 4 ) to collect the total membrane fraction that was
resuspended in 1mL extraction-bu er. After solubilization of the inner membrane fraction
by addition of 1% N-lauroyl sarcosine, the outer membrane fraction was pelleted by ul-
tracentrifugation (107 000 g, 20min, 4 ) and resuspended in 1mL extraction-bu er. PgaA
was extracted from the outer membrane with 0.2% lauryldimethylamine-oxide (LDAO). An
additional centrifugation step (107 000 g, 20min, 4 ) was performed to remove the residual
membrane. 15µL supernatant, containing PgaA extracted from the outer membrane, were
loaded on an SDS-PAGE to follow the expression.
Expression of PgaA
PgaA was produced using the E.coli BL21(DE3) strain transformed with the pET28a/PgaA
plasmid. Cells were cultivated at 37  in LB-medium supplemented with kanamycin
(100mg/mL) until the OD600 had reached 0.7. Protein expression was induced by adding
1mM IPTG. After 3 h of incubation, cells were harvested by centrifugation (6800 g, 10min,
4 ) and the pellets were frozen at ≠20 .
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DsbC-PgaA fusion protein was expressed in BL21(DE3) cells containing the pET40b/PgaA
plasmid. Cells were grown at 37  in LB-medium supplemented with kanamycin
(100mg/mL) and chloramphenicol (34mg/mL) until the OD600 had reached 0.5. Tem-
perature was reduced to 18  and protein expression was induced with 0.1-1mM IPTG.
After 20 h of incubation, cells were harvested by centrifugation (6800 g, 10min, 4 ) and
pellets were frozen at ≠20 .
Expression tests of PgaATPR
The pET28a/PgaATPR plasmid was transformed in di erent E.coli strains BL21(DE3) (No-
vagen), BL21(DE3)pLysS (Novagen), Rosetta(DE3) (Novagen), C43(DE3) (Lucigen) and
ArcticExpress(DE3)(Agilent Technologies). 50mL LB-medium supplemented with antibi-
otics were inoculated with 1mL overnight culture. Cells were grown at 37 . At an OD600
of 0.7, protein expression was induced with 1mM IPTG. For the expression test at lower
temperatures, cells were grown at 37  until an OD600 of 0.5 was reached before tempera-
ture was reduced to 18 . Before and at several time points after induction, samples were
taken, which were centrifuged (10 000 g, 10min, RT) and the cell pellet was resuspended
in 8mL 50mM NaH2PO4, pH 7.5, 200mM NaCl. Cells were lysed with a French press at
15 000 psi and centrifuged (4500 g, 15min, RT) to remove unbroken cells and inclusion bod-
ies. The supernatant, containing the soluble protein fraction, was loaded on an SDS-PAGE
to follow PgaATPR expression.
Expression of PgaATPR
PgaATPR was produced using the E.coli Rosetta(DE3) strain transformed with the
pET28a/PgaATPR plasmid. Cells were cultivated at 37  in LB-medium supplemented with
kanamycin (100mg/mL) and chloramphenicol (34mg/mL) until the OD600 had reached 0.5.
Temperature was reduced to 18  and protein expression was induced with 1mM IPTG.
After 20 h of incubation, cells were harvested by centrifugation (6800 g, 10min, 4 ) and
the pellets were frozen at ≠20 .
Expression tests of PgaB
pET21b/PgaB and pET28a/PgaB were transformed in di erent E. coli strains BL21(DE3)
(Novagen), BL21(DE3)pLysS (Novagen), Rosetta(DE3) (Novagen), C43(DE3) (Lucigen)
and ArcticExpress(DE3)(Agilent Technologies). 125mL LB-medium supplemented with
antibiotics were inoculated with 1mL overnight culture. Cells were grown at 37 . At
an OD600 of 0.7 protein expression was induced with 1mM IPTG. For the expression test
at lower temperatures, cells were grown at 37  until an OD600 of 0.5 was reached before
temperature was reduced to 18 . Before and at several time points after induction, 25mL
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samples were taken, which were centrifuged (10 000 g, 10min, RT) and the cell pellet was
resuspended in 8mL 50mM NaH2PO4, pH 7.5, 200mM NaCl. Cells were lysed with a
French press at 15 000 psi and centrifuged (4500 g, 15min, RT) to remove unbroken cells
and inclusion bodies. The supernatant, containing the soluble protein fraction, was loaded
on an SDS-PAGE to follow PgaB expression.
Expression of PgaB
PgaB was produced using the E.coli BL21(DE3) strain transformed with the pET21b/PgaB
plasmid or using the E.coli Rosetta(DE3) strain transformed with the pET28a/PgaB
plasmid. Cells were cultivated at 37  in LB-medium supplemented with ampicillin
(100mg/mL) or with kanamycin (100mg/mL) and chloramphenicol (34mg/mL), respec-
tively until the OD600 had reached 0.5. Temperature was reduced to 18  and protein
expression was induced with 1mM IPTG. After 20 h of incubation, cells were harvested by
centrifugation (6800 g, 10min, 4 ) and the pellets were frozen at ≠20 .
2.2.2 Protein purification
Purification of YdeH
Prior to lysis, the frozen cell pellets were thawed and resuspended in YdeH-Ni-A bu er
(50mM NaH2PO4, pH 7.5, 200mM NaCl, 10mM imidazole, 50mM L-glutamic acid, 50mM
L-arginine). After addition of DNAse (2.5mg/mL) and EDTA-free protease-inhibitor cock-
tail (Roche, 1 tablet/50mL bu er), cells were disrupted with a French press at 15 000 psi.
The lysate was cleared by centrifugation (28 000 g, 45min, 4 ), and the supernatant was
filtered (0.22µm) and loaded onto a 5mL HisTrap column (GE Healthcare). After washing
the column with YdeH-Ni-A bu er (10 column volumes (CV)), the protein was eluted with
a linear gradient of imidazole from 10 to 500mM in 10CV. YdeH containing fractions were
pooled and concentrated to 1mL and further purified by size-exclusion chromatography us-
ing a HiLoad-16/60-Superdex-75 prep grade column (GE Healthcare) and YdeH-GF bu er
(20mM Tris-HCl, pH 7.6, 150mM NaCl, 50mM L-glutamic acid, 50mM L-arginine). The
purification process was monitored by SDS-PAGE. Protein concentration was determined
by measuring the absorbance at 280 nm (‘280 = 39 880M≠1cm≠1).
Purification of individual domains of YdeH
For the purification of individual domains of YdeH (YdeHCZB and YdeHGGDEF) the same
procedure as described above for full-length YdeH was used.
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Table 2.1: Detergents and concentrations used for the stepwise extraction of PgaA from the outer
membrane.
Detergent Concentration %
Step 1 Step 2 Step 3 Step 4
DM 0.15 0.3 0.6 1
DDM 0.01 0.02 0.03 0.04
LDAO 0.05 0.1 0.2 0.3
OG 0.5 1 2 3
OPOE 0.5 1 2 3
C12E9 0.005 0.01 0.02 0.04
FOS-12 0.1 0.2 0.3 0.4
Cymal-6 0.04 0.08 0.15 0.3
Purification of selenomethionine labeled YdeHCZB
Purification of selenomethionine labeled YdeHCZB was done with the same protocol as for
wildtype YdeHCZB, but with 0.5mM Tris-(carboxyethyl)phosphine (TCEP) added to all
bu ers.
Extraction test of PgaA
Cells were resuspended in 8mL extraction-bu er (50mM NaH2PO4, pH 7.5, 200mM NaCl),
lysed with a French press at 15 000 psi and centrifuged (4500 g, 15min, 4 ) to remove un-
broken cells and inclusion bodies. The supernatant was ultracentrifuged (100 000 g, 30min,
4 ) for collection of the total membrane fraction, that was resuspended in 1mL extraction-
bu er. After solubilization of the inner membrane fraction by addition of 1% N-lauroyl sar-
cosine, the outer membrane fraction was pelleted by ultracentrifugation (107 000 g, 20min,
4 ). For the stepwise extraction of PgaA from the outer membrane di erent detergents us-
ing increasing concentrations were tested, which are listed in Table 2.1. Therefore, the outer
membrane was resuspended in 1mL extraction bu er supplemented with the corresponding
detergent. After centrifugation (107 000 g, 20min, 4 ), the pellet was again resuspended
in 1mL extraction bu er containing a higher detergent concentration (see Table 2.1). This
extraction step was repeated two more times. The supernatant of each extraction step was
loaded on an SDS-PAGE to follow the extraction of PgaA from the outer membrane.
To find the optimal bu er composition for the extraction of PgaA from the outer mem-
brane, the extraction was performed in one step with 0.5% LDAO in the following di erent
extraction bu ers: 100mM MES, pH 6.5, 100mM Na2HPO4, pH 7.5, 100mM Tris-HCl, pH
8.0 or 100mM Bicine, pH 9.0 with and without 200mM NaCl.
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Purification of PgaA
Prior to lysis, the frozen cell pellets from 5L culture were thawed and resuspended in 50mL
extraction bu er (100mM NaH2PO4, pH 8.0, 200mM NaCl). After addition of DNAse
(2.5mg/mL), cells were disrupted with a French press at 15 000 psi. Two centrifugation steps
(4500 g, 15min, 4  followed by 100 000 g, 30min, 4 ) allowed the elimination of unbroken
cells and inclusion bodies and subsequent collection of the total membrane fraction that
was resuspended in 40mL extraction bu er. After solubilization of the inner membrane
fraction by addition of 1% N-lauroyl sarcosine, the outer membrane fraction was pelleted
by ultracentrifugation (107 000 g, 20min, 4 ) and resuspended in 20mL extraction bu er.
PgaA membrane extraction was achieved by stepwise solubilization of the outer membrane
using increasing detergent concentrations (from 0.05% to 0.5%) of LDAO. Solubilized PgaA
was filtered (0.22µm) and loaded onto a 5mL HisTrap column (GE Healthcare) in a circle
for 18 h. After washing the column with extraction bu er containing 0.1% LDAO (10CV),
protein was eluted with a linear gradient of imidazole from 0 to 500mM in 10CV. PgaA
containing fractions were pooled and concentrated to 0.5mL and further purified by size-
exclusion chromatography using a Superdex-200 10/30 column (GE Healthcare) and PgaA-
GF bu er (20mM Tris-HCl, pH 8.0, 150mM NaCl, 0.1% LDAO). The purification process
was monitored by SDS-PAGE. Protein concentration was determined by measuring the
absorbance at 280 nm (‘280 = 200 420M≠1cm≠1).
Purification of PgaA as DsbC fusion
For the purification of DsbC-PgaA the same procedure as for PgaA was used as described
above.
Purification of PgaATPR
Prior to lysis, the frozen cell pellets were thawed and resuspended in PgaATPR-Ni-A bu er
(50mM NaH2PO4, pH 7.5, 200mM NaCl, 10mM imidazole, 50mM L-glutamic acid, 50mM
L-arginine). After addition of DNAse (2.5mg/mL), cells were disrupted with a French
press at 15 000 psi. The lysate was cleared by centrifugation (28 000 g, 45min, 4 ), and the
supernatant was filtered (0.22µm) and loaded onto a 5mL HisTrap column (GE Healthcare).
After washing the column with PgaATPR-Ni-A bu er (10CV), protein was eluted with a
linear gradient of imidazole from 10 to 500mM in 10CV. PgaATPR containing fractions
were pooled and concentrated to 1mL and further purified by size-exclusion chromatography
using a HiLoad-26/60-Superdex-200 prep grade column (GE Healthcare) and PgaATPR-
GF bu er (20mM Tris-HCl, pH 8.0, 150mM NaCl, 50mM L-glutamic acid, 50mM L-
arginine). The purification process was monitored by SDS-PAGE. Protein concentration
was determined by measuring the absorbance at 280 nm (‘280 = 99 000M≠1cm≠1).
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Purification of PgaB
Prior to lysis, the frozen cell pellets were thawed and resuspended in PgaB-Ni-A bu er
(50mM NaH2PO4, pH 7.5, 200mM NaCl, 10mM imidazole). After addition of DNAse
(2.5mg/mL), cells were disrupted with a French press at 15 000 psi. The lysate was cleared
by centrifugation (28 000 g, 45min, 4 ), and the supernatant was filtered (0.22µm) and
loaded onto a 5mL HisTrap column (GE Healthcare). After washing the column with
PgaB-Ni-A bu er (10CV), protein was eluted with a linear gradient of imidazole from 10
to 500mM in 10CV. PgaB containing fractions were pooled and concentrated to 3mL
and further purified by size-exclusion chromatography using a HiLoad-26/60-Superdex-200
prep grade column (GE Healthcare) and PgaB-GF bu er (50mM HEPES, pH 7.5, 50mM
NaCl). The purification process was monitored by SDS-PAGE. Protein concentration was
determined by measuring the absorbance at 280 nm (‘280 = 47 220M≠1cm≠1).
2.3 Protein biochemistry
2.3.1 Zinc removal from YdeH
To obtain zinc-free protein, YdeH (1mg/mL) was incubated with 50mM ethylenediaminete-
traacetic acid (EDTA) for 16 h at 4 . To remove the chelator, a gel filtration was per-
formed using a HiLoad-16/60-Superdex-75 prep grade column (GE Healthcare) with 20mM
Tris-HCl, pH 7.6, 150mM NaCl, 50mM L-glutamic acid and 50mM L-arginine as running
bu er.
2.3.2 PAR assay
To control the release of zinc from YdeH after treatment with EDTA, the amount of zinc
bound to the protein was measured with a PAR assay [105]. Therefore 5µM YdeH was
incubated in 50mM Tris-HCl, pH 8.0 with 6M guandinium hydrochloride and 0.5mM
methylmercury(II)acetate for 16 h. After addition of 100µM 4-(2-pyridylazo)resorcinol
(PAR), the absorption at 495nm was measured. The zinc content was quantified with
a ZnCl2 standard.
To measure the amount of zinc in solution, a variation of the PAR assay was used. The
procedure was the same as described above, but the addition of guandinium hydrochloride
and methylmercury(II)acetate was omitted.
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DGC activity measurement using ion-exchange chromatography
To test for diguanylate activity, 2µM purified YdeH was incubated with 100µM GTP in
50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mM MgCl2. The reaction was stopped after
2 or 15min by heating the sample to 99  for 2min. Subsequently, 100µL of the reaction
mixture were diluted in 900µL 5mM NH4HCO3, pH 8.0, filtered (0.22µm) and loaded on
an ion-exchange column (ResourceQ 1µL, GE Healthcare). The nucleotides were separated
with a gradient from 0.005 to 1M NH4HCO3, pH 8.0, in 14CV. The elution of the reaction
was compared to the elution profiles of GTP (Sigma) and c-di-GMP (Biolog, Bremen).
The reaction product of YdeH was further analyzed by high-performance liquid chromatog-
raphy coupled to mass spectrometry. For this, the samples were diluted with 10mM
NH4OAc, pH 6.4, and injected into a SupercosilTM LC-18-T column (Supelco). The run was
performed at a flow rate of 0.7mL/min using a linear gradient (50%) of acetonitrile. The
electron spray ionization mass spectrometry with a time-of-flight analyzer was performed
using a microTOF Focus system (Bruker Daltronics). The capillary voltage was 4500V,
and the end-plate o set was 500V (negative mode); the dry temperature was 200 , the
dry gas flow was 9L/min, and the nebulizer pressure was 2bar.
DGC activity measurement with a colorimetric assay
To measure initial velocities of YdeH under various conditions, enzymatic activity was mea-
sured with the Baykov assay [106]. This coupled spectrophotometric assay quantifies the
amount of pyrophosphate, the by-product of the cyclization reaction. Therefore, the re-
action mixture contained YdeH in 50mM Tris-HCl, pH 8.0, 50mM NaCl, 5mM MgCl2,
500milliunits/mL pyrophosphatase from bakers yeast (Sigma) and GTP. In order to stop
the reaction at di erent time points, a 100µL sample was transferred into 900µL phos-
phate detection solution (0.55M H2SO4, 0.46mMmalachite green, 2.66mM (NH4)6Mo7O24,
0.04% Tween) and the absorption was measured at 630nm 10min after incubation. The
production of phosphate was quantified with a phosphate calibration curve.
To determine KM and vmax, 2µM zinc-free YdeH was incubated with di erent concentra-
tions of GTP (5-100µM). The measured initial velocities were plotted against GTP concen-
trations and fitted with a simple Michaelis-Menten curve. Product inhibition of YdeH was
measured by mixing 1µM zinc-free YdeH with di erent c-di-GMP concentrations (0-2mM)
and 100 or 500µM GTP. The measured initial velocities were plotted against c-di-GMP
concentrations and fitted.
The KI of the zinc binding was measured with a competition experiment of EDTA and
YdeH using the activity measurement with the Baykov assay as readout. Therefore, 0.2µM
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zinc-free YdeH was mixed with 0.2µM ZnCl2 and di erent EDTA concentrations (0.1nM -
1mM). The activity was plotted against the EDTA concentration and the data were fitted
with an exact mathematical model [107] describing competitive binding of EDTA and YdeH
to zinc.
The influence of oxidizing conditions on the activity of YdeH was tested with the Baykov
assay. For this, 1µM YdeH and 1µM ZnCl2 were incubated for 10 or 30min with 5, 50,
500, and 5000µM of the following oxidizing agents: iodacetamide, N-ethylmaleimide, H2O2,
KSCN, NaAsO2, 4-chloromercuribenzoic acid, oxidized glutathione, Paraquat, pyocyanin,
pyocianin/NADH, phenylselenyl chloride and oxidized glutathione/glutathione reductase
from bakers yeast (1U, Sigma). Activity measurement was started by adding 100µM GTP.
2.3.4 Deacetylase activity assay
Preparation of membrane fragments containing PgaC and PgaD was developed by S. Steiner.
Therefore, PgaC and PgaD were produced using the strain AB1638 transformed with the
plasmid pCD-3xF (S. Steiner). Cells were cultivated at 30  in LB-medium supplemented
with ampicillin (100mg/mL) until the OD600 had reached 0.2. Gene expression was induced
by adding 0.2% L-arabinose. After 5 h of incubation, cells were harvested by centrifugation
(6800 g, 10min, 4 ) and the pellets were frozen at ≠20 . Prior to lysis, the frozen cell
pellets from 5L culture were thawed and resuspended in 50mL 50mM HEPES, pH 7.5,
50mM NaCl. After addition of DNAse (2.5mg/mL), cells were disrupted with a French
press at 15 000 psi. Two centrifugation steps (8600 g, 10min, 4  followed by 200 000 g,
60min, 4 ) allowed the elimination of unbroken cells and subsequent collection of the total
membrane fraction that was resuspended in 20mL 50mM HEPES, pH 7.5, 50mM NaCl.
After an additional centrifugation step (200 000 g, 60min, 4 ) the membrane fraction was
resuspended in 1.25mL 50mM HEPES, pH 7.5, 50mM NaCl and stored at ≠80 .
For the enzymatic reaction, 1µM PgaB was incubated for 16 h with 4µL membranes con-
taining PgaC and PgaD and with 2mM UDP-GlcNAc in 50mM HEPES, 50mM NaCl.
Subsequently, the proteins were precipitated by heating the sample to 99  for 15min fol-
lowed by centrifugation (20 800 g, 10min, 4 ). The cleared supernatants were analyzed for
PgaB deacetylase activity by the detection of acetate with a coupled assay based on enzyme
acetate kinase. As readout, the oxidation of NADH to NAD+ was measured. The measure-
ments were performed using the acetic acid kit (K-ACETAK) from Megazyme. Therefore,
143µL supernatant were mixed with 138µL R1 (containing 4mL bottle 1, 4 tablets from
bottle 2, 16mL water) and 19µL R2 (1mL bottle 3, 1.75mL water) in a flat bottom mi-
crotiter plate (falcon) and incubated for 10min at room temperature before the absorption
at 340 nm was measured. The assay was quantified with an acetate calibration curve.
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2.3.5 Analysis of complex formation by gel filtration
2.86nmol PgaATPR were incubated with 2.86 or 8.56nmol PgaB in 0.5mL complex-bu er
(20mM Tris-HCl, pH 8.0, 150mM NaCl) for 1h at room temperature. In other samples,
1mMMgCl2 or 1mM GlcNAc was added to the protein mixture. All samples were analyzed
for complex formation by gel filtration using a Superdex-200 10/30 column (GE Healthcare)
and complex-bu er.
2.3.6 Reductive lysine methylation
1mg/mL PgaB or YdeH in PgaB-GF bu er (50mM HEPES, pH 7.5, 50mM NaCl) was
mixed with 20mM dimethylamine-borane complex and 40mM formaldehyde and incubated
at 4  in the dark. After 1 h, 20mM dimethylamine-borane complex and 40mM formalde-
hyde was added again, mixed and incubated again for 1 h at 4  in the dark. The reaction
was quenched by adding 100mM Tris-HCl, pH 8.0. The sample was filtered, concentrated
to 500µL and purified from aggregates by gel filtration. For PgaB, a Superdex-200 10/30
column (GE Healthcare) and PgaB-GF bu er was used. YdeH was purified using a HiLoad-
16/60-Superdex-75 prep grade column (GE Healthcare) and YdeH-GF bu er (20mM Tris-
HCl, pH 7.6, 150mM NaCl, 50mM L-glutamic acid, 50mM L-arginine).
2.3.7 Limited proteolysis
1mg/mL PgaB was incubated with 5ng/mL or 1ng/mL trypsin, proteinaseK or pepsin in
PgaB-GF bu er (50mMHEPES, pH 7.5, 50mMNaCl) at room temperature. After di erent
time points of 1, 2, 5, 15, 30, 60, 120 and 240min, a 10µL sample was taken and mixed
with 1µL 10mM protease inhibitor 4-(2-aminoethyl)-benzensulfonylfluorid (AEBSF). The
samples were loaded on an SDS-PAGE to follow the proteolytic digestion of PgaB. For large
scale digestion, 20mg PgaB were incubated with 0.1mg trypsin in 20mL PgaB-GF bu er
for 10min at room temperature before proteolysis was stopped by adding 1mM AEBSF.
The sample was concentrated to 3mL and purified by gel filtration using a HiLoad-26/60-
Superdex-200 prep grade column (GE Healthcare) and PgaB-GF bu er.
2.4 X-ray crystallography
2.4.1 Protein crystallization
For protein crystallization, the vapor di usion method was used. Initial screening was per-
formed with commercial screens in 96-well plates using the sitting drop method. For each
drop, 0.2µL protein solution was mixed with an equal amount of reservoir bu er. The
reservoir volume was 75µL. Afterwards the trays were sealed and stored at a constant
temperature of 20 .
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Initial crystallization hits were refined by altering pH, precipitant or salt concentration,
protein concentration and temperature. Refinement was carried out in 24-well plates using
hanging drops on siliconized cover slips, which were sealed with grease. Protein and reser-
voir solutions were mixed, usually in a 1:1 ratio and the drop sizes varied between 2µL and
4µL. The drops were equilibrated against 500µL reservoir bu er.
In order to get complex crystals of YdeH with bound product or substrate analog, cocrys-
tallization experiments were performed. Therefore, the protein solution was mixed with the
corresponding compound and used in subsequent initial screening experiments.
2.4.2 Data collection
For measurements under cryogenic conditions, crystals were mounted in cryo loops and
directly plunged in liquid nitrogen. Prior to freezing, YdeHCZB crystals were successively
placed in reservoir bu er supplemented with 10 and 20% glycerol, using soaking times of
5 sec per bu er. YdeHGGDEF crystals were successively soaked in reservoir solution contain-
ing 10 and 15% glycerol. YdeH crystals were directly frozen from mother liquor without
using any additional cryoprotectant.
Measurements using synchrotron radiation were performed at beamline PXIII at the Swiss
Light Source (Villigen, Switzerland). Single wavelength anomalous di raction data was
collected on a single selenomethionine containing crystal at the selenium absorption peak,
which was determined from a fluorescence scan. For processing and scaling, the XDS pack-
age [108] or MOSFLM/SCALA [109, 110] were used.
2.4.3 Structure determination
Structure determination of YdeHCZB
Phase determination of YdeHCZB was done with the single anomalous data method (SAD)
using the program autoSHARP [111]. Automated model building was carried out with
ARP/wARP [112]. Further model building was performed manually with Coot [113] and
refinement was performed with REFMAC [114] using TLS and NCS restraints. Model
geometry was analyzed using the programs MolProbity [115] and RAMPAGE [116].
Structure determination of YdeHGGDEF
Phase determination of YdeHGGDEF was done by molecular replacement. The program
Phaser was used with chain A of the GGDEF domain of PleD (PDB: 1w25) as search model.
After rigid body refinement with REFMAC [114], the model was rebuilt using AutoBuild
implemented in Phenix [117]. Refinement was done with REFMAC using one TLS group.
Water molecules were placed automatically using Phenix AutoBuild and manually checked
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in Coot [113]. Model geometry was analyzed, using the programs MolProbity [115] and
RAMPAGE [116].
Structure determination of YdeH
Phase determination was done with molecular replacement using the program Phaser [118]
with the CZB domain and the GGDEF domain of YdeH as search models. The model was
manually rebuilt in Coot [113] and was refined with BUSTER [119] using NCS restrains and
two TLS groups per monomer as well as the two individual domains as target restrains in
later stages of refinement. Model geometry was analyzed, using the programs MolProbity
[115] and RAMPAGE [116].
2.4.4 Structure analysis and bioinformatics
Secondary structure was assigned using DSSP [120] and STRIDE [121]. Protein interfaces
were analyzed with the PISA server [122]. Structure superpositions were performed with
SSM [123] and TOPP [124]. Illustrations were made in Pymol (DeLano Scientific). Search
for structural homologous was done with the Dali server [125], and a search for binding
motifs was performed with PDBeMotif [126]. Structure based sequence alignment was done
using the programm ALAdeGAP [127] and illustrated with WebLogo [128] or as conservation
mapping with the program ProtSkin [129]. A model of TlpD was created with MODELLER
[130] based on the structural sequence alignment with YdeHCZB.
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3 Zinc dependent regulation of the
diguanylate cyclase YdeH from E.coli
3.1 Results and Discussion
3.1.1 Design and cloning of YdeH constructs
The plasmid pET28a/YdeH containing the complete sequence of ydeH with a C-terminal
Histag was kindly provided by Dr. A. Böhm, Biozentrum Basel. Several constructs com-
prising the individual domains of YdeH were designed for the study of their biochemical
properties and to apply them in crystallization attempts. Therefore structures of GGDEF
domains in the PDB were analyzed. In all cases, three amino acids in front of the —0, —0’-
hairpin were visible in the structures. Thus the construct of the GGDEF domain of YdeH
was designed to start at this position corresponding to amino acid Ile127. The construct of
the N-terminal CZB domain contained the first 126 amino acids ending with Thr126. These
gene fragments were cloned in the pET28a vector as described in section 2.1.
In order to enhance the success of crystallization, surface entropy reduction mutants of
YdeH were generated [131, 132]. To identify sites that are most suitable for mutation, the
SERp server was used [133]. This server found three sites. The first site contained residues
Glu259 and Glu260, the second site included Lys40 and Glu42 and the third site consisted
of Lys3 and Lys4. Based on this prediction the following point mutants were designed:
E259A-E260A, E259A-E260T, E259T-E260T, E259N-E260N, K40A-K42A and YdeH 1-4.
The mutations were introduced by site-directed mutagenesis using the QuikChange-method
with the pET28a/YdeH plasmid serving as starting vector.
In order to conduct functional studies, mutations of amino acids that may be involved in
activation or inhibition of YdeH were designed and generated by site direct mutagenesis,
using the Quik-Change-method. All constructs and mutations are listed in Table 3.1.
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Table 3.1: YdeH constructs used in this thesis.
Name Feature
pET28a/YdeHa full-length (1-296)
pET28a/YdeHCZB N-terminal CZB domain containing the residues 1-126
pET28a/YdeHGGDEF C-terminal GGDEF domain containing the residues 127-296
pET28a/YdeH-E259A-E260A surface entropy reduction mutant
pET28a/YdeH-E259A-E260T surface entropy reduction mutant
pET28a/YdeH-E259T-E260T surface entropy reduction mutant
pET28a/YdeH-E259N-E260N surface entropy reduction mutant
pET28a/YdeH-K40A-E42A surface entropy reduction mutant
pET28a/YdeH- 1-4 surface entropy reduction mutant
pET28a/YdeH-C52A zinc-binding mutant
pET28a/YdeH-R56A possible Is-site mutant
pET28a/YdeH-R73A possible Is-site mutant
pET28a/YdeH-R87A possible Is-site mutant
pET28a/YdeH-R271A-Y274A possible Is-site mutant
pET28a/YdeH-D174R GGDEF dimer interface mutant
pET28a/YdeH-D174R-R140D GGDEF dimer interface mutant
All constructs contain a C-terminal Histag.
a Kindly provided by Dr. A. Böhm, Biozentrum Basel.
3.1.2 Expression and Purification
Expression of YdeH
Expression tests of YdeH were performed by using di erent E. coli strains at two di erent
temperatures of 37  and 18 . Expression was induced with 1mM IPTG. In most of the
tested conditions, YdeH was expressed highly in inclusion bodies. The best soluble expres-
sion was achieved in the Rosetta(DE3) strain at 37  using 4h of induction. Exemplarily
an expression gel is shown in Figure 3.1.
For protein production, bacteria was cultivated on a 2L or 5L scale with the conditions
established in the expression tests.
Purification of YdeH
YdeH was purified to homogeneity using a two-step purification procedure, consisting of
Ni-a nity and size-exclusion chromatography. After cell lysis with French press, Ni-a nity
chromatography using a Histrap column was performed. A chromatogram of a typical run is
shown in Figure 3.2 and the corresponding SDS-PAGE is shown in Figure 3.3. YdeH is elut-
ing at high imidazole concentrations of about 280mM, which results in almost pure protein.
After Ni-chromatography, YdeH was subjected to gel filtration as a final purification step.
Gel filtration was performed in order to remove aggregates, although the protein was rather
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lane 1: marker
lane 2: before induction
lane 3: 2 h after induction
lane 4: 2 h after induction, soluble fraction
lane 5: 4 h after induction
lane 6: 4 h after induction, soluble fraction
lane 7: 6 h after induction
lane 8: 6 h after induction, soluble fraction
lane 9: 20 h after induction
lane 10: 20 h after induction, soluble fraction
Figure 3.1: SDS-PAGE of the expression test of YdeH in the pET28a vector in Rosetta(DE3) cells.
Expression temperature was 37  and induction was carried out with 1mM IPTG. Same
amount of cells were loaded in each line.
pure already. YdeH ran as one single peak at an elution volume of 60.5mL (Figure 3.4 and
Figure 3.5). According to a calibration curve for the present column, this corresponds to a
molecular mass of 71 kDa. Assuming the mass of one protein chain of 34 kDa, this clearly
indicates that YdeH is a dimeric protein. The final yield was about 5mg/L culture. To
achieve a protein concentration above 0.8mg/mL, the addition of arginine and glutamic
acid to all the bu ers was essential to avoid protein aggregation [134].
For YdeH mutants, the same purification protocol was used. However not all mutants were
expressed solubly, therefore the expression temperature was reduced to 18  and the cells
were induced for 20 h. The elution profiles of the gel filtration were identical for all soluble
expressed mutants, which indicates that the introduced mutations had no e ect on the fold
of YdeH. The individual protein yields of YdeH mutants obtained after purification are listed
in Table 3.2.
Expression and purification of individual domains of YdeH
The protocol for expressing the individual domains of YdeH was adapted from the ex-
pression of the full-length YdeH. Rosetta(DE3) cells grown at 18  for 20 h were chosen,
which yielded soluble protein in good amounts for both constructs (pET28a/YdeHCZB,
pET28a/YdeHGGDEF). For purification, the same procedure as for full-length YdeH was
used, consisting of Ni-a nity chromatography followed by gel filtration. The gel filtration
chromatograms for both constructs are shown in Figure 3.6 and the corresponding SDS gels
are depicted in Figure 3.7. YdeHCZB and YdeHGGDEF ran as a single peak at elution vol-
umes of 71.8mL and 78.7mL, respectively. According to a calibration curve for the present
column, this corresponds to a molecular mass of 36.8 kDa for the CZB domain. The mass of
14.5 kDa per one protein chain indicates that the CZB domain is dimeric. For the GGDEF
domain, a molecular mass of 24.6 kDa was determined with the calibration curve, which
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Figure 3.2: Chromatogram of YdeH purification by Ni-a nity chromatography using a 5mL HisTrap
column. YdeH elutes at an imidazole concentration of 280mM. Fractions pooled and
used for subsequent purification are marked by a line.
lane 1: marker
lane 2: soluble fraction of the cell extract
lane 3: flow through (0-55mL)
lane 4: wash (55-90mL)
lane 5: fraction 104-105mL
lane 6: fraction 108-109mL
lane 7 -10: fractions 117-128mL
Figure 3.3: SDS-PAGE of the YdeH purification by Ni-chromatography. 2µL protein solution were
loaded in lane 2-4 and 10µL in lane 5-10.
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Figure 3.4: Chromatogram of YdeH purification by gel filtration chromatography using a HiLoad-
16/60-Superdex-75 prep grade column. YdeH was separated from minor amounts of
aggregates, which elute at about 40mL. Pooled YdeH fractions are marked by a line.
lane 1: marker
lane 2: load
lane 3-4: fractions 40-44mL
lane 5-10: wash (55-90mL)
lane 5-10: fractions 51-72mL
Figure 3.5: SDS-PAGE of the YdeH purification by gel filtration. 1µL protein solution was loaded
in lane 2 and 10µL in lane 5-10.
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Table 3.2: Expression and purification results of YdeH mutants.
Mutant Expression Yield [mg/L culture]
YdeH wildtype soluble 5
YdeH-E259A-E260A not solublea -
YdeH-E259A-E260T solublea 0.03
YdeH-E259T-E260T solublea 0.4
YdeH-E259N-E260N solublea 0.3
YdeH-K40A-E42A soluble 2.2
YdeH 1-4 solublea 0.2
YdeH-C52A solublea 7.2
YdeH-R56A soluble 3.6
YdeH-R73A soluble 3.0
YdeH-R87A soluble 1.1
YdeH-R271A-Y274A soluble 8.4
YdeH-D174R soluble 6.0
YdeH-D174R-R140D not solublea -
a Expression performed at 18  for 20 h.
is in agreement with the mass of one protein chain of 20.4 kDa. These results show, that
the CZB domain is responsible for YdeH dimerization. The final yield were 22mg/L and
2mg/L culture for YdeHCZB and YdeHGGDEF, respectively.
Expression and purification of selenomethionine incorporated YdeHCZB
Due to the high expression level and a high number of methionine (4 out of 126 amino acids),
the incorporation of selenomethionine was used for phase determination of YdeHCZB. The
insertion of methionine was carried out in the methionine-auxotrophic strain B834(DE3)
in LeMaster-Medium as described in section 2.2.1. The purification was performed under
reducing conditions by adding 0.5mM TCEP in all bu ers. The purification procedure was
the same as for wild type YdeHCZB (see section 3.1.2). The obtained protein was pure and
the final yield was about 2.5mg/L culture. To verify the incorporation of selenomethionine,
mass spectral analysis was performed. In comparison to wildtype YdeHCZB the di erence
in mass was 184Da, which corresponds exactly to four incorporated selenomethionines.
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Figure 3.6: Chromatograms of YdeHCZB and YdeHGGDEF purification by gel filtration chromatog-
raphy using a HiLoad-16/60-Superdex-75 prep grade column. YdeHCZB (black line) and
YdeHGGDEF (grey line) were separated from aggregates, which elute at about 40mL.
lane 1: marker
lane 2: YdeHCZB after gel filtration
lane 3: YdeHGGDEF after gel filtration
lane 4: marker
Figure 3.7: SDS-PAGE of YdeHCZB and YdeHGGDEF after gel filtration. 10µL protein solution were
loaded in each lane.
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3.1.3 Crystallization
Crystallization of full-length YdeH
Many attempts were made to obtain crystals of full-length YdeH. For this, commercial crys-
tallization screens were employed at di erent protein concentrations in 96-well sitting drop
set-ups. All trials are listed in Table 3.3. As the first attempts to obtain crystals of wildtype
YdeH were not successful, YdeH was transferred to YdeH-GF-bu er without the addition
of arginine and glutamate. However, no crystals were growing under such conditions either.
Since YdeH has five cysteines, which could crosslink YdeH and form oligomeric species,
YdeH was crystallized under reductive conditions by adding 0.5mM TCEP to all bu ers
during protein purification. However, no di erence was observed in gel filtration experi-
ments and in precipitation behavior in the crystallization setups.
Thereupon, cocrystallization was tested with the non-reactive substrate analogs ddGTP,
GTP–S and GDP in the presence of magnesium and with GTP and calcium, which inhibits
YdeH. In addition, crystallization set-ups in the presence of the reaction product c-di-GMP
and magnesium were performed, since most of the crystallized DGCs so far have c-di-GMP
bound to the I-site. In these structures, c-di-GMP is involved in domain crosslinking and
thus, stabilizes the proteins by mediating crystal contacts. However, in all cocrystallization
experiments, no crystals could be observed.
To mimic the transition state of the catalytic reaction, an inhibitor (TSA) was designed.
In this state, the formation of the first bond between the two GTP molecules is already
generated, whereas the second bond is not yet formed. The inhibitor TSA should crosslink
the two active sites of the two GGDEF domains and fix them in one conformation. This ar-
rangement should provide more insights into the mechanism of the catalysis. This inhibitor
was synthesized by YdeH from ddGTP and GTP–S as it is described in appendix ??. The
cocrystallization experiments with this inhibitor did not yield any crystals.
Surface entropy reduction mutants were tried to allow crystallization. In these mutants
large hydrophilic residues were changed to smaller residues like alanine, which leads to a
local reduction of conformational entropy and generates contact-forming, conformationally
homogenous surface patches [131, 132]. As the surface charge was reduced along with the
solubility, not all mutants gave enough protein for crystallization experiments. The mutants
K40A-E42A, YdeH 1-4, E259T-E260T and E259N-E260N could be tested in cocrystalliza-
tion experiments with substrate analogs and product as it is listed in Table 3.3. However, no
protein crystals could be obtained from these mutants in the di erent crystallization set-ups.
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Figure 3.8: Chromatogram of YdeH after methylation of surface lysines. A HiLoad-16/60-Superdex-
75 prep grade column was used. Most of the YdeH elutes as aggregates at about 45mL.
The pooled fractions, which were used for crystallization experiments, are marked by a
black line.
A method, which is based on a similar principle, is the methylation of surface lysines [135]:
dimethylated lysines will reduce their interaction with solvent molecules, thereby forcing
them to adopt a more ordered conformation that may facilitate crystallization. Fore this,
YdeH was methylated as described in section 2.3.6 and purified from aggregates by gel fil-
tration. Because of the rather harsh conditions for the methylation, the loss of protein is
high, even by performing the experiment at 4 . Not surprisingly, the major part of YdeH
elutes as aggregates in gel filtration experiments (Figure 3.8). Although the peak containing
YdeH was not well separated from the aggregates, the fractions marked with a line in the
chromatogram were further used for crystallization experiments. However, no crystals of
methylated YdeH could be obtained.
After the structure of the CZB domain of YdeH was solved and showed the presence of a
zinc ion (see section 3.1.6), YdeH was tried to crystallize in the presence of zinc in order to
obtain a homogenous sample, which should crystallize more easily. This did not result in
protein crystals as well.
In addition, a zinc binding mutant C52A was tried to crystallize. For this, initial screening
was performed in the presence of zinc as well as cocrystallization experiments with GTP–S
and c-di-GMP as it is listed in Table 3.3. In the presence of GTP–S, crystals were obtained
in two similar conditions containing 200mM magnesium acetate and 20% PEG 3350 or
200mM calcium acetate and 20% PEG 3350 (Figure 3.9). They grew after three days and
reached their final size after about three weeks. These conditions were refined, but the
crystals could not be reproduced. However, the crystals from the initial screen were large
enough to use them in di raction experiments at the synchrotron.
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3.1.3
Crystallization
continued from previous page
YdeH Concentration
[mg/mL]
Additives Used screens
K40A-E42A 5 5mM c-di-GMP, 5mM MgCl2 Crystal Screen, PEGs Suite, AmSO4 Suite, Index, SaltRx
K40A-E42A 8 5mM c-di-GMP, 5mM MgCl2 Crystal Screen, PEGs Suite, AmSO4 Suite, Index, SaltRx
YdeH 1-4 5 - Crystal Screen, Classics light Suite, PEGs Suite, MPD Suite,
AmSO4 Suite, Wizard I+II, Anions Suite, Cations Suite, Index,
SaltRx, MbClass Suite
E259T-E260T 6.4 - Crystal Screen, PEGs Suite, Wizard I+II, SaltRx
E259N-E260N 5 - Crystal Screen, Wizard I+II, Index
E259N-E260N 8 - Crystal Screen, Wizard I+II, Index
E259N-E260N 5 3mM GTP–S, 5mM MgCl2 Crystal Screen, Wizard I+II, Index
C52A 8 200µM ZnCl2 PACT premier, Structure screen, Crystal Screen, PEGs Suite
C52A 8 200µM ZnCl2, 3mM GTP–S, PACT premier, Structure screen, Crystal Screen, PEGs Suite
5mM MgCl2
C52A 8 200µM ZnCl2, 5mM c-di-GMP,
5mM MgCl2
PACT premier, Structure screen, Crystal Screen, PEGs Suite
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Figure 3.9: Crystals of YdeH-C52A obtained in the initial screening. On the left, crystals were grown
in 200mM magnesium acetate and 20% PEG 3350 and on the right in 200mM calcium
acetate and 20% PEG 3350. In both conditions, 3mM GTP–S, 5mMMgCl2 and 200µM
ZnCl2 was present.
The di culty of getting full-length YdeH crystals might be due to variability in the domain
arrangement. This flexibility may be important for catalysis, but prevents the protein to be
present in one conformation, which usually facilitates crystallization. Recombinant YdeH
is active in solution (section 3.1.10) and elutes as a single peak in gel filtration. The same
results could be obtained after storing YdeH at 4  for 20 days. This indicates, that full-
length YdeH is indeed properly folded and stable. In order to avoid the variability between
the two domains of YdeH, isolated domains, YdeHCZB and YdeHGGDEF, were used to per-
form crystallization trials.
Crystallization of YdeHCZB
Initial crystallization trials with YdeHCZB were set up in 96-well sitting drop trays. The
commercial screens Crystal Screen, Classic light Suite, SaltRx and PEGs Suite were tested
at protein concentrations of 10, 20 and 36mg/mL. Crystals were obtained under a variety
of conditions ranging from pH 4.6 to 8.5. Most of the conditions contained PEG from size
of 2000 to 8000 and an ammonium salt. The obtained crystals are shown in Figure 3.10
and the corresponding conditions are listed in Table 3.4.
In order to get bigger crystals, all the initial conditions were refined by altering pH, PEG
or salt concentration, protein concentration and temperature. The di raction quality of the
refined crystals was tested on the home source. The refined conditions of hit 1, 4, 6, and
12 gave the most promising results and were used for di raction experiments at the syn-
chrotron. The best results were obtained in the condition containing 200mM ammonium
tartrate, 12.5% PEG 3350 with a protein concentration of 34mg/mL at 20 .
Crystallization experiments with the selenomethionine incorporated protein were set up in
24-well plates using the best four conditions (1, 4, 6 and 12) obtained for the wildtype
YdeHCZB. In all four conditions, crystals of SeMet YdeHCZB could be obtained. The best
39
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Table 3.4: Initial crystallization conditions of YdeHCZB.
Hit Protein Condition
concentration
[mg/mL]
1 20 200mM ammonium acetate, 100mM sodium citrate, pH 5.6, 30% PEG 4000
2 36 200mM ammonium acetate, 100mM sodium citrate, pH 5.6, 15% PEG 4000
3 10, 20 200mM ammonium acetate, 100mM sodium acetate, pH 4.6, 15% PEG 4000
4 20, 36 200mM sodium acetate, 100mM sodium cacodylate, pH 6.5, 15% PEG 8000
5 36 800mM sodium citrate
6 10 200mM ammonium tartrate, 20% PEG 3350
7 10, 20 200mM ammonium fluoride, 20% PEG 3350
8 10, 20 200mM ammonium acetate, 20% PEG 3350
9 20 200mM ammonium nitrate, 20% PEG 3350
10 20, 36 200mM ammonium formiate, 20% PEG 3350
11 36 200mM ammonium citrate, 20% PEG 3350
12 20 100mM MES, pH 6.5, 25% PEG 2000 MME
13 36 100mM HEPES, pH 7.5, 700mM sodium citrate
14 20 100mM Bis-Tris propane, pH 7.0, 3.5M sodium formiate
15 10, 20 100mM Tris-HCl, pH 8.5, 3.5M ammonium chloride
di raction could be achieved from crystals using a protein concentration of 30mg/mL grown
in 200mM sodium tartrate, 12.5% PEG 3350 at 20 .
Crystallization of YdeHGGDEF
Initial crystallization trials using YdeHGGDEF at a concentration of 5 and 10mg/mL using
the commercial screens Crystal Screen, Index, PEGs Suite and AmSO4 Suite failed to
produce any crystal. However, the addition of 5mM c-di-GMP and 5mM MgCl2 at a
protein concentration of 5mg/mL yielded crystals in 92 conditions. The crystals grew
under a wide pH range from 4.6 to 9.0 using di erent bu ers. Di erent salts were used and
all PEG sizes were represented along with other precipitants. A variety of crystal forms
could be observed, such as plates, needles, rods, with most of the hits being octahedral
crystals (71). Two conditions, which are listed in Table 3.5 and shown in Figure 3.11,
were refined by varying pH and PEG concentration as well as protein concentration. The
crystals grown in the refined condition 100mM Tris-HCl, pH 8.5, 22.5% PEG 4000 with
5mg/mL YdeHGGDEF gave the best di raction in-house and were used for data collection
at the synchrotron.
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Figure 3.10: Crystals of YdeHCZB obtained in the initial screening. The numbering is the same as
in Table 3.3. Dimension are in µm.
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Table 3.5: Initial crystallization conditions of YdeHGGDEF.
Hit Protein Additive Condition
concentration
[mg/mL]
1 5 5mM c-di-GMP, 5mM MgCl2 100mM HEPES, pH 7.5, 30% PEG 400
2 5 5mM c-di-GMP, 5mM MgCl2 100mM Tris-HCl, pH 8.5, 25% PEG 4000
Figure 3.11: Crystals of YdeHGGDEF, which were obtained in the initial screening and were chosen
for further refinement. The numbering is the same as in Table 3.5. Dimension are in
µm.
3.1.4 Structure determination
Structure determination of YdeHCZB
Data collection
For data collection, a cryoprotection protocol was developed that involved successive trans-
fer of YdeHCZB crystals into reservoir solution supplemented with 10 and 20% glycerol and
were subsequently flash frozen in liquid nitrogen. The soaking time in each drop was kept
as short as possible to minimize osmotic stress.
Because of the absence of a search model for molecular replacement, the single anomalous
di raction method (SAD) on selenomethionine incorporated crystals was chosen. The data
collection was performed at beamline PXIII at the Swiss Light Source (Villigen, Switzer-
land). One high-resolution native dataset and a SAD dataset at the peak wavelength of the
selenium edge (0.9792 A˚) of a SeMet crystal were collected. An X-ray fluorescence scan was
performed to determine the correct wavelength for the SAD experiment.
All di raction data were processed with XDS and scaled with XSCALE [108]. Data collec-
tion parameters and statistics are given in Table 3.6. Indexing was straightforward and the
crystals belonged to the monoclinic space group C2 with two molecules per asymmetric unit
and a solvent content of 48%. Despite the rather low redundancy of the anomalous data,
the signal to noise ratio of the anomalous di erences and the correlation of anomalous dif-
ferences between two randomly chosen subsets were significant up to a resolution of 2.55 A˚
(Table 3.7).
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Table 3.6: Data collection parameters and statistics for the native and SeMet dataset of YdeHCZB.
Native SeMet
Wavelength [A˚] 0.9792 0.9792
Detector MarCCD 225 MarCCD 225
Detector distance [mm] 180 160
Space group C2 C2
Cell axes [A˚] a = 121.46, b = 60.26, c = 38.46 a = 119.07, b = 59.04, c = 37.63
Angles [¶] – = “ = 90, — = 99.04 – = “ = 90,— = 99.12
Resolution [A˚] 50.0-2.20 (2.25-2.20) 50.0-2.55 (2.62-2.55)
Observed reflections a 57817 (7079) 67492 (4933)
Unique reflections a 14022 (1739) 16332 (1159)
Multiplicity 4.1 4.1
Rmerge [%] a 6.9 (39.5) 5.6 (14.2)
I/‡(I)a 14.6 (4.1) 19.1 (10.7)
Completeness [%] a 99.7 (100) 99.0 (100)
Wilson B [A˚2] 38.1 35.0
Protomers per ASU 2 2
VM [A˚3 · Da≠1] 2.39 2.24
Solvent content [%] 48.5 45.1
a Values in parentheses refer to the highest resolution bin.
Table 3.7: Signal-to-noise (S/N) ratio and correlation coe cients (CC) of the anomalous di erences
in the SAD dataset of YdeHCZB.
Resolution 30.0 10.0 6.0 5.0 4.0 3.5 3.1 2.9 2.7 2.6 2.5
shell [A˚] - - - - - - - - - - -
10.0 6.0 5.0 4.0 3.5 3.1 2.9 2.7 2.6 2.5 2.4
S/N ratioa 3.0 3.4 3.0 2.3 1.9 1.7 1.6 1.5 1.3 1.2 1.1
CC [%]b 89 90 87 79 65 64 58 53 46 38 32
aCalculated as the ratio of anomalous di erences to their standard deviations.
bCorrelation coe cient of the anomalous di erences between to subsets.
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Table 3.8: Heavy atom parameters and SAD phasing statistics for YdeHCZB.
Phasing statistics
Resolution range [A˚] 35.0 - 2.2
Phasing power
isomorphous 0.90
anomalous 2.31
Rcullis
isomorphous 0.82
anomalous 0.54
FOM 0.33
Heavy atom site x y z occupancy B-factor [A˚2]
Se1 82.070 3.676 17.061 0.79 30.30
Se2 77.161 10.584 2.078 0.69 32.49
Se3 92.613 0.644 21.618 0.81 38.53
Se4 85.236 8.599 1.099 0.71 32.66
Se5 69.725 2.042 12.548 0.83 46.49
Se6 96.779 10.625 0.475 0.79 41.31
Se7 72.096 11.095 0.918 0.75 43.41
Se8 74.445 2.004 13.256 0.74 49.72
Zn9 29.236 14.827 36.824 0.87 37.08
Zn10 21.707 27.571 17.020 0.79 41.16
Selenium substructure determination and phase determination by SAD
For heavy atom detection and phasing the program autoSHARP [111] was used. A clear
solution with eight selenium atoms was obtained corresponding to the four methionine
residues per protomer. All heavy atoms were refined to occupancies close to unity and
similar isotropic B factors (Table 3.8), indicating nearly complete incorporation during
protein synthesis and a similar degree of order for all SeMet side chains. During refinement
of the heavy atom sites two new sites were detected, which were later modeled as zinc ions.
The first hint that the additional atoms were zinc was given by the fluorescence scan, in
which an anomalous signal was measured at the zinc edge (0.7478 A˚). Later this finding
was confirmed by the typical coordination and bond lengths of zinc. Finally the program
autoSharp performed density modification, which resulted in an electron density map of
high quality that was easily interpretable (Figure 3.12).
Model building and refinement
Automatic model building was performed with ARP/wARP [112], that places 195 out of 264
residues in the electron density. Loops were manually built with Coot [113] in the electron
density belonging to the protomer B, which was judged to be better defined as protomer A.
44
Figure 3.12: Experimental electron density for YdeHCZB after SAD phasing and density modification.
Electron density map at 1.5‡ contour level is shown together with residues 25-35 of the
final model.
Monomer A was deleted and newly generated from protomer B by application of the NCS
operator. This model of the YdeHCZB dimer was subjected to a first round of refinement in
REFMAC [114]. Strong NCS restraints were used in early stages of refinement, but loosened
later on. Both monomers exhibited strong di erence density, which was filled with a zinc
ion. In further rounds of rebuilding and refinement, TLS parameterization was added in
form of one group per protomer and water molecules were added in Coot. This resulted in
a final model of YdeHCZB with R and Rfree values of 21.1% and 24.6%, respectively (Table
3.9).
Validation of the YdeHCZB model
The refined model of YdeHCZB consists of a two-fold symmetric dimer. The electron density
was well defined for the whole main chain except for a 14 residue segment (38-51) of chain
A as well as for the first four residues of chain A and the first five residues of chain B.
Refinement progress was followed by monitoring the values of R and Rfree and checking for
model geometry. The final statistics are given in Table 3.9. The values for the R-factors
were reasonable for the resolution of 2.2 A˚ and the RMS deviations of bond lengths and
angles were in the standard range. All main chain torsion angles lay in the allowed regions
of the Ramachandran plot, with most of them in the favored region (Figure 3.13).
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Table 3.9: Refinement statistics for the YdeHCZB model.
Resolution[A˚] 2.2
Space group C2
R [%] 21.1
Rfree [%] 24.6
Number of atoms
protein 1844
water molecules 61
zinc 2
B factors
main chain A / main chain B 32.3 / 32.7
side chain A / side chain B 33.9 / 34.6
zinc 23.3
water molecules 34.9
RMS deviations
bond lengths [A˚] 0.012
bond angles [¶] 1.206
Ramachandran statistics [%]
in favored regions 98.6
in allowed regions 1.4
Figure 3.13: Ramachandran diagram for YdeHCZB. Main chain torsion angles were analyzed with
RAMPAGE [116] and are indicated for each residue by crosses (glycines) or squares
(all others). Dark and light background shading indicates energetically favorable and
allowed regions, respectively. (A) General plot for all non-glycine residues. (B) Special
plot for glycine residues. (C, D) Plots for pre-proline and proline residues, respectively.
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Table 3.10: Data collection parameters and statistics of YdeHGGDEF.
Wavelength [A˚] 0.979
Detector MarCCD 225
Detector distance [mm] 180
Space group P62
Cell axes [A˚] a = b = 79.62, c = 51.21
Angles [¶] – = — = 90, “ = 120
Resolution [A˚] 50.00-1.80 (1.90-1.80)
Observed reflections a 216535 (30101)
Unique reflections a 17292 (2509)
Multiplicity 12.5
Rmerge [%] a 7.5 (34.6)
I/‡(I)a 24.1 (7.6)
Completeness [%] a 100 (100)
Wilson B [A˚2] 14.9
Number of protomers per ASU 1
VM [A˚3 · Da≠1] 2.30
Solvent content [%] 46.5
a Values in parentheses refer to the highest resolution bin.
Structure determination of YdeHGGDEF
Data collection
Crystals of YdeHGGDEF were soaked in reservoir solution containing glycerol as cryoprotec-
tant. The concentration of the glycerol has been increased in two steps from 10 to 15%
before the crystals were flash frozen in liquid nitrogen.
A high-resolution dataset (1.8 A˚ was collected at the SLS beamline PXIII (Villigen, Switzer-
land). Data were processed with MOSFLM [109] and scaled with SCALA [110]. The pa-
rameters and statistics of the data collection are shown in Table 3.10. The crystal belonged
to the space group P62 with one molecule in the asymmetric unit and a solvent content of
46%. The analysis of the relevant map selections of the self-rotation function showed no
signs for closed rotational NCS.
Phase determination by molecular replacement, model building and refinement
As several structures of GGDEF domains were already available, molecular replacement
could be used for phase determination. Di erent programs (MOLREP[136], Phaser [118])
combined with several di erent search models (PDB: 1w25, 3i5b, 3ign) were tested. All
gave very poor solutions with Z-scores below eight. The best result was achieved with
the program Phaser and with chain A of the GGDEF domain of PleD (PDB: 1w25) as a
search model. This initial solution had no clashes, a Z-score of 7.8 and a log likelihood of 71.
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3.1.4 Structure determination
After a rigid body refinement with REFMAC [114], the model was rebuilt using AutoBuild
implemented in Phenix [117]. The programm placed 157 out of 170 residues and improved the
model drastically resulting in much better R and Rfree values of 26% and 30% respectively.
Refinement was done with REFMAC using one TLS group. In the active and the I-site well
defined di erence electron density was visible, which could be clearly assigned to c-di-GMP.
The c-di-GMP molecule in the A-site sits on a two-fold crystallographic axis, so that only
half of the c-di-GMP molecule had to be built in the electron density. A c-di-GMP dimer
was placed in the di erence electron density close to the I-site. Water molecules were placed
automatically using Phenix AutoBuild and manually checked in Coot [113]. Towards the
end of refinement, a magnesium ion could be placed in the di erence electron density close
to c-di-GMP in the I-site. After several rounds of rebuilding in Coot and refinement with
REFMAC, the final model resulted in R and Rfree values of 16.6% and 20.1%, respectively
(Table 3.11).
Validation of the YdeHGGDEF model
Electron density was well defined for the whole main chain of YdeHGGDEF as well as for a
c-di-GMP molecule at the active site, a c-di-GMP-dimer at the I-site and a magnesium ion.
Refinement statistics of the YdeHGGDEF model are given in Table 3.11. Refinement progress
was followed by monitoring the values of R and Rfree throughout model building. Stereo-
chemical parameters such as RMS deviations of bond length and angles were in the normal
range. The geometry of the YdeHGGDEF model was analyzed using the programs MolPro-
bity [115] and RAMPAGE [116]. All main chain torsion angles were in the most favored
or allowed region of the Ramachandran plot (Figure 3.14). The side chain conformations
showed no outliers, either.
Structure determination of full-length YdeH
Data collection
As before tested in-house, full-length YdeH crystals didn’t need any additional cryoprotec-
tant and were directly flash frozen in liquid nitrogen. A dataset up to 3.9 A˚ was collected
at the SLS beamline PXIII (Villigen, Switzerland). Data were processed with MOSFLM
[109] and scaled with SCALA [110]. The parameters and statistics of the data collection are
shown in Table 3.12. The crystal belonged to the space group P61, with two molecules in
the asymmetric unit and a solvent content of 57%.
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Table 3.11: Refinement statistics for the YdeHGGDEF model.
Resolution[A˚] 1.8
Space group P62
R [%] 16.6
Rfree [%] 20.1
Number of atoms
protein 1519
water molecules 140
c-di-GMP 115
magnesium 1
B factors
main chain 16.7
side chain 20.8
c-di-GMP 16.0
magnesium 29.6
water molecules 26.0
RMS deviations
bond lengths [A˚] 0.009
bond angles [¶] 1.281
Ramachandran statistics [%]
in favored regions 99.4
in allowed regions 0.6
Figure 3.14: Ramachandran diagram for YdeHGGDEF. Main chain torsion angles were analyzed with
RAMPAGE [116] and are indicated for each residue by crosses (glycines) or squares
(all others). Dark and light background shading indicates energetically favorable and
allowed regions, respectively. (A) General plot for all non-glycine residues. (B) Special
plot for glycine residues. (C, D) Plots for pre-proline and proline residues, respectively.
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Table 3.12: Data collection parameters and statistics for full-length YdeH.
Wavelength [A˚] 0.979
Detector MarCCD 225
Detector distance [mm] 320
Space group P61
Cell axes [A˚] a = b = 102.59, c = 129.16
Angles [¶] – = — = 90, “ = 120
Resolution [A˚] 50.0-3.90 (4.1-3.9)
Observed reflections a 92268 (8301)
Unique reflections a 7085 (1047)
Multiplicity 13.0
Rmerge [%] a 13.6 (77.4)
I/‡(I)a 13.6 (2.7)
Completeness [%] a 99.9 (99.9)
Number of protomers per ASU 2
VM [A˚3 · Da≠1] 2.89
Solvent content [%] 57.4
a Values in parentheses refer to the highest resolution bin.
Phase determination by molecular replacement, model building and refinement
As the structures of the two individual domains of YdeH were already solved, molecular
replacement was used for phase determination. This was done with the program Phaser
[118] with the CZB domain and the GGDEF domain of YdeH as search models. Two
molecules of the CZB domain and two molecules of the GGDEF domain were placed by the
procedure in the asymmetric unit in a sensible arrangement. By placing more and more of
the domains, the Z-score and the log likelihood increased continuously from 8.1 to 16.3 and
from 86 to 712, respectively.
The linker between the two domains and the termini were manually rebuilt in Coot [113]
and the model was refined with BUSTER [119] using NCS restrains and two TLS groups
per monomer in later stages of refinement. In the CZB domain, strong anomalous density
was visible at the position, where a zinc ion is bound in YdeHCZB. In the two active sites,
well defined di erence electron density was observed, which was comparable with GTP–S
and a magnesium ion. Additionally, di erence electron density was visible in the I-site of
the GGDEF domains. In this density, part of a GTP–S molecule and a c-di-GMP molecule
could be fitted. After further rounds of rebuilding in Coot and refinement with BUSTER
using the model of the two individual domains as target restrains, the final model ended up
in R and Rfree values of 23.2% and 23.4%, respectively (Table 3.13).
50
Table 3.13: Refinement statistics for the YdeH full-length model.
Resolution[A˚] 3.9
Space group P61
R [%] 23.2
Rfree [%] 23.4
Number of atoms
protein 4349
nucleotides 158
magnesium 2
zinc 2
B factors
main chain A / main chain B 68.1 / 52.8
side chain A / side chain B 78.4 / 62.1
nucleotides 62.7
magnesium 30.8
zinc 32.8
RMS deviations
bond lengths [A˚] 0.010
bond angles [¶] 1.08
Ramachandran statistics [%]
in favored regions 97.9
in allowed regions 1.3
Validation of the YdeH full-length model
Electron density was well defined for the whole main chain of full-length YdeH except for
residues 36-53 of chain A, residues 37-64 of chain B as well as for the first four residues of
chain A. Refinement progress was followed by monitoring the values of R and Rfree and
checking for model geometry. The final statistics are given in Table 3.13. The values for the
R-factors were reasonable for the given data resolution of 3.9 A˚ and the RMS deviations of
bond lengths and angles were in the standard range. Most of the main chain torsion angles
were in the allowed regions of the Ramachandran plot, with most of them in the favored
region (Figure 3.15).
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Figure 3.15: Ramachandran diagram for full-length YdeH. Main chain torsion angles were analyzed
with RAMPAGE [116] and are indicated for each residue by crosses (glycines) or squares
(all others). Dark and light background shading indicates energetically favorable and
allowed regions, respectively. (A) General plot for all non-glycine residues. (B) Special
plot for glycine residues. (C, D) Plots for pre-proline and proline residues, respectively.
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3.1.5 Overall structure of YdeH
The structure of full-length YdeH (C52A mutant) was determined by molecular replacement
to a resolution of 3.9 A˚. YdeH folds into two domains, the N-terminal CZB domain and the
C-terminal catalytic GGDEF domain. The overall shape of YdeH is that of a mushroom
(Figure 3.16). The stipe is formed by the two CZB domains and the two GGDEF domains
represent the cap that sits on the stipe. The CZB domains and the GGDEF domains are
each related by a non-crystallographic two-fold axis. Since this axis is di erent for the two
domains, the YdeH dimer is non-symmetric. This becomes apparent at the domain interface
between the CZB and the GGDEF domain. While the domain contact in chain A is very
small, the surface area in chain B is 4.5 times larger, being 550 A˚2 . The presence of a dimer
is in agrement with the results from gel filtration experiments (sec section 3.1.2).
The crystal contacts are listed in Table 3.14 and the crystal packing is shown in Figure
3.17. The largest crystal contact (II) with 625 A˚2 and another contact (III) is mediated via
the 61-fold axis. The crystal contact IV via the 31-fold axis is additionally stabilized via a
c-di-GMP and two GTP–S molecules. Thus, the two Ip-sites are connected with each other.
The crystal solvent content of 57% is not very high, but the formation of only three crystal
contacts could be a reason for the low resolution of 3.9 A˚.
The characteristics of the domains will be discussed in detail later. Next the structures
of YdeHCZB and YdeHGGDEF will be analyzed. They were determined to a much better
resolution of 2.2 A˚ and 1.8 A˚, respectively.
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3.1.5 Overall structure of YdeH
(A) (B)
Figure 3.16: Ribbon representation of YdeH. The CZB domains are colored in green and the GGDEF
domains are colored in orange. Chains A and B are shown in dark and light colors,
respectively. The bound zinc atom is depicted as sphere and colored in red. The
disordered regions are marked as dashed lines. The non-crystallographic dimer axis for
the CZB and GGDEF domain are indicated as black lines. (A) Side view. (B) Top view
along the dimer axis of the CZB domain.
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Table 3.14: Crystal contacts in the YdeH crystal.
Name Contacting Symmetry Surface Interfacing residues
chains operation area [A˚2] chain 1 chain 2
I A-B NCS 2017.7 12, 13, 16, 19, 20,
22-24, 26-31, 33-
35, 89, 90, 93,
98, 100, 103, 104,
106, 107, 110,
111, 113-115, 118,
121, 122, 125,
126, 129, 130,
133, 134, 140,
141, 144, 170,
173, 177-179, 182,
186, 204, 205,
207, 263, 266,
267, 270, 271, 274
12, 13, 16, 19, 20,
22-24, 26-31, 33-
36, 89, 90, 93,
98, 100, 103, 104,
106, 107, 110,
111, 113-115, 118,
121, 122, 125,
128, 129, 130,
133, 134, 140,
141, 144, 170,
174, 177-179, 182,
185, 204, 205,
207, 209, 263,
266, 270
II A-A x-y-1, x-1, z+1/6 624.5 168, 171, 174,
175, 176, 227,
231, 234, 235,
244-246, 248, 280-
283, 295
73, 74, 77, 78,
80, 81, 84, 87,
88, 91, 92, 97,
99, 101, 102, 104,
105, 108, 112
B-A x-y-1, x-1, z+1/6 10.9 271 99
III B-B x-y, x, z+1/6 195.4 152, 155, 258, 259 167, 168, 171,
246, 248, 280,
281, 282
IV A-B -y, x-y+1, z+1/3 102.2 60, 62, 63, 197,
239
17, 197, 239, 241,
242-244
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(A)
(B)
Figure 3.17: Crystal packing of YdeH in space group P61 with one dimer (orange) per asymmetric
unit. The content of the unit cell is shown and the coloring has been carried out by
symmetry operations. Crystallographic related dimers are crosslinked by c-di-GMP
(e.g. orange-green). (A) Stereo view along the z axis. (B) Stereo view along the y axis.
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Figure 3.18: Secondary structure assignments for YdeHCZB chain A and B. Every tenth residue is
marked by a dot and disordered parts of the model are indicated by gaps.
3.1.6 Structural analysis of the CZB domain
Structure of YdeHCZB
The secondary structure of YdeHCZB was assigned using DSSP [120] and STRIDE [121].
Both programs essentially delivered the same results, which is shown in Figure 3.18.
YdeHCZB folds into a single elongated domain and forms a four helical bundle in which the
helix –2 is rather short and is proceeded by a large loop (Figure 3.19). This part of the
structure is not visible in chain A. The N- and C-termini are on the same side of the molecule
and relatively close together in space. The distance between the C-termini of both chains
is 16.1 A˚. A zinc ion is located in the center of the helical bundle and mediates contacts
between the four helices. The asymmetric unit consists of two monomers (Figure 3.19).
This non-crystallographic dimer is thought to be functional in vivo. From size exclusion
experiments (see section 3.1.2) it is known that YdeHCZB forms dimers in solution. The
dimer interface is formed by helices –1 and –4. The dimer contact covers 1278 A˚2, which
corresponds to 17% of the total surface area of a monomer and is mediated by ten H-bonds,
two salt bridges, four aromatic stackings and several non polar interactions (Figure 3.20).
In addition to the dimer interface, there are two dominant crystal contacts (II and III)
present. The interactions lie along the y-axis. Crystal contacts are listed in Table 3.15 and
the crystal packing is shown in Figure 3.21. The YdeHCZB dimer makes seven contacts with
other molecules to build up the lattice. The total surface area of the dimer involved in
crystal contacts is 1560 A˚2 or 12.2% of the complete surface area. While the residues 38-51
of chain B are involved in crystal contacts (contact IV) and chain A is not, the unstructured
loop of chain A has more freedom and is not visible in the electron density (Figure 3.22).
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3.1.6 Structural analysis of the CZB domain
(A) (B)
Figure 3.19: Ribbon representation of a YdeHCZB dimer. Chains A and B are colored in green and
dark green, respectively. The bound zinc atom is depicted as a sphere and colored in
red. The disordered region in monomer A is marked as a dashed line. The C-terminal
GGDEF domain would be located on the top. The distance between the C-termini
(Tyr126) is 16.1 A˚. (A) Side view. (B) View along the dimer axis.
Figure 3.20: Stereo view of the dimer interface of YdeHCZB. The protein backbone of chain A and
B is shown in green and dark green, respectively. The bound zinc ion is shown as a red
sphere and the interacting residues at the dimer interface are depicted as sticks. The
dimer interface is formed by helices –1 and –4 and is mediated via H-bonds and salt
bridges, aromatic stackings and non polar interactions.
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(A)
(B)
Figure 3.21: Crystal packing of YdeHCZB in space group C2 with one dimer (green) per asymmetric
unit. The content of the unit cell is shown and the coloring has been carried out by
symmetry operations. (A) Stereo view along the z axis. (B) Stereo view along the x
axis.
Figure 3.22: Stereo view of the crystal contact IV of the YdeHCZB crystal. Monomer A is shown
in light and monomer B in dark colors. The interfacing residues are shown as green
sticks. The large loop of monomer B (dark red) is involved in crystal contacts and has
no freedom to adopt other conformations.
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3.1.6 Structural analysis of the CZB domain
Table 3.15: Crystal contacts in the YdeHCZB crystal.
Name Contacting Symmetry Surface Interfacing residues
chains operation area [A˚2] chain 1 chain 2
I A-B NCS 1277.3 16, 19, 20, 22-
24, 26-31, 33-
35, 89, 90, 93,
98, 100, 103,
104, 106, 107,
110, 111, 113,
114, 118, 121,
125
16, 19, 20, 22-
24, 26-31, 33-
35, 89, 90, 93,
98, 100, 103,
104, 106, 107,
110, 111, 113,
114, 118, 121,
125
II B-A x, y, z-1 364.2 66, 69-71, 73,
74, 77-78, 81,
84, 88, 115,
119, 122
66, 67, 69-71,
73, 74, 77, 78,
81, 84, 88, 119
III A-B -x+1/2, y-1/2, -z+1 351.8 59, 60, 61, 62,
63-66, 68, 73,
76
17, 20, 21, 24,
25, 28, 40-43,
51, 53, 56
A-A -x+1/2, y-1/2, -z+1 95.6 6, 7, 60-62 100, 101, 104,
107, 111
IV A-B -x+1/2, y-1/2, -z 202.9 6, 9, 10, 13, 17,
20, 24, 28, 53
45-47, 49, 59,
60, 62, 63
B-B -x+1/2, y-1/2, -z 66.2 107, 111 60-62
V B-B -x, y, -z 180.9 33, 34, 36, 94-
96
33, 34, 36, 94-
96
VI B-A -x, y, z 162.6 95, 96, 97, 98,
99
36, 93, 94, 96,
98
VII A-A -x, y, -z+1 136.3 95-97 95-97
Figure 3.23: Stereo view of the zinc binding site of YdeHCZB. The zinc coordinating residues (His22,
Cys52, His79, His83) and the conserved residues Gly55 and Trp57 are shown as sticks.
The zinc ion is depicted as a red sphere. The omit map for the zinc is countered at 4‡.
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Table 3.16: Zinc coordination geometry in YdeHCZB.
Residue Distance to zinc in chain A / chain B [A˚]
His22 2.23 / 2.11
Cys52 2.34 / 2.32
His79 2.20 / 2.16
His83 2.15 / 2.17
(A) (B)
Figure 3.24: Superposition of the C–-backbone of the CZB domain of YdeHCZB (green) and full-
length YdeH (blue). (A) Total stereo view and (B) zoom in the zinc binding site of
monomer A.
Zinc binding
An unexpected finding during structure solution of YdeHCZB was the presence of a zinc ion.
This was surprising, as zinc had not been added during protein purification or crystalliza-
tion. A first indication for the presence of zinc was already seen in the fluorescence scan
during data collection and also ShelX found two more heavy metal sites during phasing. The
zinc is coordinated by His79 and His82 from helix –3, His22 from helix –1 and Cys52 from
the beginning of helix –2. The coordination is tetrahedral with ideal distances comparable
to other zinc coordinations [137], and is virtually identical in both chains (Table 3.16). A
detailed view of protein zinc interactions is given in Figure 3.23.
A zinc binding site consisting of three histidines and one cysteine is exceedingly rare. A
search of the PDB with PDBeMotif [126] for structures containing zinc binding sites revealed
over 6850 structures, but only ten with a 3His1Cys arrangement as in YdeH. These include
five members of the matrix metalloproteinase family, the human Stromelysin-1 (PDB: 1slm),
the human matrix metalloproteinase-2 (PDB: 1ck7), the human matrix metalloproteinase
MMP-9 (PDB: 1l6j), the human matrix metalloproteinase MMP-1 (PDB: 1su3) and the
human morphogenetic protein 1/tolloid-like metalloproteinase (PDB: 3edi). These proteins
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are synthesized as inactive precursors and contain a catalytic zinc ion that is coordinated by
three histidines from the catalytic domain and one cysteine from the N-terminal propeptide.
The metalloproteinases get activated by interruption of the Cys-Zn interaction (cysteine-
switch mechanism) and as a result, the active site is now accessible for the substrate and
the fourth coordination partner of the zinc is available for a water molecule [138–142].
The second group of enzymes containing the 3His1Cys coordination are the class II aminoacyl-
tRNA synthetases. In the editing domain of threonyl-tRNA synthetase from Staphylococcus
aureus (PDB: 1nyr), of alanyl-tRNA synthetase from Pyrococcus horikoshii OT3 (PDB:
1v4p) and of alanyl-tRNA synthetase from Archaeoglobus fulgidus (PDB: 2ztg), the zinc ion
bridges the two subdomains and might activate the carbonyl group of a mismatching amino
acid in the deacylation catalysis [143–145].
Another protein with this zinc coordination is the human AMSH-LP deubiquinating en-
zyme (PDB: 2znv). The function of the zinc coordination is the accurate positioning of the
substrate to allow e cient deubiquitination [146].
In the zinc-binding domain of the viral envelope glycoprotein from Junin virus (PDB: 2loz),
the 3His1Cys zinc coordination has a structural function to maintain the correct fold [147].
An additional hit was the engineered human carbonic anhydrase II (PDB: 1dca). In this
structure, an additional cysteine was introduced to the naturally occurring 3His-zinc bind-
ing motif, to inactivate the enzyme by replacing the catalytically important water molecule
[148].
The zinc binding site consisting of three histidines and one cysteine in these proteins adopt
di erent functions in vivo. A pure structural role, protein activation by ligand exchange
and a catalytic function can be performed by using this zinc binding site.
In YdeH, the zinc is coordinated by four protein ligands and can therefore be assigned as a
structural zinc site. On the other hand, after removal of zinc by incubation with a chelator,
YdeH was still stable and well folded as evidenced by gel filtration experiments (section
3.1.10). This suggests that zinc does not only display a pure structural role. YdeH might be
able to sense the zinc concentration as it is the case for zinc-responsive signal transduction
proteins and in this way could regulate YdeH activity. The unstructured loop right before
the Cys52 is ideally suited to allow fast exchange kinetics. Furthermore, the regulation
of the GGDEF domain can be performed by a redox switch of the Cys52. The a nity is
reduced by oxidizing the cysteine so that the zinc can not bind anymore. Kinetic experiment
were performed as described in section 3.1.10 to elucidate the specific role of the zinc.
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Figure 3.25: Stereo view of the superposition of YdeHCZB chain B (green) with the ligand-binding
domain of the Tar receptor from S. typhimurium (yellow). The helices –1, –3 and –4
superimpose quite well, but there are di erences in helix –2 and the dimer orientation
towards each other.
Structural comparison of YdeHCZB and the CZB domain of full-length YdeH
The folding of the CZB domain is the same in the YdeHCZB and full-length YdeH structure.
A superposition of both models is shown in Figure 3.24. The RMS deviation of the C–
position is 0.7 A˚ and there are only minor di erences at the termini. The dimer interface is
identical. One di erence is that in the full-length structure helix –2 and the preceding loop
region is not visible in one subunit. Furthermore, the mutant C52A was used for determi-
nation of the YdeH full-length structure. This mutation does not impede the zinc binding
to YdeH, but makes the zinc binding site more accessible so that the unstructured loop
can adopt a completely free conformation, which is consequently disordered as evidenced
by missing electron density.
Comparison with homologous proteins
To assess structural similarities between YdeHCZB other proteins, a search for structural
homologous was performed. The Dali program found only one hit with a Z-score above
ten (10.2), the ligand-binding domain of the aspartate receptor Tar from Salmonella ty-
phimurium (PDB: 1vlt). Monomer B of YdeHCZB has a RMS deviation of 1.6 A˚ to monomer
B of the aspartate receptor and a sequence identity of 14%.
The Tar receptor is an inner membrane spanning chemosensory protein that interacts with
the histidine kinase CheA. Upon binding of one of its cognate ligands (aspartic acid or
maltose-binding protein), Tar modulates the autophosphorylation activity of CheA, which
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(A) (B)
Figure 3.26: Structure based sequence alignment of the members of the Pfam domain PB0001058
with the CZB domain of YdeH. The sequence alignment was done with the programm
ALAdeGAP [127]. (A) Sequence alignment shown as WebLogo [128]. The letter height
represent the degree of conservation. (B) Conservation mapping of the sequence align-
ment performed with the program protskin [129]. The color ranges from blue (not con-
served) to red (strongly conserved).
in turn regulates the swimming behavior of the bacterium. Within the TAR family, the
only characteristic is the overall conservation pattern of hydrophobic and polar residues
that reflects the coiled coil nature of this domain. There are no obvious conserved binding
sites, which is expected as known homologs bind very di erent ligands [149].
Both proteins, YdeHCZB and Tar, fold into a four helical bundle and are able to form dimers.
However, the dimer orientation towards each other are di erent (Figure 3.25). The most
outstanding di erence is the absence of the zinc binding motif in the aspartate receptor
and di erences in helix –2. While the aspartate receptor forms a long –2 helix, YdeHCZB
has a short one preceded by a unstructured loop region. The structural similarity of the
N-terminal domain of YdeH with the sensory domain of the Tar receptor is based on the
characteristics of a four helical bundle with hydrophobic residues pointing to the inner of
the protein and polar residues pointing outside. It seems that this four helical bundle fold
is suited to transfer signals to associated domains.
As no other structures of CZB proteins are known, a structure based sequence alignment
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(A) (B)
Figure 3.27: Superposition of the model of TlpD from H. pylori (blue) on chain B of YdeHCZB
(green). The model of TlpD was generated with MODELLER based on a structural se-
quence alignment with YdeHCZB. (A) Ribbon representation. The zinc binding residues
are shown as sticks. (B) Close up view of the zinc binding site.
with members of the new Pfam domain PB0001058, where YdeHCZB belongs to, was per-
formed. The alignment carried out with WebLogo and a mapping of conserved residues are
shown in Figure 3.26. A high degree of conservation is identified for the zinc binding motif
(His22, His78, His83, Cys52) and for a region of helix –2 containing Gly55 and Trp57. The
conservation of Gly55 is probably due to steric reasons to allow a correct zinc coordination.
The role of the aromatic residue Trp57 is not really obvious. The side chain of Trp57 is not
completely hidden in the structure, but is also not completely solvent exposed. This region
may be a possible interaction area for other proteins to give a input signal that has to be
transferred to the catalytic output domain. The transfer of the signal could be via a zinc
release. The hydrophobic core of the helical bundle is conserved, that is not the case for the
dimer interface. For this domain the zinc binding seems to be a crucial function, but the
dimerization of the CZB domain seems to be quite unusual.
The only characterized member of this new Pfam domain is the cytosolic chemoreceptor
TlpD from H. pylori. In addition to the CZB domain, TlpD contains a methyl-accepting
chemotaxis-like (MA) domain. A model of TlpD was created with MODELLER [130] based
on the structural sequence alignment with YdeHCZB performed with ALAdeGAP [127] (Fig-
ure 3.27). The model displays a RMS deviation of the C– positions of 1.2 A˚ to YdeHCZB and
has the same arrangement of the zinc coordinating residues. This is in agrement with the
experimental results of TlpD, where zinc binding was shown by ICP-MS experiments [52]. It
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seems that in this domain, which often occurs in combination with signaling domains, zinc
acts as the sensory signal, which transfers the signal to the associated domain to modulate
its activity.
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Figure 3.28: Secondary structure assignments for YdeHGGDEF. Only one chain is shown, because
the two monomers have the same secondary structure assignments. Every tenth residue
is marked by a dot.
3.1.7 Structural analysis of the DGC domain
Structure description of YdeHGGDEF
Secondary structure elements of the YdeHGGDEF structure were determined with DSSP[120]
and STRIDE [121] with an identical result, which is shown in Figure 3.28. The DGC domain
of YdeH consists of five –-helices and eight —-strands.
YdeHGGDEF folds into a globular domain with a diameter of 46 A˚ and exhibits the typi-
cal fold of diguanylate cyclases. These domains consist of a central five-stranded —-sheet
surrounded by helices. Compared to the structurally best known DGCs PleD and WspR,
YdeH has an additional —-strand at the C-terminus. The topology of the GGDEF domain
of YdeH is depicted in Figure 3.29 and the overall fold is shown in Figure 3.30. The active
site with the signature motif GGDEF is located on the loop between the —-strands —2 and
—3. The Ip-site is located on the opposite side of the protein between helix –2 and —-strand
—2.
YdeHGGDEF crystallized with one monomer in the asymmetric unit, which is also the major
species in solution, known from gel filtration experiments (section 3.1.2). YdeH must form
as a dimer to be active. Dimerization is probably mediated via the CZB domain and not the
GGDEF domain, since the GGDEF domain requires some conformational flexibility during
the catalysis. Indeed, all existing crystal contacts are between 380 and 114 A˚2 and are
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Figure 3.29: Topology of the GGDEF domain of YdeH. –-helices are depicted as blue cylinders and
—-strands as red arrows. The active side loop is marked in magenta and the I-site loop
in green. The plot was created with TopDraw [150].
(A) (B)
Figure 3.30: Ribbon representation of the GGDEF domain of YdeH. C-di-GMP bound to the active
site and a c-di-GMP dimer bound to the Ip-site are shown as sticks. (A) Side view and
(B) top view.
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Table 3.17: Crystal contacts in the YdeHGGDEF crystal.
Name Symmetry Surface H-bonds/ Interfacing residues
operation area [A˚2] salt bridges chain 1 chain 2
I x-y, x, z+1/3 379.8 0/0 149, 156, 157,
197-199, 215,
217
258-260, 263,
264, 267, 268,
271, 287, 289-
291
II x-y, x, z-2/3 192.3 4/1 217, 218, 220,
221, 224
126, 127, 128,
129, 141
III -y+1, x-y+1, z-1/3 191.5 1/0 168, 171, 231,
234, 235, 279,
280, 282, 283,
295
191, 194, 195,
235, 236, 239,
240, 241, 243,
244
IV -y+1, x-y+1, z+2/3 127.5 0/0 179, 180, 241,
242
283, 295, 297
V -x+1, -y+1, z 114.2 0/2 140, 170, 174,
209, 274
140, 170, 174,
209, 274
VI x, y, z-1 27.5 0/0 290, 292 126, 128
therefore to small to form a dimer in a biological assembly. All crystal contacts are listed in
Table 3.17 and the packing is shown in Figure 3.31. In contact V, the two GGDEF domains
are linked over the two-fold axis via a c-di-GMP molecule in the two active sites (see Figure
3.34). The surface area is only 114 A˚2 but an additional contact area of 235 A˚2 is generated
by c-di-GMP. This interaction is stabilized by two salt bridges. Such an arrangement is
thought to be the end point of catalysis, where the c-di-GMP has already formed but has
not left the active site, yet. Furthermore, two GGDEF monomers are cross linked with a
c-di-GMP dimer bound to the I-site via the six-fold axis (contact I) (see Figure 3.37). This
arrangement might represent a natural inhibition mode.
Structure description of the GGDEF domain in full-length YdeH
Full-length YdeH crystallized with two monomers in the asymmetric unit and had the sub-
strate analog GTP–S bound to both active sites. Furthermore, a c-di-GMP with a stacked
GTP–S was bound to the I-site. The structure is shown in Figure 3.32. The dimer interface
between the two monomers in the asymmetric unit covers an area of 719 A˚2, whereof 536 A˚2
is made by protein-protein interaction and the remaining 183 A˚2 are contacts between pro-
tein and GTP–S (Figure 3.32). The contact is mediated via five H-bonds between the
proteins and three between protein and substrate analog (Table 3.18). The dimer interface
is larger than in the YdeHGGDEF structure but is still not large enough to form a biological
assembly. One reason for this could be that the catalysis takes place at this interface and
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(A)
(B)
Figure 3.31: Crystal packing of YdeHGGDEF in space group P62 with one monomer (orange) per
asymmetric unit. The content of the unit cell is shown and the coloring has been
carried out by symmetry operations. C-di-GMP that crosslinks two active sites lies
on the two-fold axis in the middle of the cell and crosslinks the orange and light-blue
molecule (contact V). The linkage of c-di-GMP of the I-sites is via the six-fold axis for
example between the orange and the red molecule (Contact I). (A) Stereo view along
the z axis. (B) Stereo view along the y axis.
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(A) (B)
Figure 3.32: Structure of the GGDEF domain in full-length YdeH. (A) Ribbon representation of
the dimer. Chain A and B are colored in dark and light orange, respectively. The
GTP–S and c-di-GMP molecules are shown as sticks. The view is along the two-fold
axis. (B) Close up view of the dimer interface. The interacting residues are shown in
stick representation.
therefore the interface must be rather variable to allow product binding, catalysis and sub-
strate release.
The overall fold of full-length YdeH is identical to the YdeHGGDEF model with C– RMS
deviation of 0.12 A˚ (Figure 3.33).
Product binding to the active site
The active site of the DGCs is defined by the GGDEF motif, located on the turn between
the —-strands —2 and —3. In the YdeHGGDEF structure, the reaction product c-di-GMP is
bound in the active site and thereby symmetrically crosslinks two GGDEF domains (Figure
Table 3.18: H-bonding in the dimer interface of the GGDEF domains of full-length YdeH.
Chain A Chain B Distance [A˚]
His178-N”1 Arg140-N‘ 2.9
His178-N‘2 Tyr205-OH 3.3
His178-N Asp263-O”2 3.0
Tyr205-OH His178-N”1 3.3
Asp263-O”2 Leu179-N 3.0
Arg140-N÷2 GTP–S-O6 2.9
GTP–S-O2’ Arg104-N÷2 2.9
GTP–S-O2’ Tyr205-OH 2.7
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Figure 3.33: Stereo view of the superposition of the GGDEF domain of YdeHGGDEF (blue) and
full-length YdeH (orange).
3.34). The guanyl base of c-di-GMP is fixed in a hydrophobic pocket, which is formed by
Leu134, Phe169 and Leu185. In addition, the base is positioned by H-bonding with Asn173,
Asp182, Arg204 and the backbone oxygen of His178. Asn173 is interacting with the 2’OH
of the ribose. The phosphate groups are not in contact with the protein. A detailed view
of the active site is given in Figure 3.34 and the distances for the interacting residues are
listed in Table 3.19.
The present binding arrangement could reflect the end point of catalysis, where the reaction
product c-di-GMP has already been formed, but has not left the active site, yet. The dimeric
GGDEF arrangement may be stabilized by two salt bridges between the conserved residues
Arg140 and Asp174. The N-termini (Ile127) of the GGDEF domains are located next to
each other with a distance of 26 A˚, which is 9 A˚ more than the distance of the C-termini in
the CZB domain in the YdeHCZB structure.
So far, two other DGC structures are known, which have c-di-GMP bound in the active
site. In the non-activated structure of PleD (PDB: 1w25) [15], c-di-GMP is present in the
active site and thereby crosslinks two symmetry related GGDEF domains, which are from
di erent dimers (Figure 3.35). The binding of c-di-GMP is similar as in YdeHGGDEF. The
guanyl base is positioned in the same hydrophobic pocket and the interacting residues are
the same, apart from Gly369. The homologous residue Gly207 seems not to be in direct
contact in YdeHGGDEF. The dimer arrangement of the GGDEF domains in both structures
is slightly di erent as shown in Figure 3.35. Therefore, the c-di-GMP can not be aligned
perfectly.
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(A)
(B)
Figure 3.34: The active site of YdeHGGDEF. (A) Ribbon representation of the dimer, which is
crosslinked by c-di-GMP in the two active sites. The active site loop is marked in ma-
genta and c-di-GMP and the amino acids involved in the salt bridge formation (Arg140,
Asp174) are shown as sticks. The view is along the two-fold axis from the N-terminus.
(B) Stereo view of the c-di-GMP coordination geometry at the active site. The inter-
acting protein residues and c-di-GMP are shown in stick representation. The omit map
for c-di-GMP is countered at 2.5‡.
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(A) (B)
(C)
Figure 3.35: C-di-GMP binding to the active site of PleD (PDB: 1w25) compared to YdeHGGDEF.
(A) Ribbon representation of non-activated PleD. The DGC domain of the dimer is
shown in blue and the REC domains are shown in green. A symmetry related monomer
is shown in light colors, which is crosslinked via c-di-GMP in the active site. C-di-GMP
is shown in stick representation. (B) Superposition of non-activated PleD chain A (blue)
onto YdeHGGDEF (orange). (C) Stereo close up view of the c-di-GMP coordination in
the superposition of PleD (blue) onto YdeHGGDEF (orange). The interacting residues
are shown in sticks and the labeling corresponds to PleD.
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Table 3.19: H-bonding between YdeHGGDEF and c-di-GMP in the active site.
C-di-GMP YdeHGGDEF Distance [A˚]
N1 Asp182-O”1 2.7
N2 Asp182-O”1 3.1
N2 His178-O 3.1
N2 Asn173-N”2 2.8
N3 Asn173-O”1 3.2
O2’ Asn173-O”1 3.1
N7 Arg204-NH2 3.4
O6 Arg204-NH2 3.4
A structure of a GGDEF domain of Xanthomonas campestris (PDB: 3qyy) was solved very
recently, which has c-di-GMP bound to the active site [151]. There, two GGDEF domains
form a dimer by partial intercalation of the guanyl bases of two c-di-GMP molecules. In
literature it is claimed that this c-di-GMP binding is an alternative inhibition mode to the
domain crosslinking via the RxxD-motif, which is lacking in this enzyme. In comparison to
YdeHGGDEF, the binding of the guanyl base is the same in both structures, but the dimer
arrangement is di erent.
In all three DGCs, the guanyl base of c-di-GMP binds in the identical hydrophobic pocket
and the molecule is positioned through a H-bonding network consisting of the same residues.
However, the dimer arrangement is di erent. The DGC structure from X. campestris shows
a non-productive dimer, which is probably not of physiological relevance. The measured
competitive KI of 7µM is too high in order to compete with GTP, which is present in
millimolar concentrations in bacteria. However, in the structure of YdeHGGDEF the dimer
organization may resemble a physiological arrangement, because both active sites are linked
with one c-di-GMP molecule in a symmetrical manner with the N-termini pointing in the
same direction.
Substrate binding to the active site
In the full-length YdeH structure, the substrate analog GTP–S is bound to both active sites
of the dimer in the same way. The guanyl base binds to the same hydrophobic pocket as
the base of c-di-GMP in the YdeHGGDEF structure. Furthermore, the base is positioned via
H-bonding involving the same residues (Asn173, Asp182, Arg204 and His170). The ribose
and the phosphate groups are interacting with Glu208, Arg281 and the backbone atoms of
Lys170, Phe169, Ile166 and Arg168. Additionally, there are interactions with the residues
Arg140 and Tyr205 of the other GGDEF domain. Furthermore, a magnesium ion, which is
octahedrally coordinated by two oxygens of the — and “ phosphate of the GTP–S molecule
and Asp165, Glu208 and Ile166, could be placed in the active site. The binding geometry is
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Table 3.20: H-bonding between YdeH and GTP–S bound mainly to the A-chain in the active site.
GTP–S YdeH Distance [A˚] GTP–S YdeH Distance [A˚]
N1 Asp182-O”1 3.03 O1B Lys170-N 3.3
N2 Asp182-O”1 3.5 O1B Phe169-N 3.3
N2 His178-O 3.1 O2B Glu208-O÷2 2.9
N2 His178-N”1 3.4 O2B Ile166-O 2.7
N2 Asn173-N”2 2.4 O2B Arg168-N 2.6
N3 Asn173-O”1 2.6 O2B Phe169-N 2.5
N3 Arg140-N÷2 (chain B) 2.6 O3G Asp165-O”2 3.0
O6 Arg204-N÷2 3.0 O3G Lys277-N’ 2.8
N7 Arg140-N÷1 (chain B) 3.3 O3G Ile166-O 3.4
N9 Arg140-N÷2 (chain B) 3.2 O3G Arg281-N÷1 3.4
O4’ Glu208-O÷1 3.3 O3G Arg168-N 3.5
O2’ Arg140-N÷2 (chain B) 2.7 O1G Arg168-N 3.0
O2’ Tyr205-OH (chain B) 2.9 O1G Arg281-N÷1 2.5
O3A Glu208-O÷1 2.9 O2G Arg281-N÷2 3.4
O3A Glu208-O÷2 3.1
shown in Figure 3.36 and the distances of the interacting residues are listed in Table 3.20.
In the full-length structure, of YdeH both active sites with bound GTP–S are facing each
other. The distance between the – phosphate and the O3 of the GTP–S, which have to be
linked during catalysis, is 10 A˚ (Figure 3.36). This means that the two GGDEF domains
have to approach each other to allow the production of c-di-GMP. The zinc bound to the
N-terminal CZB domain may cause the arrangement of the GGDEF domains to be in a
non-productive conformation. The arrangement seen in YdeH full-length structure might
represent a conformation, where the substrate has already bound, but needs minor rear-
rangement to initiate catalysis.
In the activated structure of PleD (PDB: 2v0n), the substrate analog GTP–S is also bound
to the active site. The binding is very similar, only the conformation of the – phosphate
is di erent. This results in a di erent position for Glu208 in YdeH. A superposition of the
activated PleD structure onto YdeH is shown in Figure 3.36.
Inhibitory site
The Ip-site of DGCs is defined by the RxxD-motif, located at the opposite side of the active
site on the loop between helix –2 and —-strand —2. YdeH has a slightly di erent variant of
this motif, RxxE. In the YdeHGGDEF structure dimeric c-di-GMP is bound to this Ip-site.
Dimeric c-di-GMP has intercalated purine bases and forms two isologous intermolecular
H-bonds between the guanine N1 and the phosphate groups, like it is known from small
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(A)
(B)
(C)
Figure 3.36: GTP–S binding to the active site in the full-length YdeH structure. (A) Ribbon repre-
sentation of the two GGDEF domains. GTP–S is shown as sticks. The two active sites
are facing each other. The two bonds, which have to be formed during catalysis, are
marked as dashed lines. (B) Stereo view of the GTP–S coordination geometry at the
active site. The interacting protein residues and GTP–S are shown in stick representa-
tion. The residues from chain A are colored in orange and the residues from chain B in
light orange, respectively. The omit map for GTP–S is countered at 2.5‡. (C) Stereo
view of the GTP–S coordination in the superposition of activated PleD (green) onto
YdeHGGDEF (orange). The interacting residues are shown as sticks and are labeled for
PleD. 77
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molecule crystal structures of c-di-GMP [12, 13]. The c-di-GMP molecules are positioned
with a strong H-bonding network involving Arg197 and Glu200 from the RxxE-motif and
additional residues Arg224, Arg228, Asp198 and the backbone oxygen of Lys215 (Figure ).
The oxygen O1 from one phosphate group is involved additionally in the coordination of a
magnesium ion together with Asp198 and four water molecules.
As it is known from other DGCs, binding of dimeric c-di-GMP to the I-site crosslinks two
domains to prevent catalysis by domain immobilization [16]. In the YdeHGGDEF structure,
the c-di-GMP links two GGDEF domains, where the Is-site is located on helix –4. Arg271
is interacting with both c-di-GMP molecules and the aromatic ring of Tyr274 stacks with
one guanyl base. In addition, a third GGDEF molecule interacts weakly with c-di-GMP.
The backbone nitrogen of Ala126 is in H-bonding distance to O11 of the phosphate group.
The exact binding geometry is shown in Figure 3.37 and all distances of the interactions are
listed in Table 3.21.
It is very likely that crystal packing is responsible for crosslinking of the third GGDEF
molecule, which only participates with one H-bond of the backbone of Ala126, which is
located on the N-terminus of the construct. The interaction with Arg271 and Tyr274 on
helix –4 seems to be more relevant. The N-termini (Ile127) of the GGDEF domains are
pointing in the same direction and are 31 A˚ apart. This might still occur in a dimer that
is held together by a dimeric N-terminal domain and could therefore reflect an inhibition
mode, which has to be proven by enzymatic experiments.
C-di-GMP was bound to the I-site in the full-length YdeH structure, as well. This was sur-
prising, because neither c-di-GMP was added to the crystallization condition nor the protein
used for crystallization contained c-di-GMP as confirmed by UV spectra. The bound c-di-
GMP, which could be seen clearly in the initial electron density map, had been probably be
slowly produced by YdeH from the substrate analog GTP–S during crystallization. This
might explain, why crystals needed three days to occur and that they grew over a period
of three weeks. Furthermore, the low amount of c-di-GMP could explain why only a c-
di-GMP monomer was bound to the I-site and not a dimer as in all other known DGC
structures. To compensate the limiting amount of c-di-GMP, additional GTP–S was bound
to the I-site. This c-di-GMP/GTP arrangement does not use base intercalation, but the
bases of c-di-GMP are stacked with GTP–S. Thereby, two GGDEF domains of symmetry
related YdeH dimers are crosslinked. The Ip-site consists of residues Arg197 and Glu200
from the RxxE-motif and residues Arg228, Lys215 and Trp215, which position c-di-GMP
and one GTP–S through a strong H-bonding network. The Is-site on the symmetry related
GGDEF domain is compromised of residues Tyr199, Glu200, Lys215, Arg224 and Arg228.
These residues take part exclusively in the binding of the second GTP–S molecule. The
domain crosslinking and the binding geometry of the I-site are shown in Figure 3.37 and all
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interactions are listed in Table 3.21.
Since there are no interactions with c-di-GMP, the Is-site is more likely a crystal artefact,
which was due to the depletion of c-di-GMP in the crystallization solution. The GTP–S
molecule bound to the Ip-site probably mimics one half of the missing c-di-GMP molecule.
This would explain, why only the “ phosphate of the GTP–S has a defined position and is
visible in the structure. On the other hand the – and — phosphate, which do not exist in
c-di-GMP are not involved in the binding and are therefore not visible.
Comparing the binding of c-di-GMP to the I-site in the two YdeH structures, it becomes ap-
parent that the c-di-GMP has a slightly di erent conformation (Figure 3.37). This happens,
because only monomeric c-di-GMP is bound in the full-length structure of YdeH, which al-
lows rotation of one guanyl base compared to the dimeric c-di-GMP in the YdeHGGDEF
structure. Arg197 is interacting with the intercalated base of the second c-di-GMP in the
YdeHGGDEF structure, while in the full-length structure Arg197 can adopt an other con-
formation and is involved in the binding of the guanyl base of monomeric c-di-GMP. The
secondary I-sites are completely di erent, which is mainly caused by the binding of the
additionally GTP–S molecules.
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(A) (B)
(C)
(D)
(E)
80
Figure 3.37: The inhibitory site of YdeH. (A) Ribbon representation of c-di-GMP crosslinked
GGDEF domains in the YdeHGGDEF structure. The GGDEF domain with the c-di-
GMP dimer bound to the Ip-site is shown in orange, the second GGDEF domain, where
the c-di-GMP interacts with helix –4, is shown in green and the N-terminus of a third
interacting GGDEF domain is shown in cyan. C-di-GMP is shown in sticks and a mag-
nesium ion as green sphere. The N-termini of the orange and green GGDEF domains
are pointing in the same direction and are 31 A˚ apart. (B) Ribbon representation of
c-di-GMP crosslinked GGDEF domains in the YdeH full-length structure. The GGDEF
domains are shown in orange and the CZB domains in green. Chain A and B are colored
in dark and light colors, respectively. C-di-GMP is depicted as sticks. (C) Stereo view
of the c-di-GMP coordination geometry at the I-site in the YdeHGGDEF structure. The
color code is the same as in (A). The interacting protein residues and c-di-GMP is shown
in stick representation and the magnesium ion and the water molecules are represented
as green and red spheres, respectively. The omit map for c-di-GMP is countered at 3‡.
(D) Stereo view of the c-di-GMP and GTP–S coordination geometry at the I-site in the
full-length YdeH structure. The color code is the same as in (B). The interacting protein
residues and c-di-GMP is shown in stick representation. The omit map for c-di-GMP is
countered at 2.5‡. (E) Stereo view of the comparison of the I-sites in the YdeHGGDEF
and the full-length YdeH structure. Interacting residues of YdeHGGDEF and c-di-GMP
are depicted in green and of full-length YdeH in orange.
In most of the other known DGC structures (PleD, PDB: 1w25, 2v0n; WspR, PDB: 3bre,
3i5c; and a DGC from M. aquaeolei, PDB: 3ign), c-di-GMP is bound to the I-site, as well
[15–18]. In all these structures the primary I-site is very similar. It is defined by residues
from the RxxD-motif and an additional arginine. Since YdeH has a glutamate in the I-
site motif, which has one CH2-group more than aspartate, the c-di-GMP dimer in YdeH
is moved a little bit further from the protein (Figure 3.38). By that Arg228 can adapt an
other conformation and is interacting with c-di-GMP only by the N‘ and not with the both
N÷ as in PleD for example. Nevertheless the exchange of the aspartate with a glutamate in
the RxxD-motif does not impede c-di-GMP binding.
The secondary I-site compromises an arginine in the helix –0 like in the activated structure
of PleD, WspR and in the DGC structure fromM. aquaeolei or lies on the additional domains
of the DGCs like in the non activated structure of PleD. All these binding modes have in
common, that many arginines are involved, which can specifically interact with the O6-N7
edge of the guanyl bases. By crosslinking two domains, the two DGC domains are prevented
from getting in close proximity to perform catalysis. This inhibition mode is therefore called
’inhibition by domain immobilization’.
The inhibition of YdeH can be induced by crosslinking the two DGC domains as it is seen in
PleD, WspR and 3ign or by crosslinking the DGC domain to the CZB domain comparable to
the non-activated structure of PleD. Additionally, crosslinking of two DGC domains might
occur via the arrangement observed in the YdeHGGDEF structure. To further investigate
the inhibition of YdeH, activity assays had been performed ( see section 3.1.10).
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Table 3.21: H-bonding of nucleotides with YdeHGGDEF and full-length YdeH in the inhibitory site.
H-bonding in YdeHGGDEF H-bonding in full-length YdeH
C-di-GMP YdeH Distance [A˚] Nucleotide YdeH Distance [A˚]
primary I-site
503-O6 Arg197-N÷2 2.9 c-di-GMP-O61 Arg197-N÷2 2.5
503-N7 Arg197-N‘ 2.9 c-di-GMP-N7 Arg197-N‘ 2.9
503-O4’ Trp195-O 3.1 c-di-GMP-O4’ Trp195-O 3.4
503-O1P Asp198-O”2 2.8 c-di-GMP-O1P Asp198-O”2 2.7
505-O6 Arg228-N÷2 2.7 GTP-O6 Arg228-N÷2 2.9
505-N7 Arg228-N‘ 3.0 GTP-N7 Arg228-N‘ 3.1
505-N1 Glu200-O÷1 2.6 GTP-N1 Glu200-O÷1 3.2
505-N2 Glu200-O÷2 2.7 GTP-N2 Glu200-O÷2 3.0
505-N2 Lys215-O 2.8 GTP-N2 Lys215-O 2.7
505-O1P Arg224-N÷1 2.7
505-O21 Arg197-N÷2 2.9
secondary I-site (x-y, x, z+1/3) secondary I-site (-y, x-y+1, z+1/3)
503-O2P Arg271-N÷1 2.8 GTP-O6 Arg228-N÷2 3.3
503-N21 Arg271-N÷2 3.0 GTP-N7 Arg228-N‘ 3.2
505-N7 Arg271-N÷2 2.9 GTP-N1 Glu200-O÷1 2.7
GTP-N2 Glu200-O÷2 3.1
GTP-N2 Lys215-O 2.7
GTP-N2 Tyr199-OH 3.2
GTP-O3A Arg224-N÷1 3.3
tertiary I-site (x-y, x, z-2/3)
505-O11 Ala126-N 2.8
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Figure 3.38: I-site of the activated structures of PleD (PDB: 2v0n) compared to YdeHGGDEF.
GGDEF domains of PleD are depicted in cyan and the N-terminal REC domains are
shown in green. Chain A and B are colored in dark and light colors, respectively. (A)
Ribbon representation of PleD, where c-di-GMP crosslinks the DGC domains.(B) Close
up stereo view of the I-site of PleD. C-di-GMP and the interacting residues are shown
as sticks. The coloring is the same as in (A). (C) Stereo view of the overlay of the I-site
of PleD with the I-site of YdeHGGDEF. In YdeH c-di-GMP is colored in light orange
and the interacting residues of the Ip-site are depicted in orange and the residues of the
Is-site in light orange. The color code for PleD is the same as in (B).
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3.1.8 Model of a catalytically competent YdeH-dimer
In all solved X-ray structures of DGCs the proteins are in a non-productive state meaning
that the competent dimer is not known so far. In the full-length structure of YdeH, the
substrate analog GTP–S is bound to both active sites. However, the dimer arrangement
of the GGDEF domains is not in a competent state, because the intermolecular distance of
10 A˚ to form a bond between the 3’OH and the – phosphate of the GTP–S molecules is far
too long (Figure 3.36).
In the structure of YdeHGGDEF, the two active sites are crosslinked via c-di-GMP (Figure
3.34). GTP–S was modeled in the active sites of this YdeHGGDEF dimer by superimposing
with the YdeH full-length structure and revealed, that this dimer arrangement can not be
a productive state as well (Figure 3.39). The distance of 9.3 A˚ between the 3’OH and the
– phosphate of the GTP–S molecules is still too long to form a bond and is not in-line
with the leaving group. The base of a GTP–S molecule overlays very well with the bases
of c-di-GMP, but the position and conformation of the ribose and the – phosphate moiety
is completely di erent. Thus, the position of the base is not changed during catalysis and
always stays in the same binding pocket. The ribose and the – phosphate adopt di erent
conformations during catalysis to end up in the relatively rigid conformation of the c-di-
GMP macrocycle. To allow this conformational change, the domains of the GGDEF dimer
have to rearrange too in order to enable catalysis.
A model was generated to mimic the competent state of YdeH, setting the distance of the
forming bond between the 3’OH and the – phosphate of the GTP–S molecules to 3 A˚ and
the attack occurs in-line (Figure 3.39). In this model no clashes appeared, but the N-
termini (Asn130) of both GGDEF domains are 14.2 A˚ apart from each other. This distance
is probably too far to allow dimerization via the N-terminal CZB domains. However, the
generated model can serve as a starting point for further model refinement, because already
smallest changes of the torsion angles of the glycosidic bond and the bond between C5’-
O5’-P– of the GTP cause a big impact on the dimer arrangement of the DGC domains. By
adjusting these torsion angles, the model can be refined in such way, that the N-termini of
the GGDEF domains can come closer together in order to allow the dimerization via the
CZB domains.
Independent of how the exact competent state of YdeH looks like, a reorientation of the
GGDEF domains relative to each other has to occur to switch from the substrate bound state
to the product bound state. To accomplish this transition, flexibility is required between
the GGDEF and the CZB domain.
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Figure 3.39: (A) Dimer arrangement seen in the YdeHGGDEF structure applied on the DGC domains
as found in the full-length YdeH structure. One monomer is shown in orange and one in
blue. The residue Asn130 representing the C-terminus is shown as sphere and GTP–S
is depicted as sticks. (C) Close up view of (A). The forming bonds are marked with
dashed lines. (D) Close up view of (A) overlayed with c-di-GMP (green) as it is bound
in the YdeHGGDEF structure. (B) Model of the competent dimer of YdeH. The forming
bond has a distance of 3 A˚ and the O3’ is in-line with the leaving group. One monomer
is shown in orange and one in blue. The residue Asn130 representing the C-terminus
is shown as sphere and GTP–S is depicted as sticks. (E) Close up view of (B). The
forming bonds are marked with dashed lines.
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3.1.9 Summary of the YdeH structures
Three structures of YdeH could be determined including the full-length structure at a reso-
lution of 3.9 A˚ and the structures of the CZB domain and the GGDEF domain of YdeH at
2.2 A˚ and 1.8 A˚ resolution, respectively.
In the structure of full-length YdeH, substrate binding to the active site could be identified,
which is similar to the binding in the activated structure of PleD. However the dimer ar-
rangement of the two GGDEF domains is di erent. In YdeH the two active sites are facing
each other, but are still not in a competent conformation, because the substrate molecules
are too far apart from each other to perform catalysis.
Product binding to the active site could be shown in the structure of YdeHGGDEF. Here, c-di-
GMP crosslinks the two active sites. The guanyl bases of c-di-GMP bind to the same pocket
as the substrate, but the ribose and the – phosphate moiety adapt di erent conformations
and are not involved in protein interactions. In this structure, the dimer arrangement of the
two GGDEF domains is stabilized via two salt bridges, consisting of the conserved residues
Arg140 and Asp174. To confirm the importance of this GGDEF arrangement enzymatic
experiments will have to be performed.
In the presented structures of full-length YdeH and YdeHGGDEF, c-di-GMP was bound to
the I-site of YdeH. The dimeric binding of c-di-GMP to the Ip-site in the YdeHGGDEF struc-
ture was very similar to other known structures of DGCs, where c-di-GMP is bound to the
I-site, as well. Since YdeH has a variation in the Ip-site motif (RxxD), where the aspartate
is exchanged to a glutamate, it could be shown that this does not impede the c-di-GMP
binding. The Is-site in the YdeHGGDEF structure is completely di erent from the other
known DGC structures. The seen Is-site is located on helix –4 and consists of Arg271 and
Tyr274. Since the N-termini of this crosslinked DGC domains are pointing in the same
direction, this Is-site has to be analyzed in enzymatic experiments. Furthermore a Is-site
on the N-terminal CZB domain has to be considered.
The N-terminal CZB domain of YdeH shows a new fold consisting of a four helical bundle.
One interesting finding was that the CZB domain of YdeH harbors a zinc-binding site
compromised of three histidines and one cysteine, which mediates contact between the
helices and fix them in a rather rigid arrangement. Consequently the question arises, if zinc
is the input signal for YdeH and can therefore regulate the diguanylate cyclase activity of
YdeH upon binding to the zinc binding site in the N-terminal domain. This was tried to
answer by enzymatic investigations shown in the next section.
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YdeH shows DGC activity
To test if YdeH shows diguanylate cyclase activity, 2µM YdeH was incubated with 100µM
GTP in 50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mM MgCl2. The reaction was stopped
after 2 and 15min by boiling 2min and analyzed by ion-exchange chromatography as de-
scribed in section 2.3.3. The elution of the reaction was compared to GTP and c-di-GMP
elution profiles. As shown in Figure 3.40, the peak of the substrate GTP decreased, while
the c-di-GMP peak increased during the reaction. The reaction product of YdeH overlays
with the c-di-GMP-standard peak and mass analysis confirmed the product to be c-di-GMP.
Thus, it could be shown that YdeH indeed acts as a diguanylate cyclase in vitro.
To determine the kinetic parameters of YdeH, enzymatic activity of YdeH was measured
with the Baykov assay as described in section 2.3.3. For this, 2µM zinc-free YdeH was
incubated with di erent concentrations of GTP (5-100µM) and the initial velocities were
measured. Maximal velocity of 5.5min≠1 was measured up to a GTP concentration of 30µM
(Figure 3.41). Below 20µM GTP, no linear initial velocity could be measured, even if the
enzyme concentration was decreased and the reaction time was shortened. With a enzyme
concentration, which would result in a initial linear velocity such small amounts of product
would be produced, which is under the detection limit of the assay. Only an upper limit for
the KM of 5.8µM could be determined. vmax was calculated to 5.5min≠1.
These values for Km and vmax are in the same range as already described for other DGCs
[16, 31, 103]. The velocity of YdeH is very slow for an enzyme. This might be due to not
optimal reaction conditions or to the absence of an additional factor that is required to
stimulate activity. On the other side, catalysis is a quite complicated process, where two
domains have to approach each other in the right orientation to form the complete active
site. The requirement for these specific conformation could also limit the velocity of the
catalyzed reaction.
The CZB domain is necessary for YdeH activity
To investigate the importance of the N-terminal CZB domain of YdeH, activity measure-
ments of full-length YdeH were compared with YdeHGGDEF, in which the complete CZB
domain is missing. Enzymatic activity was measured with the Baykov assay with 2µM en-
zyme and 100µM GTP in 50mM Tris-HCl, pH 8.0 , 50mM NaCl and 5mMMgCl2. At time
points of 1, 2, 3 and 4 min the production of pyrophosphate was measured. Under these
condition, no activity of YdeHGGDEF was measurable. This indicates, that the GGDEF
domain alone is much slower or even not active compared to full length YdeH.
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Figure 3.40: Time course of the reaction catalyzed by YdeH. The samples were analyzed by ion-
exchange chromatography. In black, a run of a c-di-GMP standard is shown. The left
most small and constant peak corresponds to a GDP contamination in the commercial
GTP batch.
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Figure 3.41: Initial velocity at di erent GTP concentrations. KM and vmax values were determined
by fitting the Michaelis-Menten curve. Error bars are standard deviations.
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Figure 3.42: Gel filtration runs with YdeH samples before and after treatment with EDTA. The
column S200/10/30 with 20mM Tris-HCl, pH 8.0, 150mM NaCl, 50mM arginine and
50mM glutamate as running bu er was used.
Furthermore, reaction setups with 20 and 100µM YdeHGGDEF and 500µM GTP with time
points at 6, 23 and 26h were performed. Under these conditions very little activity could
be measured resulting in a turnover of 1.8◊ 10≠5min≠1 and 2.9◊ 10≠5min≠1, which is
250000 times slower compared to full-length YdeH. This shows, that the DGC domain alone
is not able to perform catalysis in a reasonable timescale. Thus, the dimer formation of
the N-terminal CZB domain is essential to perform the catalytic reaction, as it raises the
likelihood of the productive encounter of two GGDEF domains.
YdeH is inhibited by zinc
To investigate the e ect of zinc on YdeH activity, enzyme that is completely devoid of zinc
has to be produced for comparison. Therefore, YdeH was incubated with EDTA over night
as described in section 2.3.1. To control, if YdeH is still well folded after zinc removal and to
remove the EDTA, gel filtration was performed. As it is shown in Figure 3.42, the protein
behaves the same as before EDTA treatment, meaning that YdeH is stable and well folded
without zinc. This was a first indication, that zinc has no important structural role.
To prove that YdeH is zinc-free after EDTA treatment, a PAR assay was performed. With
this assay it could be demonstrated, that all zinc was released from the protein. For com-
parison, a protein sample before EDTA treatment was analyzed resulting in a zinc content
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of 40%. This indicates, that YdeH has a high a nity binding site for zinc, because zinc is
still bound after all the purification steps, in which no zinc was added. The removal of zinc
with EDTA was possible because a high excess of EDTA and a long incubation time was
used.
To elucidate the e ect of zinc on YdeH activity, 50µM zinc free YdeH was incubated with
di erent zinc concentrations (0-150µM). To measure the amount of zinc, which has bound
to YdeH, part of the sample was analyzed with the PAR assay. A small variation of the
PAR assay was used, in which the mercury derivative was omitted, in order to measure
the remaining zinc in solution. To compare zinc binding with activity of YdeH, a second
part of the sample was used to perform a Baykov assay. Therefore 2µM zinc treated YdeH
sample was incubated with 100µM GTP in 50mM Tris-HCl, pH 8.0 , 50mM NaCl and
5mM MgCl2. In Figure 3.43, the activity and the amount of zinc bound to YdeH was plot-
ted against the total zinc concentration added. At the beginning a linear increase of zinc
binding to YdeH takes place until the protein concentration of 50µM is reached, meaning
that up to 50µM all added zinc is completely bound to YdeH. Above 50µM further zinc is
bound by YdeH, which probably results from unspecific binding to the protein surface. The
divalent cation zinc can function as a crosslinker, which leads to protein aggregation. This
could be shown in gel filtration experiments (Figure 3.44), where YdeH, incubated with an
excess of zinc, forms higher aggregates.
An increase of zinc bound to YdeH results in a reduced enzymatic activity. Hardly any
detectable activity is measurable at equimolar zinc and protein concentration indicating
that YdeH is inhibited by zinc.
This experiment showed, that zinc inhibits the activity of YdeH. The zinc binding is very
strong with a KI below 50µM, because until the YdeH concentration of 50µM is reached
nearly every zinc added is bound by the protein. In order to determine the exact KI for the
zinc binding to YdeH at least ten times lower protein concentration than the KI have to be
used. Since this is not possible with the employed Baykov assay, competition experiments
were performed. For this competition assay, where YdeH and the chelator EDTA compete
for the zinc, 0.2µM YdeH was incubated with 0.2µM ZnCl2 and di erent EDTA concentra-
tions (0.1nM-1mM). The activity was measured with the Baykov assay with 100µM GTP
in 50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mMMgCl2. The activity was plotted against
the EDTA concentration, as it is shown in Figure 3.45. The data was fitted with an exact
mathematical model [107] describing competitive binding of EDTA and YdeH to zinc. The
KD (EDTA/Zn) was set to 1◊ 10≠14M to achieve a stable fitting. The determined values
were than adjusted to the real KD (EDTA/Zn) of 4.79◊ 10≠16M [152], which resulted in a
KI (YdeH/Zn) of 3.4◊ 10≠17M.
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Figure 3.43: Inhibition of YdeH by zinc. The total zinc concentration is plotted against the amount
of zinc, which is bound to YdeH (⌅), and against the activity of YdeH (N). The amount
of free zinc was measured with the PAR assay and the activity was determined with
the Baykov assay.
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Figure 3.45: YdeH DGC activity in the presence of a zinc binding competitor (EDTA). Inhibition
of wildtype YdeH activity (orange) and YdeH-C52A activity (green) is relived by zinc
sequestration to EDTA. Protein and zinc concentrations were 0.2µM. The data were
fitted with an exact mathematical model [107] describing competitive binding of EDTA
and YdeH to zinc. The KD (EDTA/Zn) was set to 1◊ 10≠14M to achieve a stable
fitting yielding in KI (YdeH/Zn) of 7.2◊ 10≠16M for wildtype YdeH and in a KI
(YdeH-C52A/Zn) of 4◊ 10≠15M for the C52A mutant. For the C52A mutant an upper
and lower limit with a KI of 4◊ 10≠14M and 4◊ 10≠16M was additionally plotted in
the graph.
Noteworthy the activity is not completely abolished at small EDTA concentrations. This
can either result from incorrect determined YdeH or ZnCl2 concentrations, or the a nity
of YdeH for zinc is not high enough to bind an equimolar amount of zinc. Furthermore,
the residual activity may be due to the encounter of GGDEF domains from di erent dimers.
Based on this exquisitely small KI value, it appears very unlikely that the inhibition of YdeH
is due to nonspecific zinc binding. Nevertheless to corroborate the idea, that zinc binding
to the CZB domain of YdeH controls its enzymatic activity, it was tried to generate zinc
binding mutants of YdeH. It was attempted to individually change all four zinc coordinating
residues His22, Cys52, His79 and His83. However, despite several repeated attempts using
two di erent cloning strategies, it was not possible to generate mutations in pET28a/YdeH
that would exchange any of the zinc coordinating histidines to leucines. The only variant
that could be generated was the C52A mutant.
To analyze the zinc content after purification of YdeH-C52A, a PAR assay was performed.
Surprisingly, in contrast to the wildtype there was no zinc detectable, which already indi-
cates a weaker a nity of this mutant for zinc.
To investigate the influence of zinc binding on the activity of YdeH, the same competition
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experiment was performed with the C52A mutant. As shown in Figure 3.45, the residual
activity of the mutant at low EDTA concentrations is much higher than for the wildtype. In
addition, the inflection point of the fitted data curve is shifted to lower EDTA concentration
compared to wildtype. This results in a ten times higher KI of 2◊ 10≠16M. This indicates
clearly, that Cys52 is involved in zinc-binding as it is seen in the crystal structures. To
demonstrate that the fitted KI is in the right range, an upper and lower limit with a KI of
2◊ 10≠15M and 2◊ 10≠17M was additionally plotted in the graph.
The measured inhibition of YdeH by zinc is in the femtomolar range and is comparable to
a nity constants of the zinc sensor proteins ZntR and Zur from E. coli that are zinc depen-
dent transcriptional regulators [54, 64]. This remarkably high a nity for zinc is required
to allow full occupation of zinc containing proteins, because the free zinc concentration in
the bacterial cell is very limited due to the reactivity of zinc as a potent Lewis acid. This
very low concentration of free zinc and the high a nity binding sites in zinc containing
proteins, however, have important consequences for the kinetics of zinc binding to proteins.
Ligand exchange mechanisms for zinc transfer from occupied to unoccupied bindings sites
are necessary to circumvent the kinetic limitations of dissociation/assosiation mechanisms,
which are caused by the virtual absence of free zinc ions. A mechanism of zinc transfer
between alternative binding partners via ternary complexes was proposed, where a consid-
erable fraction of individual ligands of a zinc binding site might be in a rapid equilibrium of
bound and unbound state. This results in a transient availability of binding sites for com-
peting acceptor molecules. The transfer via zinc-bridged complexes can be many orders of
magnitude faster and does not depend on free zinc ions for rapid mediation of zinc signals
[153]. The unstructured loop region close to the zinc binding cysteine in the N-terminal
domain of YdeH is ideally suited for this fast zinc exchange. This findings strongly sup-
ports the idea that zinc binding controls YdeH activity, rather than playing a structural role.
YdeH is a zinc sensor and not regulated by a redox mechanism
As the activity of YdeH is regulated by zinc, the question arises if YdeH is a zinc sensor
and therefore acts in response to the zinc level. Another possibility might be that YdeH
is regulated by a redox mechanism, that allows the control of YdeH activity via the zinc
content as a consequence of the redox state of the coordinating cysteine residue. The sulfur
donor atoms of cysteine ligands can be oxidized and reduced again with concomitant disso-
ciation and association of zinc. In vivo oxidative stress can be caused by macrophages, that
would lead to activated YdeH. The resulting increased c-di-GMP level would induce biofilm
formation.
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To test this possibility, the a nity of YdeH for zinc should be decreased after treatment
with an oxidizing agent. This would result in zinc release and activation of the enzyme. The
following di erent oxidizing agents were tested in an excess of 5, 50, 500 and 5000: iodac-
etamide, N-ethylmaleimide, H2O2, KSCN, NaAsO2, 4-chloromercuribenzoic acid, oxidized
glutathione, Paraquat, pyocyanin, pyocianin/NADH, phenylselenyl chloride and glutathione
reductase/oxidized glutathione. Some of these di erent reagents are used in laboratory
praxis to oxidize cysteines and others are naturally occurring oxidizing agents. The incu-
bation was done with 1µM of YdeH and 1µM ZnCl2 in 50mM Tris-HCl, pH 8.0, 50mM
NaCl and 5mM MgCl2. Afterwards the samples were tested for DGC activity with the
Baykov assay by adding 100µM GTP. The result for all di erent oxidizing reagents was the
same: the protein has completely lost its enzymatic activity. This was most likely a result
of unspecific oxidation, which leads to protein aggregation.
Furthermore the same experiments were performed with the C52A mutant of YdeH, which
also resulted in a entire loss of DGC activity. This supports the idea of protein aggregation
as a result of unspecific oxidation.
Since the loss of activity also occurred under rather mild conditions by using in vivo occur-
ring systems like glutathione reductase/oxidized glutathione, it is unlikely that the activity
of YdeH is regulated via a redox mechanism. It seems to be more reasonable, that YdeH
is directly regulated by zinc. This finding is also supported by in vivo data. It could be
shown, that oxidative stress has no e ect on cellular c-di-GMP concentration and on the
PgaD level, which was shown to be controlled by c-di-GMP produced by YdeH [47]. Fur-
thermore, external zinc represses PgaD levels via YdeH. Mutations in the zinc-binding site
of YdeH results in constitutive high level of PgaD, which is not responding to external zinc.
In a  YdeH strain, the PgaD level is constantly low and is again not susceptible to external
zinc (A. Böhm, unpublished data).
The salt bridge Arg140-Asp174 is important for YdeH activity
To confirm the dimer arrangement observed in the YdeHGGDEF structure with bound c-di-
GMP (Figure 3.34), the e ect of the salt bridge Arg140-Asp174 on DGC activity of YdeH
was investigated. Therefore, two mutants were generated, whereby first the aspartate 174
was exchanged to an arginine and in a second mutant the arginine 140 was additionally
mutated to a aspartate.
Purified and zinc-free YdeH-D174R was analyzed with the Baykov assay for DGC activity.
In the beginning, the same standard conditions as for wildtype YdeH were used: 2µM
YdeH-D174R and 100µM GTP in 50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mM MgCl2.
No activity could be detected under this conditions. Then, the enzyme concentration was
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increased to 10µM and the reaction time was increased from 4 to 120min. Under these
conditions, a turnover of 4◊ 10≠4min≠1 was measured. The velocity of this mutant is
14000 times slower than for the wildtype. The exchange of a negative charged amino acid
to a positive one prevents the formation of the salt bridge and induces an electrostatic
repulsion. Thus, the formation of the salt bridge Arg140-Asp174 may be important for
YdeH to perform the catalysis. This finding confirms the dimer arrangement as it is seen in
the YdeHGGDEF structure.
In a next step, the salt bridge should be restored with the double mutant YdeH-R140D-
D174R. Because the GGDEF domains form a symmetric dimer, the formation of the salt
bridge should be possible. Unfortunately, no soluble protein could be expressed from this
second mutant YdeH-R140D-D174R. This is astonishing, because the overall charge of the
protein was not changed and no big conformational changes were expected.
YdeH shows product inhibition
Several DGCs show inhibition by the reaction product c-di-GMP [15, 17, 154]. The first
crystal structures of DGCs led to the hypothesis, that inhibition is due to the crosslinking
of the GGDEF domain to another domain, so that the two GGDEF domains can not ap-
proach each other to perform catalysis. This inhibition by domain immobilization model
was later confirmed by enzymatic experiments [16, 31]. Another proof for this mechanism
came from two structures of WspR, where one has a c-di-GMP dimer bound to the I-site
and the second is nucleotide free. By comparison it could be shown, that the structures of
the GGDEF domains are identical in both states. The active site loop is very similar and
independent from the c-di-GMP binding to the GGDEF domain and therefore a communi-
cation between the Ip-site and the active site could be excluded to cause the noncompetitive
product inhibition [18].
To investigate the mechanism of product inhibition, YdeH was analyzed by enzymatic exper-
iments. For this, 1µM zinc-free YdeH was incubated with di erent c-di-GMP concentrations
(0-2mM) in 50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mM MgCl2 and was analyzed with
the Baykov assay by adding 100µM GTP. As it is shown in Figure 3.46, YdeH is inhib-
ited by c-di-GMP with a KI of 58µM. To exclude that the measured inhibition is not a
competitive inhibition, the same experiment was performed with a di erent GTP concen-
tration of 500µM GTP. This resulted in the same KI value, which proves that YdeH is
non-competitively inhibited by c-di-GMP. The measured inhibition constant of 58µM is far
above the physiological concentration of c-di-GMP in vivo, which means that the measured
inhibition is probably not physiological. One explanation for this high KI could be the
di erence in the RxxD-motif compared to other studied DGCs. The exchange from an as-
partate to a glutamate in YdeH might result in higher KI , or the di erence in KI is located
in the nature of the secondary so far not reliably identified I-site.
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Figure 3.46: Product inhibition of YdeH. The activity is plotted against c-di-GMP concentration.
The KI was determined to be 58µM. Error bars are standard deviations.
As in the YdeHGGDEF structure, a c-di-GMP mediated crosslinking between two GGDEF
domains is seen (Figure3.37). It was tested, if this domain interaction is involved in inhibi-
tion of YdeH. Therefore, the interacting residues of the possible Is-site Arg271 and Tyr274
were mutated to alanines. Surprisingly, the double mutant showed no enzymatic activity.
As the protein was highly expressed, very soluble and showed no aggregation on gel filtration
experiments, the loss of activity is rather unlikely due to misfolded protein. One explanation
might be, that the mutated residue Tyr274 is important to form the competent dimer to al-
low catalysis. As it is shown in Figure 3.47, this residue is nearly in H-bonding distance with
its symmetry mate in the dimer interface of the two GGDEF domains in the YdeHGGDEF
structure. During catalysis, in which the two DGC monomers have to be closer together, the
Tyr274 can be important for forming a tighter dimer. In addition, both mutated residues
Arg271 and Tyr274 are located at the dimer interface of the two GGDEF domains in the
full-length structure of YdeH. Arg271 is 9.0 A˚ away from Asp174 and Tyr274 is about 9.0 A˚
away from Lys170, which is not completely visible in the structure. These two pairs might
also form salt bridges in the competent dimer during catalysis, when the two GGDEF
domains are in close proximity. To further investigate the role of Arg271 and Tyr274, the
single mutants would have to be generated and analyzed for activity and product inhibition.
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(B)
Figure 3.47: Role of Tyr274 and Arg271 in the dimer interface of YdeH. (A) Ribbon representation
of YdeHGGDEF. The two monomers are colored in light and dark orange, respectively.
C-di-GMP and the interacting residues in the dimer interface (Arg140 and Asp174)
are shown as sticks as well as the Tyr274, that are 4.0 A˚ apart and therefore close to
H-bonding distance. (B) Ribbon representation of the GGDEF domains of full-length
YdeH. The two monomers are colored in light and dark orange, respectively. C-di-GMP
and the residues in the dimer interface that could interact with Arg271 and Tyr274, if
the dimers move closer together are shown as sticks. In the right corner, a zoomed view
of the possible interacting residues is depicted.
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Figure 3.48: Investigation of a secondary I-site on the CZB domain of YdeH. (A) Ribbon representa-
tion of the CZB domain of YdeH. All arginines on the surface are represented as sticks
and labeled. (B) Product inhibition of the R56A, R73A and R87A mutants of YdeH. To
determine the KI the activity was plotted against c-di-GMP concentration and fitted
with a exponential decay function. Error bars are standard deviations.
Furthermore, the presence of a Is-site located on the CZB domain of YdeH, comparable
to the N-terminal REC domain of PleD [15] was investigated. Since arginines are always
involved in c-di-GMP binding, the arginines on the surface of the CZB domain were chosen
for a possible interaction with the I-site of the GGDEF domain (Figure 3.48). Of the four
arginines of the CZB domain, Arg36 can be excluded, because this residue is to far away
to interact with the Ip-site on the GGDEF domain. For the other three arginines, Arg56,
Arg73 and Arg87, single mutations were generated by exchanging the arginines to alanines.
All three mutants were tested for product inhibition by incubating the zinc-free protein with
di erent concentrations of c-di-GMP (0-1mM) and checking for activity with the Baykov
assay, as it was done for the wild-type. For all three mutants, the calculated KI values
lay in the same range as for wild-type YdeH (Figure 3.48). This supports that the tested
arginines are not involved in a Is-site. It cannot fully excluded that a Is-site is present in
the CZB domain comprised of other residues, however, this is rather unlikely as arginines
are involved in all so far known binding modes of c-di-GMP.
With the mutants tested so far, no Is-site could be identified. The possible Is-site on the
GGDEF domain, which was seen in the YdeHGGDEF structure needs further investigation
by using the single mutants of this site. In addition, the Is-site on the GGDEF domain,
which is used in PleD, WspR and in the DGC from M. aquaeolei corresponding to residue
Arg152 in YdeH, is also a possible site, which has to be analyzed. As it is the case for PleD,
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where two di erent Is-site are present, which operate redundantly, the integrity of only one
of the Is-sites is required for noncompetitive product inhibition. Therefore a correct Is-site
might already be tested, but it showed no e ect on the inhibition by c-di-GMP, because
another Is-site is existing in parallel and still inhibits YdeH.
3.1.11 Model of zinc dependent regulation of YdeH activity
The presented structures of full-length YdeH and YdeHCZB represent an inhibited state of
YdeH, because they have zinc bound to the CZB domain. This is in agreement that in the
full-length structure the two substrates molecules are too far away to react with each other
and produce c-di-GMP. The binding of zinc to the CZB domains keeps the helices of each
CZB domain in a compact and fixed arrangement, in which the linker between the CZB
and GGDEF domain is defined, too. Thereby the two GGDEF domains are fixed in an
incompetent state, which does not allow the encounter of the two GGDEF domains to form
c-di-GMP.
Upon zinc release, the variability of the CZB domain is increased, because the helices –1,
–2 and –3 are not connected to each other anymore via the zinc. One possibility to activate
YdeH after zinc release, could be due to the rearrangement of the helices in the CZB
domain, which would bring both helices –4 and consequently also both GGDEF domains
into a proximity, where the catalysis can take place (Figure 3.49). Thus the inhibition of
YdeH by zinc can be explained by the fixation of the inter domain region.
Figure 3.49: Mechanistic model of YdeH regulation by zinc. The binding of zinc to the CZB domain
fixes YdeH in a conformation, where the two actives sites of the GGDEF domain can
not approach each other to perform catalysis. If the zinc is released, the variability of
the CZB domain is increased, which allows the GGDEF domains to form a competent
dimer.
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3.2 Summary and Outlook
The synthesis of the second messenger c-di-GMP is performed by diguanylate cyclases. They
get activated either by external or internal signals, which interact with N-terminal sensory
domains of the DGCs. Only very few of these signals are discovered so far. In order to
investigate new input signals and to study the regulation of the diguanylate cyclases, the
DGC YdeH from E. coli was chosen for structural and biochemical studies.
In this thesis, the three-dimensional structure of YdeH could be solved, which provided new
insights in the input signal and regulation of YdeH. The N-terminal sensory domain of YdeH
shows a new fold, a four helical bundle, which harbors a zinc-binding site compromised of
three histidines and one cysteine. It could be shown using enzymatical studies, that this
N-terminal sensory domain is necessary for the DGC activity of YdeH. This domain me-
diates the dimerization of YdeH, which is essential for the catalysis since two monomers
built up the active site. It could be shown that YdeH is a permanent dimer. This raises
the question, if YdeH is permanently active or how it is regulated independent from the
dimerization. It could be shown that the DGC activity of YdeH is regulated by zinc via
binding to the N-terminal sensory domain. YdeH has a very high a nity for zinc in the
femtomolar range, which is comparable to other zinc sensors. Since the free cellular zinc
concentration is very low and the a nity of the zinc binding proteins is very high, there
are indications that mechanisms exists by which the zinc is directly passed from protein
to protein depending on the relative a nities. The unstructured loop region close to the
zinc binding cysteine in the N-terminal domain is ideally suited for this fast zinc exchange.
YdeH represents the first example of a biological zinc-sensor that exerts its downstream
e ects posttranscriptionally and the first example of a metal sensory c-di-GMP signaling
protein.
In the structure of full-length YdeH, substrate binding to the active site could be shown, in
which the ribose and the – phosphate moiety are not involved in protein interactions. The
dimer arrangement of the two monomers is not in a competent conformation, because the
substrate molecules are too far apart from each other to perform catalysis. This is not sur-
prising, since the structure is in an inhibited state because zinc is bound to the N-terminal
domain.
Product binding to the active site could also be shown in the structure of YdeHGGDEF.
Here, c-di-GMP crosslinks the two active sites. The guanyl bases of c-di-GMP bind to the
same pocket as the substrate, but the ribose and the – phosphate moiety adapt di erent
conformations and are involved in protein interactions. In this structure, the dimer arrange-
ment of the two DGC domains is stabilized via two salt bridges, which were shown to be
essential for the DGC activity of YdeH.
To get insights into the competent dimer arrangement of YdeH, a model was generated
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assuming an inline attack. In this model however, the N-termini of both DGC domains
are too far apart from each other to allow dimerization via the N-terminal CZB domains.
Although the competent state of YdeH is not known, the transition from the substrate
bound state to the product bound state is attended by reorientation of the DGC domains
relative to each other. The inhibition of zinc by binding to the N-terminal sensory domain
can be explained by the fixation of the inter domain region. This fixed position prevents
the variability needed to perform catalysis.
In the presented structures of YdeH, dimeric c-di-GMP could be identified, which was bound
to the inhibitory site of YdeH. In enzymatic experiments, product inhibition could be de-
tected, however the inhibition constant was far above the physiological c-di-GMP concen-
tration. This low a nity could be caused by the variation in the I-site motif compared to
PleD or WspR. A secondary I-site, which is visible in the YdeHGGDEF structure could not
be assigned definitely so far.
Product inhibition of YdeH will have to be investigated in further experiments by studying
the single mutations of the observed possible secondary I-site in the YdeHGGDEF structure.
In addition, the secondary I-site, which is seen in PleD and WspR has to be explored. One
important goal would be to determine the structure of a competent state of YdeH without
zinc bound to the N-terminal CZB domain. This would provide insights into the catalytic
mechanism and particularly into the zinc-mediated regulation of YdeH.
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Abstract Cyclic di-GMP (c-di-GMP) is an almost universal bacterial second messenger
involved in the regulation of cell surface-associated traits and the persistence of infections.
GGDEF and EAL domain-containing proteins catalyse c-di-GMP synthesis and degradation,
respectively. We report the enzymatic large-scale synthesis of c-di-GMP, making use of the
GGDEF domain-containing protein YdeH from Escherichia coli. Overexpression and
purification of YdeH have been established, and the conditions for c-di-GMP synthesis were
optimised. In contrast to the chemical synthesis of c-di-GMP, enzymatic c-di-GMP production
is a one-step reaction that can easily be performedwith the equipment of a standard biochemical
lab. The protocol allows the production of milligram amounts of c-di-GMP within 1 day and
paves the way for extensive biochemical and biophysical studies on c-di-GMP-mediated
processes.
Keywords c-di-GMP. Diguanylate cyclase . GGDEF domain . Enzymatic synthesis . E. coli
Introduction
Bis-(3′-5′)-cyclic di-GMP (c-di-GMP) is an important bacterial second messenger involved
in the regulation of a number of complex physiological processes. C-di-GMP was first
identified 20 years ago as an activating factor of cellulose synthase in Acetobacter xylinum
[1], but in the mean time, it has been shown to play a central role, among others, in the transition
between a motile, single-cell state to a sessile, surface-attached state found in biofilms [2–5]. Its
relevance for the virulence of pathogenic bacteria is well established [2–6].
C-di-GMP is synthesised by the condensation of two GTP molecules. This reaction is
catalysed by the GGDEF domain of diguanylate cyclases (DGCs) [7–10], whereas EAL
[7, 11–13] and HD-GYP [14] domains hydrolyse the compound to yield the linear pGpG
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dinucleotide. All these catalytic domains are typically found in combinations with other,
mostly sensory or regulatory, domains and control the cellular level of c-di-GMP.
Much about the mechanisms of c-di-GMP signalling in bacteria has still to be
discovered, in particular since only a few targets of c-di-GMP have been identified.
Characterised c-di-GMP receptors comprise PilZ domains [15] and degenerated GGDEF
and EAL domains [16, 17]. Furthermore, the GEMM riboswitches have recently been
discovered to regulate gene expression via c-di-GMP binding [18–20].
Recent studies have demonstrated that exogenous c-di-GMP treatment inhibits adhesive
Staphylococcus aureus cell-to-cell interactions and biofilm formation [21] and that it is
effective also in a mouse model [22]. These findings make c-di-GMP an interesting
candidate as a potential antimicrobial agent. It was demonstrated that c-di-GMP stimulates
the immune system to prevent bacterial infections and is therefore evaluated as a potential
vaccine adjuvant candidate [23–25]. It was also reported that c-di-GMP inhibits cancer cell
proliferation in vitro and could therefore be used as a therapeutic agent [26].
In order to carry out extensive studies on c-di-GMP-mediated processes, sufficient
supply of this compound is crucial. The reported chemical syntheses of c-di-GMP are
multistep reactions, which make them time-consuming, expensive and inefficient [27–33].
Most of them make use of phosphotriester, phosphoamidite or H-phosphonate chemistry based
on air- or water-sensitive reagents and involve several chromatographic purification steps.
In contrast, DGC-catalysed synthesis of c-di-GMP from GTP appears straightforward, as
has been reported for PleD, VCA0956 and WspR [12, 13, 34–37]. However, all these
DGCs show potent allosteric product inhibition with Ki values in the low micromolar range.
Furthermore, the purified proteins are rather unstable in solution. Recently, a DGC from a
thermophilic organism (Thermotoga maritima) has been employed for the enzymatic
synthesis of c-di-GMP [38]. A fragment comprising only its DGC domain with the
allosteric inhibition site (I-site) mutated to impede product inhibition has been exploited.
Large amounts (about 20 mg) of c-di-GMP were obtained employing 1 mg of this modified
version of the enzyme and by replenishing repeatedly the reaction mixture with the
substrate GTP.
In this paper, we report a large-scale production procedure of c-di-GMP employing, as
an alternative enzyme, YdeH from Escherichia coli. This enzyme consists of an N-terminal
domain of unknown fold and a C-terminal GGDEF domain. We have shown previously
[39] that YdeH, in contrast to most of the other DGCs, is a constitutively active dimer and
exhibits a turnover of 1.6 min−1 and a Km of 17 μM. The YdeH catalysed reaction shows
non-competitive product inhibition only at comparatively large c-di-GMP concentration
(Ki=44 μM), in contrast to the aforementioned DGCs. Furthermore, even at very high
c-di-GMP concentration (>1 mM), YdeH shows residual activity (15%) [39]. We show
that with this enzyme, complete conversion of GTP to c-di-GMP can be achieved within
hours, yielding milligram amount of product.
Material and Methods
Expression and Purification of YdeH
C-terminally His6-tagged YdeH was expressed in the pET28b plasmid in the E. coli Rosetta
strain. The transformed cells were cultivated at 37 °C in Luria–Bertani medium supplemented
with ampicillin (100 μg/mL) and chloramphenicol (34 μg/mL) until the OD600 had reached
0.7. Gene expression was induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside
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(IPTG). After 4 h of incubation, the cells were harvested by centrifugation (6,800×g, 10 min,
4 °C) and the pellets were frozen at −20 °C.
Prior to lysis, the frozen cell pellets were thawed and resuspended in Ni-A buffer
(50 mM NaH2PO4, pH 7.5, 200 mM NaCl, 10 mM imidazole, 50 mM L-glutamic acid,
50 mM L-arginine). After the addition of DNAse (2.5 μg/mL; Sigma) and EDTA-free
protease-inhibitor cocktail (Roche, 1 tablet/50 mL buffer), the cells were disrupted with a
French press (Thermo Spectronic) at 15,000 psi. The lysate was cleared by centrifugation
(28,000×g, 45 min, 4 °C), and the supernatant was filtered (0.22 μm) and loaded onto a 5-mL
HisTrap column (GE Healthcare). After washing the column with Ni-A buffer (10 column
volumes (CV)), the protein was eluted with a linear gradient of imidazole from 10 to
500 mM in 10 CV. The pooled fractions were concentrated to 1 mL and further purified
by size-exclusion chromatography using a Superdex 75 16/60 column (GE Healthcare)
and SEC buffer (20 mM Tris–HCl, pH 7.6, 150 mM NaCl, 50 mM L-glutamic acid,
50 mM L-arginine). The chromatographic runs were carried out with an Äkta Purifier
FPLC unit and monitored with Unicorn software. The purification process was monitored
by SDS-PAGE followed by Coomassie blue R-250 staining. Protein concentration was
determined by measuring the absorbance at 280 nm (ε280=39,880 M
−1cm−1).
Enzyme Assay
The initial rate of c-di-GMP synthesis was measured by following the substrate
consumption using ion exchange chromatography. The reaction mixture (100 μL) contained
2 μM purified YdeH, 100 μM GTP (Sigma), and 5 mM MgCl2. The effect of pH on the
activity of YdeH was tested in 50 mM MES, pH 6.5–7.5, 50 mM Tris–HCl, pH 7.5–8.5,
and 50 mM CHES, pH 9.0–10.0. Also, the effect of different salts (LiCl, NaCl and KCl)
and NaCl concentrations (25 mM–1.5 M) was investigated. The reaction was stopped by
heating of the sample for 2 min at 99 °C. Subsequently, 100 μL of the reaction mixture was
diluted in 900 μL 5 mM NH4HCO3, pH 8.0, filtered (0.22 μm) and loaded on an ion-
exchange column (ResourceQ 1 mL, GE Healthcare). The nucleotides were separated with
a gradient from 0.005 to 1 M NH4HCO3, pH 8.0, in 14 CV. The amount of substrate and
reaction product was determined by integration of the UV absorption (253 nm) peaks. The
procedure was calibrated with GTP (Sigma) and c-di-GMP (Biolog, Bremen) standards of
known concentrations.
Enzymatic Production of c-di-GMP
For the synthesis of c-di-GMP, 2 μM YdeH was incubated with 500 μM GTP in 50 mM
Tris–HCl, pH 7.5, 50 mM NaCl and 5 mM MgCl2 for 5 h. The progress of the reaction was
followed by withdrawing samples (100 μL) that were inactivated by heat denaturation.
Subsequently, the enzyme was removed by filtering and the sample content analysed by
ion-exchange chromatography. After completion of the reaction, the mixture was heated for
5 min at 99 °C, centrifuged (4,500×g, 10 min, room temperature) and filtered (0.22 μm).
For purification of the reaction product, Et3NHCO3 to a final concentration of 5 mM was
added to the reaction mixture and loaded on a reversed-phase chromatography column
(1.7 mL per 1 mL resin Resource RPC, GE Healthcare). After washing the column with
5 mM Et3NHCO3 (10 CV), c-di-GMP was eluted with a linear gradient of ethanol from 0%
to 50% in 10 CV. The reversed-phase chromatography was carried out with an Äkta Purifier
FPLC unit and monitored with Unicorn software. The c-di-GMP-containing fractions were
pooled and lyophilised. The powder was dissolved in water and the concentration was
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determined by measuring the optical density at 253 nm of an aliquot diluted to 10 μM
(assuming an ε253 of 23,700 M
−1cm−1 as reported in [29]).
Analytical Methods
Purified c-di-GMP was analysed by high-performance liquid chromatography coupled to
mass spectrometry. The samples were diluted 50-fold with 10 mM NH4OAc, pH 6.4, and
injected into a SupercosilTM LC-18-T column (Supelco). The run was performed at a flow
rate of 0.7 mL/min using a linear gradient (0–50%) of acetonitrile. The electron spray
ionisation mass spectrometry with a time-of-flight analyser was performed using a
microTOF Focus system (Bruker Daltronics). The capillary voltage was 4500 V, and the
end-plate offset was 500 V (negative mode); the dry temperature was 200 °C, the dry gas
flow was 9 L/min, and the nebulizer pressure was 2 bar.
To test the purity of the obtained c-di-GMP, a sample was analysed by 1H-nuclear
magnetic resonance (NMR) spectroscopy (Bruker Advance 600) in 10 mM Tris–HCl
(D11), pH 7.4 (Cambridge Isotope Laboratories, Inc.), 150 mM NaCl, 50 μM EDTA at
298 K. For comparison, spectra of synthetic c-di-GMP (Biolog) and GTP (Sigma) were
acquired.
Results and Discussion
Expression and Purification of YdeH
YdeH expression was tested in different E. coli strains and at different temperatures. In all
conditions, most of the expressed YdeH was found in inclusion bodies. The highest amount
of soluble protein was achieved in the Rosetta strain at 37 °C, 3–4 h after IPTG induction.
YdeH was purified to homogeneity using a two-step purification procedure, consisting of
Ni-affinity and size-exclusion chromatography. To achieve a protein concentration above
0.8 mg/mL, the addition of arginine and glutamic acid to the buffers was essential to avoid
protein aggregation [40]. The obtained protein was pure and no degradation fragments were
present, as demonstrated by the occurrence of a single band on SDS-PAGE (Fig. 1). The
final yield was about 5 mgL−1 culture.
Optimisation and Characterisation of the Enzymatic Reaction
Substrate and product amounts were analysed by ion-exchange chromatography. A peak at
a somewhat smaller elution volume than that of the final product was observed in the
Fig. 1 SDS-PAGE of the
purification of YdeH. A 12%
(w/v) gel loaded with: lane 1
molecular weight marker, lane 2
cell extract, lane 3 soluble
fraction of the cell extract, lane 4
purified YdeH after Ni column,
lane 5 purified YdeH after
size-exclusion chromatography
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chromatograms taken at early to intermediate time points, but was absent after completion
of the reaction (Fig. 2). As demonstrated by MS, this transient peak did not correspond to a
reaction intermediate, but had the mass of c-di-GMP. Probably, the two peaks correspond to
different oligomeric states of c-di-GMP.
The optimum pH for the synthesis of c-di-GMP was found to be at pH 7.5 in Tris buffer
(Fig. 3). Variation of the salt (LiCl, NaCl, KCl) had only a marginal effect. The enzymatic
activity was virtually the same in 50 mM NaCl and 50 mM KCl, but was found to be
reduced by about 20% in 50 mM LiCl. Similarly, variation of the NaCl concentration
(25 mM–1.5 M) had no significant effect on activity. Therefore, we chose a comparatively
low NaCl concentration (50 mM) to be compatible with the requirements for the subsequent
c-di-GMP purification procedure.
Enzymatic c-di-GMP Production and Purification
For the large-scale synthesis of c-di-GMP, the molar ratio of enzyme to substrate has been
optimised in order to obtain complete conversion within a convenient period. Using 2 μM
YdeH and 500 μM GTP, virtually complete substrate conversion was achieved within 5 h,
Fig. 2 Time course of the
synthesis of c-di-GMP. The
samples were analysed using
ion-exchange chromatography.
After 5 h, the reaction is virtually
complete. The leftmost small and
constant peak corresponds to a
GDP contamination in the
commercial GTP batch
Fig. 3 pH dependence of the
enzymatic activity of YdeH.
The optimum reaction velocity
for the synthesis of c-di-GMP
was found in 50 mM Tris–HCl,
pH 7.5
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as shown in Fig. 2. Initially, the reaction volume was 0.1 mL, but was eventually upscaled
to 0.5 L without any detrimental effect. C-di-GMP was purified on a reversed-phase
column with ethanol as eluent. The Resource RPC resin was chosen because of its
stability at basic pH values. The mobile phase was adjusted so as to prevent binding of the
mono-nucleotides GDP and GTP. Ethanol has the advantage of being non-toxic compared
to other typically used eluents such as acetonitrile or methanol. The procedure yielded
75 mg of pure c-di-GMP employing 30 mg of YdeH. Considering the ease of YdeH
purification, further optimisation of the procedure by recycling of the enzyme as in [38]
was not considered.
Product Analysis
LC/MS clearly identified the reaction product as c-di-GMP (Fig. 4). No impurities were
detected in the chromatogram. The observed mass of c-di-GMP was in perfect agreement
with the calculated mass. In addition, the 1H-NMR spectra of purified c-di-GMP
completely coincided with the spectrum of chemically synthesised c-di-GMP and showed
no traces of the substrate GTP (Fig. 5).
Conclusions
Here, we have described an alternative way for the enzymatic synthesis of the bacterial
second messenger c-di-GMP. We use the DGC YdeH from E. coli, which is an ideal
Fig. 4 Convoluted mass spectrum of enzymatically produced c-di-GMP. The measured mass of 690.1775 g/
mol is in agreement with the calculated mass of 690.0870 g/mol
Fig. 5 Part of the 1H-NMR
spectrum (600 MHz) showing
the chemical shift of H8 of
enzymatically produced
c-di-GMP (top, δ=8.04) and of
GTP (bottom, δ=8.13) as
reference. Comparison demon-
strates that the c-di-GMP sample
was free of GTP. Chemical shifts
are relative to H2O (δ=4.77,
298 K)
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candidate because it is constitutively active in vitro and exhibits only weak product
inhibition; thus, c-di-GMP concentrations of up to 0.25 mM can be achieved. Our system
allows producing 2.5 mg of pure c-di-GMP per milligram of YdeH with standard
biochemical lab equipment.
Enzymatic c-di-GMP production outperforms chemical synthesis with respect to time,
costs and number of chromatographic purification steps [27–33]. Moreover, most of the
chemical syntheses are based on air- and water-sensitive reagents. The enzymatic
procedures described in the literature [12, 13, 34–37], however, employ rather unstable
DGCs that, in addition, show strong product inhibition and therefore do not yield complete
substrate conversion. The recently described procedure using a DGC from a thermophilic
organism (T. maritima) [38] solved the solubility issue and provides the best specific yield
so far (20 mg/mg enzyme), but had to be mutated in the allosteric inhibition site (I-site) to
abolish product inhibition.
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4.2 Improved protocol
The protocol in the publication ’E cient enzymatic production of the bacterial second
messenger c-di-GMP by the diguanylate cyclase YdeH from E. coli’ was developed before
it was known that YdeH is inhibited by zinc. To optimize this protocol, zinc-free YdeH was
used. By using 2µM zinc-free YdeH in the same conditions as described in the publication
(500µM GTP in 50mM Tris-HCl, pH 8.0, 50mM NaCl and 5mM MgCl2), the reaction was
complete after 2 h (Figure 4.1). This is 2.5 times faster as using YdeH that is not zinc-free.
In order to achieve a higher yield of c-di-GMP the GTP concentration was doubled to
1mM. In Figure 4.1 the time course of this reaction is shown. After 5 h, most of the GTP is
consumed and after 17 h the reaction is complete. With this new protocol, the yield could
be doubled, which results in 5mg of pure c-di-GMP per milligram of YdeH.
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Figure 4.1: Time course of the synthesis of c-di-GMP. The samples were analyzed using ion-exchange
chromatography. (A) The reaction was performed by using 2µM zinc-free YdeH and
500µM GTP. After 2 h, the reaction is virtually complete. (B) The reaction was per-
formed by using 2µM zinc-free YdeH and 1mM GTP. After 5 h, the reaction is nearly
complete. The leftmost small peak corresponds to a GDP contamination in the commer-
cial GTP batch.
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5 Characterization of PgaA and PgaB,
members of the c-di-GMP controlled
exopolysaccharide synthesis machinery
5.1 Results and Discussion
5.1.1 Design and cloning of PgaA and PgaB constructs
In order to perform structural and biochemical studies on PgaA from E. coli, several con-
structs were designed. Various expression vectors were chosen for the expression of full-
length PgaA. PgaA including the N-terminal 32 amino acid containing signal sequence with
a C-terminal Histag was cloned in the vectors pET28a and pColdIV. To use other signal
sequences for the export to the outer membrane, which allow high expression levels of mem-
brane proteins in E.coli, additional expression vectors were selected. Therefore, PgaA was
cloned without the signal sequence in the vectors pET22b, pMAL-p5X and pET40b. The
signal sequence of PelB from P. aeruginosa and a C-terminal Histag are included in the
pET22b vector. In the pMAL-p5X vector, PgaA is fused to maltose-binding protein (MBP)
using its signal sequence. This construct has a cleavage site for the protease Factor Ax
between MBP and PgaA. In the pET40b vector, PgaA is fused to the periplasmic protein
DsbC, which includes a C-terminal Histag and a cleavage site for thrombin between DsbC
and PgaA.
To study the soluble domain of PgaA, a construct containing the N-terminal domain with
a C-terminal Histag, was cloned without the signal sequence in the pET28a vector. All
constructs were cloned as described in section 2.1 and are listed in Table 5.1.
For the expression of PgaB from E. coli, two di erent construct were designed. Both con-
structs started with amino acid 22 after the lipid-attached Cys21, in order to express PgaB
in the cytosol. One construct used the expression vector pET21b with an N-terminal Histag,
while for the other construct PgaB was cloned with a C-terminal Histag in the pET28a vec-
tor. The cloning was performed as described in section 2.1 and the constructs used are
listed in Table 5.2.
115
5.1.2 Expression and Purification of PgaA
Table 5.1: PgaA constructs.
Name PgaA residues Signal N-terminal Protease C-terminal
sequence fusion cleavage tag
of partner site
pET28a/PgaA full-length (33-807) PgaA - - Histag
pColdIV/PgaA full-length (33-807) PgaA - - Histag
pET22b/PgaA full-length (33-807) PelB - - Histag
pMal-p5X/PgaA full-length (33-807) MBP MBP Factor Ax -
pET40b/PgaA full-length (33-807) DsbC DsbC-Histag thrombin -
pET28a/PgaATPR soluble domain (33-519) - - - Histag
Table 5.2: PgaB constructs.
Name PgaB residues Features
pET21b/PgaB 22-651 N-terminal Histag
pET28a/PgaB 22-651 C-terminal Histag
5.1.2 Expression and Purification of PgaA
Expression of PgaA
Initial expression tests for pET28a/PgaA were performed in di erent E. coli strains
BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pGroEL, Rosetta(DE3), C41(DE3), C43(DE3),
ArcticExpress(DE3) and BL21(DE3)omp8/pLysS at two di erent temperatures of 37  and
18 . Expression was induced with 1mM IPTG. For the analysis of the expression test, sam-
ples were taken at di erent time points, from which the membranes were isolated. A detailed
description of the procedure is reported in section 2.2.1. In the strains BL21(DE3)pLysS
and BL21(DE3)pGroEL PgaA was not expressed. In the other strains, PgaA was highly
expressed in inclusion bodies and smaller amounts in the membrane fraction. The best
result was achieved in BL21(DE3) at 37  after 3h induction (Figure 5.1).
To further refine the expression conditions, the BL21(DE3) strain was used at 37  and
25  and the IPTG concentration was varied. For analysis of the expression, the membrane
fraction of the taken sample was further separated into inner and outer membrane fractions.
Under all tested IPTG concentrations (1mM, 50µM and 10µM) the extracted amount of
PgaA from the outer membrane was the same, but the amount of inclusion bodies decreased
along with lower IPTG concentrations (Figure 5.2).
Furthermore, the expression of PgaA was tested using the pColdIV vector. This vector is
designed to perform e cient protein expression at low temperature utilizing the promotor
derived from the cspA gene, which is one of the cold-shock genes in E. coli. The di erent E.
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lane 1: 3 h after induction, membrane fraction
lane 2: marker
lane 3: 6 h after induction, membrane fraction
lane 4: 20 h after induction, membrane fraction
Figure 5.1: SDS-PAGE of the membrane fractions of the expression test of PgaA in the pET28a
vector in BL21(DE3) cells. The expression temperature was 37  and the induction was
carried out with 1mM IPTG. The best expression was achieved 3 h after induction (lane
1). Sample preparation was done as described in section 2.2.1.
inclusion bodies
lane 1: before induction
lane 2: 37 , 1mM IPTG, 3 h after induction
lane 3: marker
lane 4: 37 , 50µM IPTG, 3 h after induction
lane 5: 37 , 10µM IPTG, 1 h after induction
lane 6: 37 , 10µM IPTG, 2 h after induction
lane 7: 37 , 10µM IPTG, 3 h after induction
lane 8: 25 , 10µM IPTG, 3 h after induction
lane 9: 25 , 10µM IPTG, 5 h after induction
membrane fractions
lane 1: marker
lane 2: before induction
lane 3: 37 , 1mM IPTG, 3 h after induction
lane 4: 37 , 50µM IPTG, 3 h after induction
lane 5: 37 , 10µM IPTG, 1 h after induction
lane 6: 37 , 10µM IPTG, 2 h after induction
lane 7: 37 , 10µM IPTG, 3 h after induction
lane 8: 25 , 10µM IPTG, 3 h after induction
lane 9: 25 , 10µM IPTG, 5 h after induction
Figure 5.2: SDS-PAGE of the refined expression test of PgaA in the pET28a vector in BL21(DE3)
cells. The IPTG concentration and the expression temperature were varied. The ex-
tracted amount of PgaA from the outer membrane is always the same (right panel), but
the amount of inclusion bodies is decreased along with lower IPTG concentrations (left
panel). Sample preparation was done as described in section 2.2.1.
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lane 1: marker lane 9: C41(DE3), 18 , 20 h
lane 2: BL21(DE3), 37 , 3 h lane 10: ArcticExpress(DE3), 18 , 20 h
lane 3: BL21(DE3), 18 , 20 h lane 11: C43(DE3), 37 , 3 h
lane 4: BL21(DE3)pLysS, 37 , 3 h lane 12: C43(DE3), 18 , 20 h
lane 5: BL21(DE3)pLysS, 18 , 20 h lane 13: BL21(DE3)omp8/pLysS, 37 , 3 h
lane 6: Rosetta(DE3), 37 , 3 h lane 14: BL21(DE3)omp8/pLysS, 18 , 20 h
lane 7: Rosetta(DE3), 18 , 20 h lane 15: marker
lane 8: C41(DE3), 37 , 3 h
Figure 5.3: SDS-PAGE of the membrane fractions of the expression test of PgaA in the pColdIV
vector. E.coli strains and expression temperature were varied. The induction was carried
out with 1mM IPTG. The best expression was achieved with the C41(DE3) strain at
37  after 3h induction (lane 8). Sample preparation was done as described in section
2.2.1.
coli strains BL21(DE3), BL21(DE3)pLysS, Rosetta(DE3), C41(DE3), C43(DE3), ArcticEx-
press(DE3) and BL21(DE3)omp8/pLysS were tested at two di erent temperatures of 37 
and 18 . The expression was induced with 1mM IPTG. The analysis of the expression
was performed by collecting the outer membrane fraction and yielded the best expression in
the C41(DE3) strain at 37  after 3h induction (Figure 5.3). Nevertheless, the expression
using the pET28a vector was much better compared to the pColdIV vector.
N-terminal sequencing revealed that the signal sequence of PgaA was not cleaved and there-
fore the transport to the outer membrane might be disturbed. This might be a reason for
the bad expression level of PgaA in the pET28a and pColdIV vector. To avoid this problem,
the PgaA signal sequence was substituted by other signal sequences, which are known to
express high amounts of membrane proteins.
First, the expression was tested in the pET22b/PgaA vector, where the pelB signal sequence
was used. The di erent E. coli strains BL21(DE3), BL21(DE3)pLysS, Rosetta(DE3),
C43(DE3), ArcticExpress(DE3) and BL21(DE3)omp8/pLysS were tested at two di erent
temperatures of 37  and 18 . The expression was induced with 1mM IPTG. The best
expression was achieved in the BL21(DE3)omp8/pLysS strain at 37  after 3h induction
(Figure 5.4), but was not as much as obtained with the pET28a/PgaA vector.
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lane 1: marker lane 8: C43(DE3), 37 , 3 h
lane 2: BL21(DE3), 37 , 3 h lane 9: C43(DE3), 18 , 20 h
lane 3: BL21(DE3), 18 , 20 h lane 10: ArcticExpress(DE3), 37 , 3 h
lane 4: BL21(DE3)pLysS, 37 , 3 h lane 11: ArcticExpress(DE3), 18 , 20 h
lane 5: BL21(DE3)pLysS, 18 , 20 h lane 12: BL21(DE3)omp8/pLysS, 37 , 3 h
lane 6: Rosetta(DE3), 37 , 3 h lane 13: BL21(DE3)omp8/pLysS, 18 , 20 h
lane 7: Rosetta(DE3), 18 , 20 h lane 14: marker
Figure 5.4: SDS-PAGE of the membrane fractions of the expression test of PgaA in the pET22b
vector. E.coli strains and expression temperature were varied. The induction was carried
out with 1mM IPTG. The best expression was achieved in the BL21(DE3)omp8/pLysS
strain at 37  after 3h induction (lane 12). Sample preparation was done as described
in section 2.2.1.
In a next step, the expression of PgaA was tested in the pMAL-p5X vector, where PgaA
is fused to MBP and the signal sequence of MBP is used. In expression tests, the di erent
E. coli strains BL21(DE3), BL21(DE3)pLysS, Rosetta(DE3), C41(DE3), C43(DE3), Arc-
ticExpress(DE3) and BL21(DE3)omp8/pLysS were tested at two di erent temperatures of
37  and 18 . The expression was induced with 1mM IPTG. The best expression of MBP-
PgaA was obtained in BL21(DE3) cells at 37  after 3h induction (Figure 5.5). However,
the yield of the expression was not as good as with the pET28a vector.
In the expression vector pET40b/PgaA, PgaA is fused to the periplasmic enzyme DsbC
that catalyzes the formation and isomerization of disulfide bonds. This system uses the
signal sequence of DsbC. Expression tests were performed in the di erent E. coli strains
BL21(DE3), BL21(DE3)pLysS, Rosetta(DE3), C43(DE3) and ArcticExpress(DE3) at two
di erent temperatures of 37  and 18 . The expression was induced with 1mM IPTG. The
best results were achieved in BL21(DE3) and C43(DE3) cells at 18  and in Rosetta(DE3)
cells at 37  (Figure 5.6). The expression was not as good as with the pET28a vector, but
gave the best results with a di erent signal sequence than that of PgaA itself.
The expression was further refined by varying the IPTG concentration. Reduced IPTG con-
centrations of 100 or 10µM had no influence in BL21(DE3) cells at 18 , but in C43(DE3)
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lane 1: BL21(DE3), 37 , 3 h lane 9: Rosetta(DE3), 18 , 20 h
lane 2: BL21(DE3)pLysS, 37 , 3 h lane 10: marker
lane 3: C41(DE3), 37 , 3 h lane 11: BL21(DE3)omp8/pLysS, 37 , 3 h
lane 4: marker lane 12: BL21(DE3)omp8/pLysS, 18 , 20 h
lane 5: C43(DE3), 37 , 3 h lane 13: BL21(DE3)pLysS, 18 , 20 h
lane 6: Rosetta(DE3), 37 , 3 h lane 14: C41(DE3), 18 , 20 h
lane 7: Arctic(DE3), 37 , 3 h lane 15: C43(DE3), 18 , 20 h
lane 8: BL21(DE3), 18 , 20 h lane 16: ArcticExpress(DE3), 18 , 20 h
Figure 5.5: SDS-PAGE of the membrane fractions of the expression test of MBP-PgaA in the pMal-
p5X vector. E.coli strains and expression temperature were varied. The induction was
carried out with 1mM IPTG. The best expression was achieved in BL21(DE3) cells at
37  after 3h induction (lane 1). Sample preparation was done as described in section
2.2.1.
cells at 18  the expression was reduced compared to the induction with 1mM IPTG (Fig-
ure 5.7). In Rosetta(DE3) cells at 37  using 10µM IPTG for induction, PgaA was not
expressed. With 100µM IPTG, PgaA was expressed in same amounts at 37  and 30 ,
but the expression was lower than with 1mM IPTG (Figure 5.7). The best expression level
with the pET40b/PgaA was reached in BL21(DE3) cells at 18  with an IPTG concentra-
tion between 0.1-1mM.
For large scale expression, two di erent vector systems were chosen, the pET28a/PgaA
plasmid using the signal sequence of PgaA and the pET40b/PgaA plasmid using a the signal
sequence of DsbC. Bacteria were cultivated on a 5L scale with the conditions established
in the expression tests. PgaA in the pET28a vector was expressed in BL21(DE3) cells at
37 . Induction was carried out with 1mM IPTG for 3 h. PgaA in the pET40b vector was
expressed in BL21(DE3) cells at 18 . Induction was carried out with 0.1≠ 1mM IPTG
for 20 h.
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lane 1: C43(DE3), 37 , 3 h lane 7: C43(DE3), 18 , 20 h
lane 2: Rosetta(DE3), 37 , 3 h lane 8: Rosetta(DE3), 18 , 20 h
lane 3: ArcticExpress(DE3), 37 , 3 h lane 9: ArcticExpress(DE3), 18 , 20 h
lane 4: marker lane 10: marker
lane 5: BL21(DE3), 18 , 20 h lane 11: BL21(DE3), 37 , 3 h
lane 6: BL21(DE3)pLysS, 18 , 20 h lane 12: BL21(DE3)pLysS, 37 , 3 h
Figure 5.6: SDS-PAGE of the membrane fractions of the expression test of DsbC-PgaA in the pET40b
vector. E.coli strains and expression temperature were varied. The induction was carried
out with 1mM IPTG. The best expression was achieved in BL21(DE3) and C43(DE3)
cells at 18  and in Rosetta(DE3) cells at 37  (lane 5, 7, 2). Sample preparation was
done as described in section 2.2.1.
lane 1: marker lane 7: marker
lane 2: BL21(DE3), 18 , 20 h, 10µM IPTG lane 8: Rosetta(DE3), 37 , 5 h, 10µM IPTG
lane 3: BL21(DE3), 18 , 20 h, 100µM IPTG lane 9: Rosetta(DE3), 37 , 3 h, 100µM IPTG
lane 4: C43(DE3), 18 , 20 h, 10µM IPTG lane 10: Rosetta(DE3), 37 , 5 h, 100µM IPTG
lane 5: C43(DE3), 18 , 20 h, 100µM IPTG lane 11: Rosetta(DE3), 30 , 3 h, 100µM IPTG
lane 6: Rosetta(DE3), 37 , 3 h, 10µM IPTG lane 12: Rosetta(DE3), 30 , 5 h, 100µM IPTG
Figure 5.7: SDS-PAGE of the refined expression test of DsbC-PgaA in the pET40b vector. The
IPTG concentration was varied using the strains BL21(DE3) and C43(DE3) (lane 2 - 5).
The expression in Rosetta(DE3) cells was refined by changing expression temperature
and IPTG concentration (lane 6 -12). The best expression was achieved in BL21(DE3)
cells at 18  with an IPTG concentration of 0.1-1mM (lane 2 and 3). Sample preparation
was done as described in section 2.2.1.
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lane 1: inclusion bodies
lane 2: marker
lane 3: soluble fraction
lane 4: extraction with 1% N-lauroyl sarcosine
lane 5: extraction with 0.05% LDAO
lane 6: extraction with 0.1% LDAO
lane 7 : extraction with 0.2% LDAO
lane 8: extraction with 0.3% LDAO
Figure 5.8: Extraction of PgaA from the outer membrane with the detergent LDAO. Inclusion bodies
were resuspended in 1% N-lauroyl sarcosine and loaded on the gel. 15µL were loaded in
every lane.
Purification of PgaA
The first step of the purification of PgaA was its extraction from the membrane. There-
fore, the membrane fraction was first treated with N-lauroyl sarcosine to remove the inner
membrane. In a second step, the proteins from the outer membrane were extracted with
increasing detergent concentrations. In first extraction tests, di erent detergents were used
(DM, LDAO, OPOE, OG, DDM, C12E9, Fos-12 and Cymal-6). With all detergents, PgaA
could be extracted from the outer membrane in the first extraction step, which was probably
caused by the large soluble domain of PgaA. The best result for PgaA extraction from the
outer membrane could be achieved with LDAO (Figure 5.8). As it seen, on the SDS-PAGE
of the extraction, PgaA was extracted from the inner membrane as well (Figure 5.8). This
might be due to the saturation of the export machinery, which directs PgaA to the outer
membrane.
Extraction was improved by varying the pH of the extraction bu er and the presence of
salt. Therefore, the outer membrane fraction was resuspended in di erent extraction bu ers
(100mM MES, pH 6.5, 100mM Na2HPO4, pH 7.5, 100mM Tris-HCl, pH 8.0 or 100mM
Bicine, pH 9.0 with and without 200mM NaCl) and PgaA was extracted by adding 0.5%
LDAO. As it is observed in Figure 5.9, PgaA could not be extracted at pH 6.5. The best
results were obtained at a pH of 8.0. The addition of salt always resulted in slightly higher
extracted PgaA levels. Gel filtration experiments revealed that PgaA had the tendency to
form aggregates without salt, so the extraction was performed at pH 8.0 in the presence of
200mM NaCl using LDAO as detergent.
Extracted PgaA was further purified by using Ni-a nity chromatography with 100mM
Na2HPO4, pH 7.5, 200mM NaCl, 0.1% LDAO as bu er. A chromatogram of an exemplary
run is shown in Figure 5.10 and the corresponding SDS-PAGE is shown in Figure 5.11. It
can be seen that the binding of PgaA to the column is very weak, because it already elutes
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lane 1: MES, pH 6.5
lane 2: marker
lane 3: MES, pH 6.5, NaCl
lane 4: Na2HPO4, pH 7.5
lane 5: Na2HPO4, pH 7.5, NaCl
lane 6: Tris-HCl, pH 8.0
lane 7 : Tris-HCl, pH 8.0, NaCl
lane 8: Bicine, pH 9.0
lane 9: Bicine, pH 9.0, NaCl
Figure 5.9: SDS-PAGE of the bu er screening for the extraction of PgaA from the outer membrane.
PgaA was extracted with 0.5% LDAO. The best result was obtained in Tris-HCl, pH 8.0
in the presence of salt (lane 7). 15µL were loaded in every lane.
0 20 40 60 80
0
50
100
150
200
250
300
350
A
bs
or
pt
io
n 
at
 2
80
 n
m
 [m
A
u]
Elution volume [mL]
  absorption at 280 nm
0
20
40
60
80
100
  imidazole gradient 
A
pp
lie
d 
im
id
az
ol
e 
gr
ad
ie
nt
 [%
]
Figure 5.10: Chromatogram of PgaA purification by Ni-a nity chromatography using a 5mL His-
Trap column. PgaA elutes at an imidazole concentration of 50mM. Fractions pooled
and used for subsequent purification are marked by a line.
lane 1: marker
lane 2: flow through (0-28mL)
lane 3: fraction 45.5-48mL
lane 4-9: fractions 48-53mL
lane 10: fraction 57-58.5mL
Figure 5.11: SDS-PAGE of the PgaA purification by Ni-chromatography. 2µL protein solution
loaded were in lane 2 and 10µL in lane 3-10.
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100 mM Tris-HCl, pH 8.0, 200 mM NaCl
lane 1: marker
lane 2: load
lane 3-6: elution
lane 7: loading in circle for 18 h, flow through
lane 8-10: loading in circle for 18 h, elution
100 mM Na2HPO4, pH 8.0, 200 mM NaCl
lane 1: load
lane 2: marker
lane 3: flow through
lane 4-6: elution
lane 7: loading in circle for 18 h, flow through
lane 8-10: loading in circle for 18 h, elution
Figure 5.12: SDS-PAGE of the PgaA purification by Ni-chromatography using di erent bu ers at
pH 8.0 and di erent loading modes. With 100mM Na2HPO4, pH 8.0, 200mM NaCl
and loading in circle for 18 h the best result was achieved. 10µL protein solution were
loaded in every lane.
at an imidazole concentration of 50mM and most of the PgaA has not even bound to the
column as it is found in the flow through.
To improve the binding of PgaA to the Ni column, di erent bu ers were tested. Because
best results for PgaA extraction from the membrane were achieved at pH 8.0, Tris-HCl
and phosphate bu er at pH 8.0 in the presence of 200mM NaCl and 0.1% LDAO were
used. This bu ers were already used for the extraction step and yielded same amounts of
extracted PgaA. The purification via the Ni-column was performed in two di erent ways.
One run was done with the standard procedure and a second run was performed by loading
PgaA sample in a circle for 18 h onto the column. The results are shown in Figure 5.12. The
use of Tris bu er, decreased the binding of PgaA to the column drastically. In phosphate
bu er, the binding of PgaA was much better and by loading in circle for 18 h all PgaA
has bound to the column. Therefore, the purification of PgaA by Ni-chromatography was
performed with 100mM phosphate bu er, 200mM NaCl, 0.1% LDAO and loading to the
Ni column was done in circle for 18 h to obtain the best result.
After Ni-chromatography, PgaA was subjected to gel filtration as a final purification step.
PgaA ran as one single peak with a elution volume of 12.1mL and formed no aggregates
(Figure 5.13 and Figure 5.14). The final yield of the purification was about 0.1mg/L culture.
The stability of the purified protein was tested by gel filtration experiments after storage
for four weeks at 4  and storage at ≠20  with and without 20% glycerol added. The gel
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Figure 5.13: Chromatogram of PgaA purification by gel filtration chromatography using a Superdex
200 10/30 column. Pooled PgaA fractions are marked by a line.
lane 1: marker
lane 2: load
lane 3-9: fractions 11-14mL
Figure 5.14: SDS-PAGE of the PgaA purification by gel filtration. 1µL protein solution was loaded
in lane 2 and 10µL in lane 3-9.
filtration profile was identical for all tested samples (Figure 5.15). PgaA elutes as one single
peak and did not form any aggregates. Thus, purified PgaA can be stored at least for four
weeks at 4  and also the freezing and thawing of samples does not a ect the stability of
PgaA.
Purification of PgaA as DsbC fusion
The extraction of PgaA-DsbC was done like for PgaA using 100mM Na2HPO4 pH 8.0,
200mM NaCl as bu er and LDAO as detergent. The extraction behavior was the same
as for PgaA, meaning that it was extracted in the first step (Figure 5.16). Afterwards, a
Ni-chromatography was performed. A chromatogram is shown in Figure 5.17 and the corre-
sponding SDS-PAGE is shown in Figure 5.18. PgaA is eluting at an imidazole concentration
of 125mM. After Ni-chromatography, PgaA-DsbC was subjected to gel filtration. As it can
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Figure 5.15: Chromatogram of PgaA samples stored for four weeks at 4  (black line) or at ≠20 
with (blue line) and without 20% glycerol added (grey line). PgaA elutes as one single
peak under all storage conditions and has formed no aggregates.
be seen in the chromatogram (Figure 5.19) and on the corresponding SDS-PAGE (Figure
5.20), PgaA-DsbC does not elute homogeneously. The PgaA-DsbC elution is distributed
over a range of 4.5 mL and elutes at least in two peaks. Because the purified PgaA-DsbC
was not homogeneous, the work on this construct was stopped.
lane 1: extraction with 1% N-lauroyl sarcosine
lane 2: marker
lane 3: extraction with 0.05% LDAO
lane 4: extraction with 0.1% LDAO
lane 5 : extraction with 0.3% LDAO
Figure 5.16: Extraction of DsbC-PgaA from the outer membrane with the detergent LDAO. 15µL
were loaded in every lane.
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Figure 5.17: Chromatogram of PgaA-DsbC purification by Ni-a nity chromatography using a 5mL
HisTrap column. PgaA elutes at an imidazole concentration of 125mM. Fractions
pooled and used for subsequent purification are marked by a line.
lane 1: marker
lane 2: load
lane 3: flow through (0-28mL)
lane 4: wash 85-105mL
lane 5-6: fractions 115.5-118.5mL
lane 7-10: fractions 118.5-127mL
Figure 5.18: SDS-PAGE of the PgaA-DsbC purification by Ni-chromatography. 2µL protein solution
were loaded in lane 2-4 and 10µL in lane 5-10.
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Figure 5.19: Chromatogram of PgaA-DsbC purification by gel filtration chromatography using a
Superdex 200 10/30 column. PgaA-DsbC containing fractions are marked by a line.
lane 1: load
lane 2: marker
lane 3-9: fractions 7.5-12mL
Figure 5.20: SDS-PAGE of the PgaA-DsbC purification by gel filtration. 1µL protein solution was
loaded in lane 1 and 10µL in lane 3-9.
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lane 1: before induction
lane 2: marker
lane 3: 37 , 2 h after induction
lane 4: 37 , 3 h after induction
lane 5: 37 , 4 h after induction
lane 6: 18 , 20 h after induction
Figure 5.21: SDS-PAGE of the soluble fractions of the expression test of PgaATPR in the pET28a
vector in Rosetta(DE3) cells. The expression temperature was 37  or 18  and the
induction was carried out with 1mM IPTG. The best expression was achieved at 18 
after 20h (lane 6).
Summary of the purification of PgaA
PgaA was purified by a stepwise extraction from the outer membrane in 100mM Na2HPO4,
pH 8.0, 200mM NaCl bu er with the detergent LDAO. Afterwards, a two step-purification
consisting of Ni-a nity and size exclusion chromatography was used. The Ni-column was
performed in 100mM Na2HPO4, pH 8.0, 200mM NaCl, 0.1% LDAO bu er by loading the
sample to the Ni column in circle for 18 h. The final gel filtration yielded pure and homoge-
nous protein, which could be stored for at least 4 weeks at 4  or ≠20  without forming
aggregates. The yield of the purification was about 0.1mg/L culture. The purification of
PgaA as DsbC fusion protein resulted in heterogeneous protein samples and was therefore
not continued.
Expression and Purification of PgaATPR
Expression tests for PgaATPR were performed in the di erent E. coli strains BL21(DE3),
BL21(DE3)pLysS, Rosetta(DE3), C43(DE3) and ArcticExpress(DE3) at two di erent tem-
peratures of 37  and 18 . The expression was induced with 1mM IPTG. The best soluble
expression was achieved in the Rosetta(DE3) strain at 18  20h after induction. Exem-
plarily, an expression gel is shown in Figure 5.21. For protein production, bacteria was
cultivated on a 5L scale with the conditions established in the expression tests.
For purification, a two step-procedure consisting of Ni-a nity and size exclusion chromatog-
raphy was used. After cell lysis with French press, Ni-a nity chromatography using a His-
trap column was performed. A chromatogram of a typical run is shown in Figure 5.22 and
the corresponding SDS-PAGE is shown in Figure 5.23. The protein elutes at an imida-
zole concentration of 165mM. PgaATPR containing fractions were pooled and subsequently
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Figure 5.22: Chromatogram of PgaATPR purification by Ni-a nity chromatography using a 5mL
HisTrap column. PgaATPR elutes at an imidazole concentration of 165mM. Fractions
pooled and used for subsequent purification are marked by a line.
lane 1: marker
lane 2: load
lane 3: flow through (0-28mL)
lane 4: fraction 82-83mL
lane 5: fraction 84-85mL
lane 6: fraction 87-88mL
lane 7: fraction 89-90mL
lane 8: fraction 92-93mL
lane 9: fraction 97-98mL
lane 10: fraction 106-107mL
Figure 5.23: SDS-PAGE of the PgaATPR purification by Ni-chromatography. 2µL protein solution
were loaded in lane 2 and 3 and 10µL in lane 4-10.
loaded on a gel filtration column. PgaATPR ran as one single peak with a elution volume
of 195.5mL (Figure 5.24 and 5.25). According to a calibration curve for the used column,
this corresponds to a molecular mass of 61.3 kDa. Assuming the mass of one protein chain
of 55.8 kDa, this clearly indicates that PgaATPR is monomeric. The final yield of the pu-
rification was about 3.5mg/L culture.
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Figure 5.24: Chromatogram of PgaATPR purification by gel filtration chromatography using a
HiLoad-26/60-Superdex-200 prep grade column. PgaATPR was separated from minor
aggregates, which elute at about 120mL. Pooled PgaATPR fractions are marked by a
line.
lane 1: fraction 115-120mL
lane 2: marker
lane 3: fraction 135-140mL
lane 4: fraction 165-170mL
lane 5-8: fractions 185-215mL
Figure 5.25: SDS-PAGE of the PgaATPR purification by gel filtration. 10µL protein solution was
loaded in each lane.
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lane 1: marker
lane 2: before induction
lane 3: 37 , 2 h after induction
lane 4: 37 , 3 h after induction
lane 4: 37 , 4 h after induction
lane 6: 18 , 20 h after induction
Figure 5.26: SDS-PAGE of the soluble fractions of the expression test of PgaB in the pET21b vector
in BL21(DE3) cells. The expression temperature was 37  or 18  and the induction
was carried out with 1mM IPTG. The best expression is achieved at 18  20h after
induction (lane 6).
5.1.3 Expression and Purification of PgaB
The constructs pET21b/PgaB and pET28a/PgaB in di erent E. coli strains BL21(DE3),
BL21(DE3)pLysS, Rosetta(DE3), C43(DE3) and ArcticExpress(DE3) were tested for PgaB
expression at two di erent temperatures of 37  and 18 . The expression was induced
with 1mM IPTG. In most of the tested conditions, soluble PgaB was highly expressed.
The best expression was achieved for pET21b/PgaB in BL21(DE3) cells at 18  20h after
induction and for pET28a/PgaB in the Rosetta(DE3) strain at 18  16h after induction.
Exemplarily, expression gels are shown in Figure 5.26 and 5.27.
For protein production, bacteria was cultivated on a 200mL scale with the conditions es-
tablished in the expression tests. Depending on further experiment, PgaB was expressed
with a N- or C-terminal Histag.
As the purification procedure is the same for both constructs, only the PgaB purification
from the construct pET28a/PgaB is shown. The purification protocol for PgaB consists
of a Ni-a nity and a size-exclusion chromatography. After cell lysis with French press,
Ni-a nity chromatography using a Histrap column was performed. A chromatogram of a
typical run is shown in Figure 5.28 and the corresponding SDS-PAGE is shown in Figure
5.29. The protein elutes at an imidazole concentration of 125mM. After Ni-chromatography,
PgaB was subjected to gel filtration as a final purification step. PgaB ran as one single peak
with an elution volume of 204.5mL (Figure 5.30 and 5.31). According to the calibration
curve for the used column, this corresponds to a molecular mass of 46.3 kDa. Assuming the
mass of one protein chain of 75.0 kDa, this indicates that PgaB is a monomeric protein. The
fact that the determined mass of PgaB is much smaller than the theoretical mass, indicates
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lane 1: before induction
lane 2: marker
lane 3: 37 , 2 h after induction
lane 4: 37 , 3 h after induction
lane 4: 37 , 4 h after induction
lane 6: 18 , 20 h after induction
Figure 5.27: SDS-PAGE of the soluble fractions of the expression test of PgaB in the pET28a vector
in Rosetta(DE3) cells. The expression temperature was 37  or 18  and the induction
was carried out with 1mM IPTG. The best expression is achieved at 18  20h after
induction (lane 6).
towards a very compact protein. A degradation can be excluded, because on SDS-PAGE,
PgaB runs at a size of about 75 kDa and the Histag of both constructs could be detected
in a Western blot (data not shown). The final yield of the purification was about 250mg/L
culture using the pET28a/PgaB construct and 340mg/L for the pET21b/PgaB construct.
The stability of the purified protein was tested by gel filtration experiments after storage
for seven weeks at 4  and storage at ≠20  with and without 20% glycerol added. Upon
thawing the sample, that was stored at ≠20  without 20% glycerol, PgaB was heavily
precipitating. The two other samples were clear and were analyzed by gel filtration (Figure
5.32). In both cases, PgaB eluted as one single peak and has formed no aggregates. This
means that purified PgaB can be stored at 4  for at least seven weeks and also the freezing
and thawing of samples, when 20% glycerol is added, does not a ect the stability of PgaB.
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Figure 5.28: Chromatogram of PgaB purification by Ni-a nity chromatography using a 5mL His-
Trap column. PgaB elutes at an imidazole concentration of 125mM. Fractions pooled
and used for subsequent purification are marked by a line.
lane 1: marker
lane 2: cell extract
lane 3: load
lane 4: flow through (0-21mL)
lane 5: fraction 76-77mL
lane 6-9: fractions 77-87.5mL
lane 10: fraction 90-91mL
Figure 5.29: SDS-PAGE of the PgaB purification by Ni-chromatography. 2µL protein solution were
loaded in lane 2-4 and 10µL in lane 5-10.
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Figure 5.30: Chromatogram of PgaB purification by gel filtration chromatography using a HiLoad-
26/60-Superdex-200 prep grade column. PgaB elutes as a single peak. Pooled PgaB
fractions are marked by a line.
lane 1: marker
lane 2: fraction 110-115mL
lane 3: fraction 170-175mL
lane 4-9: fractions 190-225mL
lane 10: fraction 230-235mL
Figure 5.31: SDS-PAGE of the PgaB purification by gel filtration. 10µL protein solution were loaded
in each lane.
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Figure 5.32: Chromatogram of PgaB samples stored for seven weeks at 4  or at ≠20  with 20%
glycerol added. PgaB elutes as one single peak under both storage conditions and has
formed no aggregates.
5.1.4 Crystallization attempts of PgaA
As the yield of the purification of PgaA was very low, only a few attempts were made to get
full-length PgaA crystals. The commercial crystallization screens Crystal Screen, Index and
Mb-class were tested at a PgaA concentrations of 5.5mg/mL. No crystals were obtained
under these conditions. Because most of the drops stayed clear, the protein concentrations
must be increased in further experiments.
For PgaATPR, the crystallization screens Crystal Screen and Index were used to setup
crystallization experiments at a protein concentration of 10mg/mL. None of the tested
conditions yielded protein crystals. In nearly all drops PgaATPR was heavily precipitated.
As the protein solution of PgaATPR itself, which was not used for crystallization, also starts
to precipitate at 10mg/mL, it is likely that PgaATPR is not stable at such concentration.
5.1.5 Crystallization attempts of PgaB
A lot of attempts were made to obtain PgaB crystals. Commercial crystallization screens
were tested at di erent protein concentrations in 96-well sitting drop set-ups. All trials are
listed in Table 5.3. In the first attempts, protein concentration was too high, which resulted
in precipitation in nearly every condition. In further experiments, the PgaB concentration
was decreased. Furthermore, PgaB with a C-terminal or a N-terminal Histag were both
used, because the Histag might influence the crystallization behavior.
Next, limited proteolysis was tested, which should reveal stable domains without unstruc-
136
lane 1: marker
lane 2: 0min
lane 3: 1min
lane 4: 2min
lane 5: 5min
lane 6: 15min
lane 7: 30min
lane 8: 60min
Figure 5.33: SDS-PAGE of the digestion of PgaB with trypsin. Samples after di erent time points
were loaded. A 1:200 dilution of trypsin was used. PgaB was cut in two fragments of
about 45 kDa and 25 kDa.
tured and flexible termini. Therefore, di erent proteases (pepsin, proteinaseK, trypsin) were
tested as described in section 2.3.7. Pepsin was not able to cleave PgaB, maybe due to the
high pH of 7.5 for pepsin. ProteinaseK degrades PgaB completely into a number of small
pieces. By analyzing the SDS-PAGE of the proteolysis with trypsin, PgaB was cleaved in
two fragments of about 45 kDa and 25 kDa (Figure 5.33). To produce larger amounts of
cleaved PgaB the trypsin digestion was scaled up (section 5.3) and the two protein frag-
ments were tried to separate by gel filtration without success. Because no separation could
be achieved by using a Ni-a nity chromatography or an ion-exchange chromatography us-
ing a MonoQ column as well, the two parts must still stick together indicating that trypsin
cleavage probably occurs in a loop and does not disturb the tertiary structure of PgaB. As
this could a ect the crystallization behavior, the trypsin treated PgaB was used in crystal-
lization experiments, which are listed in Table 5.3. However, no crystals could be obtained
under these conditions either.
Another method, which was used to facilitate crystallization of PgaB, was the methylation
of surface lysines. Therefore, PgaB was methylated as described in section 2.3.6 and purified
from aggregates by gel filtration. Although the conditions for the methylation were rather
harsh, PgaB did not form aggregates (Figure 5.34) and the yield was with 73% quite
high. The fractions marked with a line in the chromatogram were used for crystallization
experiments. However, no crystals were obtained with the methylated form of PgaB either.
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Figure 5.34: Chromatogram of PgaB after methylation of surface lysines. The Superdex-200 10/30
column was used. PgaB has not formed aggregates during the methylation reaction.
The pooled fractions, which were used for crystallization experiments, are marked by a
black line.
5.1.6 Investigations on PgaA-PgaB complex formation
As PgaB as well as PgaA are needed for the export of the poly-1,6-GlcNAc chain, it is likely
that PgaB interacts with the TPR domain of PgaA, which is known to be involved in protein-
protein interactions in other TPR-domain containing proteins. To prove this interaction, gel
filtration experiments were performed as described in section 2.3.5. Therefore, PgaATPR and
PgaB were incubated in a molar ratio of 1:1 and 1:3 in 20mM Tris-HCl, pH 8.0 150mMNaCl
and analyzed by gel filtration. In further experiments, 1mM MgCl2 or 1mM GlcNAc was
added for incubation to the protein mixture. In the chromatogram of all tested samples, no
complex formation could be seen (Figure 5.35). PgaA and PgaB elute at the same position,
as if they were loaded separately.
The fact that no complex formation could be detected with gel filtration experiments, might
be due to the instability of the protein complex during the experiment, especially because it
is diluted. Another reason could be, that an additional interaction partner is missing. This
might be the poly-1,6-GlcNAc chain that can induce conformational changes after binding
to PgaA or PgaB allowing complex formation. The experiment should be repeated in the
presence of poly-1,6-GlcNAc. In addition, other methods like ITC or SPR should be used
to analyze a possible PgaA-PgaB interaction.
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Figure 5.35: Gel filtration chromatograms of the investigation of complex formation of PgaATPR
and PgaB. PgaATPR (black) and PgaB (grey) alone as well as samples containing both
proteins in the presence (green) and absence of GlcNAc (blue) are shown. No complex
formation could be seen, because in the run of the complex samples no additional peak
at a smaller elution volume occur. The Superdex-200 10/30 column was used.
5.1.7 Activity of PgaB
PgaB shows sequence homology to other deacetylases and sequence alignments showed that
all residues, which are involved in the deacetylation reaction, are present in PgaB. Therefore,
experiments were carried out to prove that PgaB has deacetylation activity in vitro. For
the realization of an enzymatic assay, the substrate of PgaB, poly-1,6-GlcNAc is needed.
As poly-1,6-GlcNAc is not commercially available, it was enzymatically produced by PgaC
and PgaD with a protocol developed by S. Steiner (see section 2.3.4). In this procedure,
membrane fragments containing PgaC and PgaD were incubated with UDP-GlcNAc in
the presence of c-di-GMP to produce poly-1,6-GlcNAc. Afterwards, the membranes can be
removed by centrifugation and the produced poly-1,6-GlcNAc can be used as a substrate for
PgaB in subsequent experiments. The synthesis of poly-1,6-GlcNAc by PgaC and PgaD can
also be done in a one-step reaction together with PgaB. This approach was used, because it
has several advantages. The fact that the chain length, which is required for PgaB activity
is unknown, is not important, if PgaB is present during the poly-1,6-GlcNAc synthesis,
because it is faced with all di erent chain lengths. The problem that poly-1,6-GlcNAc with
more than ten monomers is not soluble, is also avoided. PgaB can perform the reaction
and if afterwards the chain length will increase and the sugar will precipitate, the acetate
remains soluble and can still be detected.
There are two possibilities to measure the activity of a deacetylases. One is the detection of
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Figure 5.36: Principle of the acetate assay used in this thesis. (1) Acetate kinase in the presence
of ATP converts acetate into acetyl-phosphate and ADP. (2) ADP formed in (1) is
reconverted into ATP and pyruvate, by pyruvate kinase in the presence of phospho-
enolpyruvate (PEP). (3) In the presence of the enzyme D-lactate dehydrogenase pyru-
vate is reduced to D-lactate by NADH with production of NAD+. The amount of
formed NAD+ is stoichiometric with the amount of acetate. The NADH consumption
is measured by the decrease in absorbance at 340 nm.
the generated free amines and the other is the measurement of the released acetate. In the
last years, a fluorescence based assay was used to detect the free amines [155]. For PgaB,
this assay is not suited, because if PgaB has deacetylated the sugar it precipitates, while
the sugar chain is further growing by the action of PgaC, which means the free amines are
not accessible for the detection. Therefore, an assay was used, which measures the released
acetate. This can be done with a coupled assay, based on acetate-coenzyme A synthetase
[156]. This method uses an indicator reaction catalyzed by L-malate dehydrogenase, which
is in permanent equilibrium. Therefore, a non-stoichiometric correlation is observed to the
acetate present in the sample. To overcome this problem, an alternative acetate detection
assay was used in this thesis, based on the enzyme acetate kinase (Figure 5.36). As readout,
the oxidation of NADH to NAD+ was measured.
For activity measurements, PgaB was incubated for 16 h with membranes containing PgaC
and PgaD together with UDP-GlcNAc in 50mM HEPES, 50mM NaCl. In a second sam-
ple, 5mM MgCl2 was added. Afterwards the proteins were precipitated by heating and
removed by centrifugation. The cleared supernatants were analyzed with the acetate assay
as described in section 2.3.4. PgaB activity could be measured independent of the presence
of MgCl2. The amount of acetate was such high, that the detection limit of the assay was
reached.
In further experiments, the PgaB concentration and the reaction time will have to be de-
creased in order to measure the initial velocity of PgaB. Furthermore, the influence of
di erent metal ions will have to be investigated, because it was shown that most of the
deacetylases are metal dependent. For analysis of the chain length, which is needed for
PgaB activity, poly-1,6-GlcNAc has to be chemically synthesized with di erent defined
chain lengths.
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5.2 Summary and outlook
For PgaA, an expression and purification protocol was established and resulted in stable and
homogenous protein, that can be stored several weeks at 4  and can even be frozen. Initial
crystallization trials did not yield protein crystals. However, further crystallization experi-
ments with higher protein concentrations and in the presence of poly-1,6-GlcNAc should be
done to provide insights in the sugar transport.
The soluble TPR domain of PgaA could be expressed and purified to homogeneity. Crys-
tallization experiments did not yield protein crystals but should be repeated adding poly-
1,6-GlcNAc of defined chain length and in the presence of PgaB to facilitate crystallization.
PgaB could be expressed in the cytosol by removing the lipid anchor and purified in very
high amounts. The predicted deacetylase activity could be demonstrated in vitro with a
coupled activity assay by detecting the released acetate. The substrate for PgaB was pro-
duced enzymatically by PgaC and PgaD in a one-step reaction in the presence of PgaB. In
further experiments, the initial velocity will have to be measured. In addition, the metal
dependency and the preferred chain length of PgaB needs to be investigated further. The
developed activity assay is practicable in small volume in 96-well plates, so it is suitable
for rapid screening of di erent reaction conditions and for the search of inhibitors for PgaB
and PgaC.
To test the model that PgaA and PgaB are interacting with each other in order to allow
the export of the poly-1,6-GlcNAc chain, it was tried to investigate the interaction by
gel filtration experiments. An interaction could not be demonstrated, probably due to
the limitations of the method. Another reason could be, that a poly-1,6-GlcNAc chain is
required for the interaction of these two proteins. Complex formation should be further
investigated in the presence of poly-1,6-GlcNAc and by using other techniques like ITC or
SPR.
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6 Appendix
6.1 Structure determination of KPC-2 in complex with a
diazabicyclooctane inhibitor
6.1.1 KPC-2, a —-lactamase from Klebsiella pneumoniae
—-Lactamases catalyze the irreversible hydrolysis of the amide bond of —-lactams [157], and
thereby protect the host organism against the lethal action of these antibiotics [158]. —-
Lactamases are grouped into four molecular classes A, B, C and, D [159–161]. Members
of class B are metalloproteins, whose activity is based on the presence of one or two zinc
ions in their active site [162]. The majority of —-lactamases belong to the classes A, C and
D, which use an active site serine for performing a two-step catalysis [163, 164]. —-Lactams
acylate the active site serine forming a covalent acyl-enzyme intermediate. Subsequently,
the acyl-enzyme intermediate is hydrolyzed by a water molecule. A schematic drawing of the
reaction catalyzed is shown in Figure 6.1. Class A —-lactamases are monomeric enzymes,
which consist of two domains, an all-– and an –/— domain [165–169]. The active site is
located in the groove between these two domains.
KPC-2 is a class A —-lactamase that was originally identified in K. pneumoniae. KPC-2
is plasmid-encoded, is easily disseminated and is documented in numerous pathogens [170].
KPC-2 shows a wide substrate profile [171].
—-Lactams are the most common antibiotics in clinical use for the treatment of various infec-
tions caused by Gram-negative and Gram-positive pathogens [172–174]. The global problem
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Figure 6.1: General catalytic pathway of active site serine —-lactamases. The first reaction step
involves the nucleophilic attack of the active site serine to open the lactam ring. In a
second step the deacylation by water hydrolyses the acyl-enzyme intermediate.
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Figure 6.2: Chemical structure of the diazabicyclooctane inhibitor DBO-1.
of resistance to —-lactam antibiotics is growing into a serious problem for the therapy of
infectious diseases [175, 176]. Therefore, —-lactam antibiotics have been administered with
—-lactamase inhibitors [177]. The inhibitors of class A —-lactamases acylate the active site
serine and form an acyl-enzyme intermediate which is refractory to hydrolysis. A new class
of —-lactamase inhibitors are diazabicyclooctanes (DBOs) (Figure 6.2. The five-membered
ring of a DBO contains an urea group that targets the active-site serine of the —-lactamase
via a carbamylation reaction. This carbamate group is much more stable towards hydroly-
sis than the ester group generated in the reaction of classical —-lactam-derived —-lactamase
inhibitors [178].
The structure of KPC-2 in complex with the diazabicyclooctane inhibitor DBO-1 was solved
in order to elucidate the binding mode of this novel type of inhibitor and thereby to con-
tribute to the optimization of this inhibitor class.
6.1.2 Crystallization
KPC-2 samples were received from Basilea Pharmaceutica and were further purified by size
exclusion chromatography to remove potential aggregates and to exchange the bu er. The
gel filtration chromatogram and the corresponding SDS gel are shown in Figure 6.3 and 6.4,
respectively. Fractions containing KPC-2 were pooled and concentrated to 15-18mg/mL.
The vapor-di usion method was used for protein crystallization. First, the crystallization
conditions described in ref. [169] were tested (Table 6.1). This was carried out in 24-well
plates using hanging drops on siliconized cover slides. The drops were prepared by mixing
1µL KPC-2 (17mg/mL, in 20mM Tris-HCl, pH 7.6) with 0.5µL reservoir solution and were
equilibrated against 500µL reservoir bu er. Most conditions yielded crystals (Figure 6.5).
Unfortunately, the crystallization drops contained many nuclei from which long, thin rods of
crystals up to a size of 1000 x 40 x 40µm3 emanated. To reduce the amount of crystalliza-
tion nuclei, precipitation concentration, pH value, protein concentration and crystallization
temperature were varied (Table 6.2). Decreasing temperature, PEG 6000 or protein con-
centration, did not result in bigger crystals. The crystals grew slower, but there were still
a lot of nuclei and they never reached the size reported in literature [169]. Single crystals
144
0 2 4 6 8 10 12 14 16 18 20
0
400
800
1200
1600
A
bs
or
pt
io
n 
at
 2
80
 n
m
 [m
A
u]
Elution volume [mL]
Figure 6.3: Chromatogram of the KPC-2 purification by gel filtration chromatography using a
Superdex-75 10/30 column and 20mM Tris-HCl, pH 7.6 as running bu er. KPC-2 elutes
as a single peak with a elution volume of 11.7mL.
lane 1: marker
lane 2: fraction 9-9.5mL
lane 3: fraction 9.5-10mL
lane 4: fraction 10-10.5mL
lane 5: fraction 10.5-11mL
lane 6: fraction 11-11.5mL
lane 7: fraction 11.5-12mL
lane 8: fraction 12-12.5mL
lane 9: fraction 12.5-13mL
lane 10: fraction 13-13.5mL
Figure 6.4: SDS-PAGE of the KPC-2 purification by gel filtration. 5µL protein solution were loaded
in each lane.
of su cient size were obtained by adding 10mM spermine to the original crystallization
condition. They grew to a final size of 400 x 40 x 40µm3 within 5 days (Figure 6.6).
In order to get KPC-2 inhibitor complex crystals, native KPC-2 crystals were soaked in a
5µL soaking solution, containing 100mM Bicine, pH 9.0, 16% PEG 6000, 10mM spermine
and 2mM inhibitor for 4 h. For cryoprotection, the soaked crystals were successively placed
in soaking solution supplemented with 5, 10, 15% glycerol with soaking times of 20 sec per
step. Subsequently crystals were flash-frozen in liquid nitrogen.
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Table 6.1: Original KPC-2 crystallization conditions from literature [169].
Parameter Value
Protein concentrationa 9mg/mL
Reservoir solution 16% PEG 6000, 100mM Bicine, pH 9.0
Temperature 23 
a Final concentration in the crystallization drop.
Figure 6.5: KPC-2 crystals obtained with the protocol described in ref [169]. Dimension are in µm.
Table 6.2: Parameter range explored to improve KPC-2 crystals.
Parameter Value
Protein concentrationa 6-13mg/mL
Reservoir solution 4-22% PEG 6000, 100mM Bicine, pH 8.4-9.4
Temperature 23  and 4 
a Final concentration in the crystallization drop.
Figure 6.6: KPC-2 crystals obtained in the refined condition 100mM Bicine, pH 9.0, 18% PEG 6000,
10mM spermine. Dimension are in µm.
146
6.1.3 Data collection and processing
Data collection was performed at the beamline PXI X06SA at the Swiss Light Source (Villi-
gen, Switzerland). A complete dataset was collected to a resolution of 2.2 A˚. For processing
and scaling, the programs MOSFLM [109] and SCALA [110] were used. The parameters of
the data collection and the statistics of the collected data set are summarized in Table 6.3.
The crystal belongs to space group P31 with three molecules in the asymmetric unit and a
solvent content of 50.5%.
Table 6.3: Data collection parameters and statistics.
Wavelength [A˚] 1.000
Detector Pilatus 6M
Detector distance [mm] 300
Space group P31
Cell axes [A˚] a = b = 116.29, c = 52.79
Angles [¶] – = — = 90, “ = 120
Resolution [A˚] 50-2.2 (2.1-2.2)
Observed reflections 95396
Unique reflections 40113
Multiplicity 2.4
Rmerge [%] a 7.1 (30.2)
I/‡(I)a 15.7 (2.4)
Completeness [%] a 100 (100)
Number of protomers per ASU 3
VM [A˚3 · Da≠1] 2.49
Solvent content [%] 50.5
a Values in parentheses refer to the highest resolution bin.
Unfortunately, the data set turned out to be twinned as indicated by the Merohedral Crystal
Twinning Server [179]. The twinning operation was (h, -h-k, -l) and the twinning fraction
0.41. To continue structure elucidation, the dataset was de-twinned using DETWIN [124].
The KPC-2-inhibitor complex structure was determined with the de-twinned data by molec-
ular replacement using MOLREP [180] with chain A of the KPC-2 structure (PDB entry
2OV5) as initial search model. MOLREP found a unique solution with three molecules in
the asymmetric unit. The model was refined with REFMAC [114]. NCS restrains were ap-
plied between the three chains, and TLS refinement was carried out using each chain as an
individual group. The model of the inhibitor was generated with PRODRG [181] and mod-
eled into electron density with Coot [113]. Water molecules were added with ARP [182] and
manually checked with Coot. The quality of the model was analyzed using PROCHECK
[183].
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Table 6.4: Refinement statistics.
Resolution [A˚] 2.2
Space group P31
R [%] 23.6
Rfree [%] 27.5
Number of atoms
protein 11652
water molecules 93
inhibitor 51
B factors [A˚2]
protein 40.4
inhibitor 44.2
water molecules 33.6
RMS deviations
bond lengths [A˚] 0.010
bond angles [¶] 1.174
Ramachandran statistics [%]
in favored regions 94.3
in allowed regions 5.1
6.1.4 Structure of the KPC-2-inhibitor complex
Considering that the data had to be de-twinned, the model has good quality indicators
(Table 6.4) and 99.5% of the residues had   and   angles in the allowed regions of the
Ramachandran plot. The final model is comprised of all 261 residues in all three chains, 93
water molecules and three inhibitor molecules. The complexed protein structure is virtually
identical to the native structure with a RMS deviation of the C– position of 0.06 A˚. The
three molecules in the asymmetric unit of the complex structure were considered identical,
because the RMS C– di erences of the pairwise comparisons were below 0.06 A˚. In the
following, the structure of molecule A is described.
Clear density for the inhibitor was already visible in the first electron density map. The
inhibitor appears covalently linked by an carbamate group to Ser70 and extends into the
active site cleft (Figure 6.7). KPC-2 molecule A showed the best density. The omit electron
density is shown in Figure 6.8. The average B factor for the inhibitor in KPC-2 molecule
A is 36.2 A˚2, for molecules B and C the average B factors are somewhat higher (43.6 A˚2
and 52.8 A˚2). The inhibitor is stabilized via H-bonds with residues Ser70, Ser130, Asn132,
Thr235 and Thr237 and hydrophobic contact with the residue Trp105 (Figure 6.8). The
distances are depicted in Table 6.5. In the active site, a water molecule is found in a
similar position to the deacylation water described in [169]. It is interacting with Glu166
and Asn170 and has a B factor of 37.4 A˚2. It is in a position to potentially hydrolyze the
enzyme-inhibitor complex (Figure 6.9 and Table 6.6).
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Figure 6.7: Structure of the KPC-2 —-lactamase in complex with the inhibitor. (A) Ribbon diagram
of KPC-2. One domain is shown in red and the other in grey. The inhibitor is covalently
bound to Ser70 (shown in sticks). (B) Surface representation of KPC-2; the inhibitor is
located in the catalytic cleft between both domains.
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(A)
(B)
Figure 6.8: Stereo view of the active site of the KPC-2 —-lactamase with bound inhibitor. The
interaction residues and the inhibitor are shown as sticks and the H-bonds are shown as
dashed lines. The omit map for the ligand is countered at 2‡. (A) View from the front
like in Figure 6.7. (B) View from the back.
Table 6.5: Distances of the active site residues to the inhibitor.
Protein residue Inhibitor Distance [A˚]
Ser170-N O7 2.87
Ser130-O“ O3 3.32
Asn132-N”2 O14 3.21
Thr235-O“1 O3 2.77
Thr237-O“1 O4 2.42
Thr237-N O7 2.95
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Figure 6.9: Stereo view of the active site of the KPC-2 —-lactamase with bound inhibitor and the
de-acylation water (red small sphere). The interaction residues and the inhibitor are
shown in full. The H-bonds are shown as black dashed lines. The nucleophilic attack of
the water molecule is depicted as a red dashed line.
Table 6.6: Distances of the deacylation water to the active side residues and the inhibitor.
Interaction partner Deacylation water Distance [A˚]
Glu166-O‘ 35 2.48
Asn170-O”1 35 2.32
Inhibitor-C6 35 2.89
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